The epidemiology and experience of chronic rhinosinusitis by Erskine, Sally
Other, please specify:
CHRONIC RHINOSINUSITIS
EPIDEMIOLOGY STUDY 
(CRES)
FOR DOCTOR TO COMPLETE:
CRS WITHOUT POLYPS
CRS WITH POLYPS
CONFIRMED/SUSPECTED AFRS
CONTROL
Please return the questionnaire to the Norwich Medical School, UEA, Norwich 
- for the attention of Mr Carl Philpott
Ref. 
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CONFIRMATION OF DIAGNOSIS WITH:
CT SCAN ENDOSCOPY
Please try to fill in ALL parts of the questionnaire, even if you do not have sinus 
problems and do not feel they are directly relevant to you.
Local Site Ref: 
RECRUITMENT SITE
JPUH NNUH WWL SPIRE NGH
LDH RSCH GUYS QMC FH
CI SRI SGH BCUH RAH
IRH HEFT QEH STH WI
OUH SAMBU CTHB WHH PHNT
RCH RGH AUHNT RBNFT HWPH
DBH Other
If yes please state
/ /
Date of Birth
How to fill this form in
This form will be 'read' by a computer and therefore it is important to take care when completing it.  Where you are 
asked to enter text or numbers, please print in CAPITAL letters with one letter/number per box.
Where you are asked to indicate your choice, fill in the appropriate box thus:
What is your occupation? Please enter your occupation below (One letter per box)
Retired
Unemployed
Student
If you are not currently employed, please indicate your status below
If retired, please state your occupation previously as well
If unemployed, please state your partner's occupation (if married/co-habiting)
If student living with parents, please state the occupation of your parents (both)
What is your highest academic qualification? GCSE A-Level NVQ Degree Higher Degree
Do you live in a village or a town/city or on the outskirts of a town/city? Village Suburbs Urban
How long have you lived there for? <1 year 1-3 yrs 3-5 yrs >5yrs
Do you live near any crop field e.g oil seed rape? Yes No If yes please state
What is your Post Code? (eg. NR31 6
- don't include last two letters)
,  
Please state the annual income for your dwelling/household
Do you have any specific dietary modifications? Yes No
How many people live in your house/dwelling including yourself? 1 2 3 4 >4
If yes please state
How much do you smoke per day (cigarettes/cigars etc.)? None 1 - 10 11 - 20 >20
How many units of alcohol do you drink each week?
(1 unit = 1/2 pint of beer or 1 glass of wine)
None 1 - 10 11 - 30 >30
Have you seen your GP for anxiety? Yes No
Have you seen your GP for depression? Yes No
Besides anxiety and depression, do you have any other psychiatric illness? Yes No
Male Female
Gender
Ref. 
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X
How often do you get a cold or sore throat in the space of one year?
Never Seldom Often Frequently
If yes please stateDo you have any suspected allergies? Yes No
Ref. 
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If yes, please specify what and whenHave you had any previous surgery? Yes No
If yes please state
Do you have any known confirmed allergies (on a skin prick or blood test)? 
e.g house dust mite
Yes No
If yes, please specify 
Aspirin
Spicy food
Wine
Drinks eg. tea/coffee/fruit juices & cordials
Nuts
Fruits including tomatoes
Vegetables
Yes No
Have you ever experienced any allergy symptoms such as wheezing, runny nose or itchy skin when taking any of 
the following?
If yes, please specify 
If yes, please specify 
Do you have any of the following?
Asthma?
Chronic obstructive airways disease (emphysema or chronic bronchitis)?
Bronchiectasis (disorder where the air passages widen and produce a lot of mucus)?
Diabetes (loss of blood sugar control)?
Immunodeficience (poor immune response to infections as diagnosed with blood tests)?
Yes No
Finally, please indicate your Ethnic Group
WHITE - British
WHITE - Irish
WHITE - Other White background*
MIXED - White & Black Caribbean
MIXED - White & Black African
MIXED - White & Asian
MIXED - Other Mixed background*
ASIAN or ASIAN BRITISH - Indian
ASIAN or ASIAN BRITISH - Pakistani
ASIAN or ASIAN BRITISH - Bangladeshi
ASIAN or ASIAN BRITISH - Other Asian background *
BLACK or BLACK BRITISH - Caribbean
BLACK or BLACK BRITISH - African
BLACK or BLACK BRITISH - Other Black background *
OTHER - Chinese
OTHER - Any other group *
* Please state details or country of origin
Ref. 
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Do you have any of the following?
Ciliary dysmotility (e.g Cystic Fibrosis, Kartangener's syndrome, Primary Ciliary Dyskinesia) 
(disorder where the little hairs on the cells lining the air passages don't work properly)?
Hypothyroidism (underactive thyroid gland)?
Autoimmune disorder (e.g.systemic lupus erythmatosis, rheumatoid arthritis)?
Yes No
If yes please stateDo you have any regular medications? Yes No
If yes please stateDo you have any other medical conditions? Yes No
INSTRUCTIONS:
This set of questions ask for your views about your health.  This information will help keep track of how 
you feel and how well you are able to do your usual activities.
Answer every question and mark your response by filling in the box thus:
If you are unsure how to answer a question, please give the best answer you can.
In general, would you say your health is:    (Fill one box only)
Excellent Very Good Good Fair Poor
Compared to one year ago, how would you rate your health in general now?   
(Fill one box only)
Much better than one year ago?
Somewhat better than one year ago?
About the same as one year ago?
Somewhat worse now than one year ago?
Much worse than one year ago?
Vigorous activities, such as running, lifting heavy objects, 
participating in strenuous sports
Moderate activities, such as moving a table, pushing a 
vacuum cleaner, bowling or playing golf.
Lifting or carrying groceries
Climbing several flights of stairs
Climbing one flight of stairs
Bending, kneeling or stooping
Walking more than a mile
Walking several blocks
Walking one block
Bathing or dressing yourself
Yes,
Limited
A Lot
Yes,
Limited
A Little
Not
Limited
At All
The following questions are about activities you might do in a typical day.  Does your health now 
limit you in these activities? If so, how much?  (Fill one box only per activity)
3.
2.
1.
Ref. 
X
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SF36 Health Survey
Cut down on the amout of time you spent on work or other activities
Accomplished less that you would like
Were limited in the kind of work or other activities
Had difficulty performing the work or other activities 
(for example, it took extra effort)
Yes No
During the past 4 weeks,  have you had any of the following problems with your work or other 
regular activities as a result of your physical health?  (Fill one box only per problem)
During the past 4 weeks,  have you had any of the following problems with your work or other 
regular activities as a result of any emotional problems (e.g. feeling depressed or anxious?  
(Fill one box only per problem)
Cut down on the amout of time you spent on work or other activities
Accomplished less that you would like
Didn't do work or other activities as carefully as usual
Yes No
During the past 4 weeks,  to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbours or groups?  (Fill one 
box only )
Not at all Slightly Moderately Quite a bit Extremely
How much physical pain have you had during the past 4 weeks.   (Fill one box only )
None
Very Mild
Mild
Moderate
Severe
Very Severe
During the past 4 weeks,  how much did pain interfere with your normal work (including both work 
outside the home and housework)?  (Fill one box only )
Not at all Slightly Moderately Quite a bit Extremely
4.
5.
6.
7.
8.
Ref. 
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Did you feel full of life?
Have you been a very nervous person?
Have you felt so down in the dumps 
that nothing could cheer you up?
Have you felt calm and peaceful?
Did you have a lot of energy?
Have you felt downhearted and blue?
Did you feel worn out?
Have you been a happy person?
Did you feel tired?
All of
the
time
Most of
the
time
A good
bit of
the time
Some
of the
time
A little
of the
time
None
of the
time
These questions are about how you feel and how things have been with you during the past 4 
weeks. Please give the one answer that is closest to the way you have been feeling for each 
item? (Fill one box only per item)
During the past 4 weeks, how much of the time has your physical health or emotional problems 
interfered with your social activities (like visiting friends, relatives etc)  (Fill one box only per item)
All of the time
Most of the time
Some of the time
A little of the time
None of the time
How TRUE or FALSE is each of the following statements for you? (Fill one box only per item)
I seem to get sick a little easier that other people
I am as healthy as anybody I know
I expect my health to get worse
My health is excellent
Definitely
True
Mostly
True
Don't 
Know
Mostly
False
Definitely
False
9.
10.
11.
Ref. 
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INSTRUCTIONS:
Below you will find a list of symptoms and social/emotional consequences of your nasal disorder. We 
would like to know more about these problems and would appreciate your answering the following 
questions to the best of your ability. There are no right or wrong answers and only you can provide us 
with this information.  Please rate your problems over the last two weeks.
Considering how severe the problem is when you experience it and how frequently it happens, please 
rate each item below on how "bad" it is by filling in the box that corresponds to how you feel. (Fill one 
box only per item)
Then, pick the 5 that are the most important items affecting your health and fill in the corresponding box 
in the grey column on the right.
Need to blow nose
Sneezing
Runny nose
Nasal obstruction
Loss of smell or taste
Cough
Post-nasal discharge
Thick nasal discharge
Ear fullness
Dizziness
Ear Pain
Facial pain/pressure
Difficulty falling asleep
Wake up at night
Lack of good night's sleep
Wake up tired
Fatigue
Reduced productivity
Reduced concentration
Frustrated/restless/irritable
Sad
Embarrassed
No
Problem Very mild
Mild 
or 
slight
Moderate Severe
As bad 
as it 
could be
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Most 
important 
Item 
(Pick 5)
Ref. 
Thank you for taking part in this survey
Snot - 22 Questionnaire
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Appendix  2  
CRS  Topic  Guide  
Introduce  yourself  and  explain  
•   Purpose  of  the  research  –  find  out  more  about  what  is  like  to  have  sinus  
problems  
•   Funded  by  UEA  
•   What  will  happen  to  the  information  given  by  participants  -­  confidential,  
interview  will  be  transcribed  and  anonymised.  All  identifiable  information  will  
be  held  securely.  
•   How  the  results  will  be  disseminated  –  conferences  and  academic  journals  
•   Introduce  the  tape  recorder.    
•   You  are  free  to  stop  the  interview  at  any  time.  
  
  
1.   Background  &  history  of  CRS  
  
Could  you  tell  me  a  bit  about  your  sinus  or  nasal  problems?  
  
Prompt  to  talk  about  onset  of  symptoms,  then  change  in  symptoms  over  time  
worst  or  main  symptom  
Onset  of  symptoms  –   ?  Associated  with  change  in  life  circumstances  
•   Job  
•   New  house/environment  
•   Pet  
  
  
  
2.   Treatment  history  
  
Can  you  tell  me  about  when  you  first  sort  treatment?    
Prompt:  first  diagnosis?  
  
Could  you  tell  me  a  bit  about  the  treatments  you  have  had  and  how  they  have  helped  you?  
(if  appropriate  have  you  found  them  difficult  or  inconvenient  w.r.t  nasal  douche/nasules)  
  
We  will  talk  some  more  about  whether  you  think  diagnosis  or  treatment  for  CRS  could  be  
improved  later  in  the  interview.  
  
  
  
3.   Allergies  
  
Do  you  think  you  are  allergic  to  anything?  
  
Description  of  allergy  -­  What  happens  when  you  come  into  contact  with....?  
Prompt  to  talk  specifically  about  aspirin/salicylate  containing  food/wine  and  
Environmental  e.g  crops  -­  seasonal  variation/geographical  location  
  
Prompt:  formal  diagnosis  of  allergy?  
Have  you  been  tested  for  any  allergies?  How/when?  
  
How  have  you  altered  you  lifestyle  to  accommodate  these  allergies?  
Pets/job/house  
  
 2 
  
  
4.   Health  
  
Physical  
We  would  like  to  find  out  more  about  how  you  think  your  sinus  problems  have  affected  your  
health  -­  could  you  describe  any  affects  you  think  they  have  had?  
Prompt  for  ADL/sleep/appetite/smell  
  
Some  people  with  sinus  problems  can  become  anxious  or  depressed  because  of  them  –  have  
you  ever  felt  like  this?  Could  you  tell  me  a  bit  more  about  it?  
  
  
  
  
5.   Relationships  
  
Do  you  think  your  sinus  problems  have  affected  your  relationships?  
For  example  with  your  friends  or  family  
Could  you  describe  this...  
  
When  you  meet  people  for  the  first  time,  do  you  feel  they  are  aware  of  your  symptoms,  or  are  
you  self-­conscious  about  them?  
  
  
  
  
6.   Financial  
  
Have  you  worked  whilst  you  have  had  sinus  problems?    
If  yes  what  do  you  work  as?  
Have  your  sinus  problems  ever  affected  your  work/employment?  
  
Do  you  think  your  sinus  problems  have  affected  you  financially?  
Prompt  –  missed  days,  travel  to  clinics,  OTC  or  prescription  meds  
  
  
  
  
7.   Are  there  any  ways  in  which  you  feel  your  sinus/nose  problems  could  have  
been  managed  better?  
If  relevant,  do  you  think  health  professionals  understood  your  symptoms?  
    
  
Have  you  met  other  people  with  similar  problems?  Do  you  think  this  would  be  helpful?  
  
  
  
  
  
8.   Is  there  anything  else  about  your  own  experiences  of  CRS  in  general  that  you  
would  like  to  add?  
  
  
  
  
  
  
Thank  you  very  much  for  helping  with  this  research.  
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Objectives: To assess SNOT-22 and its subscales in a non-
rhinosinusitis UK-wide population.
Design: Self-reported questionnaire.
Setting: Based from 30 ENT departments around the UK.
Participants: 250 Non-rhinosinusitis adults – no self-
reported nasal problems in the past, no chronic conditions
undergoing active treatment and no hospital admissions in
the preceding 12 months.
Main outcome measures: SNOT-22, SF-36.
Results: The mean SNOT-22 total score overall was 12.0.
Themeanwas 10.2 formales with amedian of 6.5 and amean
of 13.2 for females with a median of 9. Females scored
significantlymore highly thanmales on the sleep/fatigue and
facial domains.
Conclusions: Our data demonstrate differences in SNOT-
22 amongst males and females. These data can be used in
future studies for comparison with different disease popu-
lations with rhinosinusitis.
Chronic rhinosinusitis (CRS) affects a significant proportion
of the population; a recent European study found a preva-
lence of 11%1. Patient reported outcomemeasures (PROMs)
are a means of collecting information on the effectiveness of
care delivered to patients, as perceived by the patients
themselves, and are increasingly important in clinical prac-
tice and in research2–4 on a background of increasing costs of
healthcare across the world. The most widely accepted and
best validated patient self-report symptom evaluation tool
for use in CRS is the SNOT-22, whose 22 items incorporate
both nasal and non-nasal symptoms(Hopkins,5,6 Within
SNOT-22, self-reported symptomseverity is graded from0to
5, with five being a severe problem. It is a modification of the
31-question Rhinosinusitis OutcomeMeasure (RSOM-31).7
Factor analysis identifies four principal SNOT domains –
nasal, facial, sleep andmood8.9–11 Factor analysis for SNOT-
22 was validated in a Danish population of 40 patients.11The
four subscales are: rhinological symptoms (questions 1–5, 7
and 8), ear and facial symptoms (questions 9–12), sleep
function (questions 13–15) and psychological issues (ques-
tions 17–22). The questions regarding cough and waking up
tired were not included in these subscales. There are limited
SNOT-22 data for a non-CRS population, particularly from
within the UK.12
The overarching aim of the Chronic Rhinosinusitis
Epidemiology Study (CRES) was to aid better understanding
of medical and non-medical factors contributing to devel-
opment or worsening of CRS. The aim of the Socioeconomic
Cost of ChrOnic Rhinosinusitis study (SocCoR) was to
identify the socio-economic costs of CRS to improve the
understanding of the impact of CRS disease to the patient
and the NHS. The purpose of this analysis was to yield large
dataset of SNOT-22 information for a control population in
the UK.
Materials and methods
CRES was conducted as a cross-sectional cohort study and
recruited from a total of 30 sites from around the UK
Correspondence: S. E Erskine, Norwich Medical School, University of East
Anglia, Norwich Research Park, Norwich,NR4 7TJ,UK. Tel: +44 (0)1603 59
1105; e-mail: sally.erskine@doctors.org.uk
aMembers of the “CRES Group” are presented in Appendix 1.
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(including the devolved nations of Wales and Scotland),
between 2007 and 2013. Controls included family and
friends of those attending ENT outpatient clinics and
hospital staff, inclusion criteria required that they had no
diagnosis of persistent nose or sinus problems and had not
been admitted to hospital in the previous 12 months.
Questionnaires were returned by participants using a
Freepost envelope and scanned to a secure database using
Formic. Two members of the research team checked the
accuracy of electronic scanning of returned questionnaires.
The SocCoR study recruited participants meeting the same
criteria, but only from East Anglia.
The CRES was approved by the Oxford C Research Ethics
Committee, sponsored by the University of East Anglia
(UEA) and funded by the Anthony Long and Bernice Bibby
Trusts. The study-specific questionnaire was anonymous
and therefore no consent was taken but implied through
participation. Participant information leaflets were pro-
vided. SocCoR was approved by the North Scotland REC1
Research Ethics Committee.
Results
A total of 251 non-CRS controls completed the SNOT-22
questionnaire, including 221 from CRES and 30 from
SocCoR (Figure 1). Females tended to score more highly
than males overall. They also had a wider range of scores.
Females scoredmore highly on each of the domains; this was
statistically significant within the sleep fatigue and facial
domains. Participants were asked about the frequency at
which they suffer from upper respiratory tract infections; no
differences were found in the numbers of upper respiratory
tract infections between males and females (Table 1 and
Figure 2). Outliers were also considered (Table 2). Partic-
ipation rate for the study overall was 66%, data were not
specifically collected regarding controls.
Table 1. SNOT-22 and its subscales
n Age (range)
SNOT-22
Nasal Facial
Sleep
fatigue Emotional
Mean (SD) Median (IQR) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Total 251 47.5 (19–80) 12.0 (13.6) 8 (2–17) 2.5 (4.0) 1.1 (2.5) 2.9 (3.6) 3.5 (5.3)
Females 143 46.8 (14.4) 19–80 13.2 (15.0) 9 (2–18) 2.3 (3.6) 1.4 (2.9) 3.4 (3.9) 3.8 (6.0)
Males 96 48.8 (15.8) 22–82 10.2 (11.1) 6.5 (2–14.5) 2.8 (4.4) 0.7 (1.4) 2.2 (2.7) 3.0 (4.1)
Differences
(p values)
0.092* 0.297† 0.363‡ 0.006* 0.005* 0.193*
*t-test (unequal variances).
†Mann–Whitney test.
‡t-test (equal variances).
Table 2. Characterising outliers
Total
SNOT-22
Nasal domain
(% of total
domain score)
Facial
domain
Sleep
domain
Emotional
domain
Females
85 21 (60) 17 (85) 15 (100) 26 (87)
63 13 (37) 15 (75) 9 (60) 21 (70)
55 14 (51) 6 (30) 10 (67) 18 (60)
52 5 (14) 2 (10) 15 (100) 26 (87)
45 18 (51) 10 (50) 4 (27) 13 (43)
43 8 (23) 2 (10) 9 (60) 21 (70)
Males
62 19 (54) 9 (45) 10(75) 18 (60)
38 20 (57) 0 3 (20) 11 (37)
34 14 (51) 0 6 (40) 11 (37)
32 1 (3) 0 10 (75) 18 (60)
The table of outliers shows that outlying females tended to score
highest amongst sleep and emotional domains. Outlying males
scored highly across all domains other than facial. [Histograms
appended also show this information].
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Fig. 1. Boxplot to show SNOT-22 for males and females.
2 S.E. Erskine et al.
© 2016 John Wiley & Sons Ltd  Clinical Otolaryngology
Discussion
Our data describe a large population of non-CRS
volunteers from across the UK. We found a mean
SNOT-22 score of 10.2 for males with a median of 6.5,
and a mean of 13.2 for females with a median of 9. The
standard deviation was higher amongst females. Our
control results were not normally distributed; this is to be
expected as there should be a large number of individuals
who score very low (floor effect). Previous studies of a
healthy control population have found a median of
7–9.13,14 The population (n = 116) recruited by Gillett
et al. included a higher proportion of males and also
those recruited through a tennis club, who may have been
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Fig. 2. Histograms to show spread of data for each domains.
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healthier than the general population. A study using a
random sample of the Danish population (n = 271 for
those without CRS) similarly found a median SNOT-22
value of 7 (IQR2-15),10,15 they do not differentiate by
gender. In a study of 539 healthy volunteers in Sao Paulo,
Gregorio et al. also found SNOT-22 scores were dis-
tributed significantly differently between men and women.
Men presented significantly lower normal values than
women (men: mean = 8.58 and median = 7 versus
women: mean = 10.94 and median = 9; P = 0.005). A
median score of 7–10 for males and 9–13 for females
therefore appears to be reproducible benchmark for
‘normal’ SNOT-22. A recent systematic review of
SNOT-22 scores in a non-CRS population found that
scores varied significantly according to the nature of the
group studied.12 The review also found differences
between those with and without asthma and amongst
smokers. Similar results were found in the CRES study
between all subgroups of CRS patients and will be
reported elsewhere. The importance of using non-CRS
SNOT scores from a comparable population is therefore
key, and our data provide this for a very diverse UK
population. The average SNOT-22 score identified should
not be used as an ‘absolute’ normal score to assign care
for CRS or as a diagnostic threshold, but is a useful figure
to consider when assessing SNOT-22 in the context of
CRS in both clinic and research.
Conclusion
Our data provide reference data for scores across SNOT-22
in a non-CRS population across a wide cross section of the
UK population and they demonstrate the differences in
reporting in males and females. These data can be used in
future studies for comparison with different disease popu-
lations with rhinosinusitis.
Keypoints
• SNOT-22 is respected outcomemeasure for those with
CRS; use of non-CRS SNOT scores from a comparable
population is therefore key.
• Our data describe a large and diverse population of
non-CRS volunteers from across the UK.
• Females tend to have a higher SNOT-22 score than
males.
• Amedian score of 7–10 for males and 9–13 for females
appears to be reproducible benchmark for ‘normal’
SNOT-22
• These scores should not be used as diagnostic criteria.
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A case-control study of medical, psychological and socio-
economic factors influencing the severity of chronic 
rhinosinusitis*
Abstract 
Background: Chronic rhinosinusitis (CRS) is a common and debilitating disorder. Little is known about the epidemiology of this 
disease. The aims of the study were to identify differences in socio-economic variables and quality of life between patients with 
chronic rhinosinusitis and healthy controls, to identify any significant associations between CRS and other medical co-morbidities, 
psychiatric disease or environmental exposure and to explore the experience of CRS from the perspective of CRS sufferers.
Methods: Participants were recruited from ENT clinics from 30 centres across the UK. They completed a study-specific question-
naire considering environmental, medical and socio-economic factors, and SF-36 and SNOT-22 scores. All participants with CRS 
were diagnosed by a clinician and categorised as having CRS (with polyposis, without polyposis or allergic fungal rhinosinusitis 
(AFRS)). Controls included family and friends of those attending ENT outpatient clinics and hospital staff who had no diagnosis of 
nose or sinus problems and had not been admitted to hospital in the previous 12 months.
Results: A total of 1470 study participants (1249 patients and 221 controls) were included in the final analysis. Highly significant 
differences were seen in generic and disease-specific quality of life scores between CRS sufferers and controls; mean  SNOT-22 
score 45.0 for CRS compared with 12.1 amongst controls. There were no clear differences in socioeconomic variables including 
social class, index of multiple deprivation and educational attainment between cases and controls. Common comorbidities with 
a clear association included respiratory and psychiatric disorders, with a higher frequency of reported upper respiratory tract 
infections.
Conclusions: CRS is associated with significant impairment in quality of life and with certain medical co-morbidities. In contrast to 
other common ENT disorders, no socioeconomic differences were found between patients and controls in this study.
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Introduction
Chronic rhinosinusitis (CRS) affects a significant proportion of 
the population; a recent European study found a prevalence of 
11% (1). Despite this, the epidemiology of CRS and in particular 
its association with socioeconomic variables has not been ex-
tensively explored. The European Position Paper on Rhinosinu-
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sitis and Nasal Polyps (EPOS 2012) has stated under the heading 
‘Research Needs’ that studies are required to consider ‘the 
prevalence of and predisposing factors for CRSsNP and CRSwNP’ 
and to ‘investigate the impact of psychological problems such as 
depression, stress exposure and anxiety on subjective severity’ 
(2). A previous study of 158 patients has suggested significant 
morbidity in CRS, with quality of life scores worse than amongst 
those with other chronic diseases such as lower back pain (3). 
This significant effect on an individual’s functioning and pro-
ductivity, has an impact upon workforce productivity, since CRS 
primarily affects those aged 40-60 years. CRS has been identified 
as one of the top ten most costly diseases for US employers (4). 
Despite its high prevalence and impact, the pathophysiology 
and hence optimal treatment for CRS are not well understood, 
but it is thought to be a spectrum of diseases with different 
underlying aetiologies and pathological features. Infection (viral, 
bacterial and fungal) and underlying genetic tendencies may 
all be contributory factors. CRS is currently subdivided into two 
main types – CRS with and without nasal polyps (CRSwNP and 
CRSsNP, respectively), as exemplified by EPOS2012 (2) to reflect 
coarsely differing gross pathophysiology (eosinophilic or neu-
trophilic) but allergic fungal rhinosinusitis (AFRS) is an increasin-
gly recognised distinct subtype of CRSwNP.
Deprivation is known to be associated with increasing morbidity 
and mortality, and is therefore important to consider in under-
standing the epidemiology of any disease, since it is a poten-
tially reversible determinant of health (5). Many reasons for this 
relationship have been explored. Poor nutrition leads to poor 
mental and physical development. Cold or damp housing is 
associated with increased risk of respiratory diseases, and over-
crowded housing is associated with infectious diseases (6). Be-
havioural differences which may be related to lack of resources 
or poor education also contribute to socioeconomic variation 
in health, with smoking being the most common example. Re-
duced access to health care, genetic factors and adverse social 
conditions also contribute (7). Within otorhinolaryngology it is 
known that one of the most common risk factors for otitis media 
is socioeconomic status (8), with more deprived children more 
likely to suffer adversely with the condition. There is controversy 
as to the role of deprivation in other upper respiratory problems; 
the direction of association between asthma and socioeconomic 
status varies widely between studies (9,10).
By developing our understanding about the socio-economic 
and co-morbidity factors that may influence CRS, specific co-
morbid associations and high-risk population groups might be 
identified. This information could enable health practitioners, in-
cluding ENT specialists and General Practitioners, to better tailor 
management to individual patients’ needs. Epidemiological 
studies outwith Europe have shown varying prevalence rates. 
In Canada, the prevalence of CRS, defined as an confirmatory 
answer to the question, ‘Has the patient had sinusitis diagnosed 
by a health professional lasting for more than 6 months?’ ranged 
from 3.4% in male to 5.7% in female subjects (11). In Korea, the 
overall prevalence of CRS, defined as the presence of at least 3 
nasal symptoms persisting for more than 3 months, together 
with an endoscopic finding of nasal polyps and/or mucopu-
rulent discharge within the middle meatus, was 1.01% (12). A 
comparative study between the north of Scotland and the Carib-
bean found that in ENT clinics across both countries, there was a 
similar prevalence of CRS (9.6% and 9.3%, respectively) (13). 
To date, no large scale study into the epidemiology of CRS has 
been undertaken in the UK, and the Chronic Rhinosinusitis 
Epidemiology Study (CRES) meets this need. The primary aim of 
the study was to identify differences in socio-economic varia-
bles and quality of life between patients with chronic rhinosi-
nusitis and healthy controls. Secondary aims were to identify 
any significant associations between CRS and other medical 
co-morbidities, psychiatric disease or environmental exposure 
and to explore the experience of CRS from the perspective of 
CRS sufferers.
Materials and methods
Study design and setting
CRES was approved by the Oxford C Research Ethics Committee, 
sponsored by the University of East Anglia (UEA) and funded 
by the Anthony Long and Bernice Bibby Trusts. The study was 
conducted as a prospective case-control questionnaire study. 
Following a pilot study of the questionnaire in 2006, the study 
commenced recruitment in ENT departments of the East Anglia 
region (East of England Deanery) of the UK in 2007. Following 
elevation to the National Institute of Health Research Clinical Re-
search Network Portfolio in 2012, a total of 30 sites from around 
the UK (including the devolved nations of Wales and Scotland) 
joined the study which ran between 2007 and 2013. The study 
specific questionnaire was anonymous and therefore consent 
was implied through participation. Participant information 
leaflets were provided. Questionnaires were completed on one 
occasion only either before leaving the clinic or taken home and 
returned by post in Freepost envelopes. A qualitative arm of the 
study was undertaken in 2012. This is published elsewhere (14, 15).
Participants
The diagnosis of CRS was confirmed by an Otorhinolaryngolo-
gist. CRS patients presenting to secondary care ENT outpatient 
clinics were invited to participate in the study, regardless of 
symptom or disease severity or previous treatment, provided 
they conformed to the following criteria:
Inclusion criteria:
CRS with or without polyps as defined by the criteria laid out in 
EPOS 2012 (2). Symptoms must be present for at least 12 weeks 
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Sample size calculation
The purpose of the study was to look for common associations 
between CRS, and primarily social class (as determined by oc-
cupation, highest qualification and household income), and CRS 
and housing status (as determined by occupancy of household 
in conjunction with social class). These two factors have been 
used to determine the size of the study sample required. For 
socio−economic scores, the standard approach is to compare 
the proportion of subjects in the lower social classes to eve-
ryone else. In order for the study to have 80% power to detect a 
difference of 10% in “low social class” between controls and CRS 
patients, assuming a 30% rate in the CRS patients, with approxi-
mately 5 CRS patients to 1 control patient, 965 CRS patients and 
193 controls were required. 
 
For the purposes of assessing QoL, assuming that a change in 
QoL of 10 units on SF-36 can be shown (standard deviation of 
20), then to have 80% power to detect this difference (at the 
5% level of significance), 38 controls and 190 cases would be 
needed. This would need to be increased by 20% to allow for the 
non−normality of QoL and the study would need 46 controls 
and 228 cases. 
Results 
Participants
A total of 1470 participants with an age range of 17-102 years 
were recruited. Following adoption on to the NIHR portfolio, 
recruitment rates improved to a peak of 120 subjects per month. 
After adoption, the overall recruitment was 66% of those invited 
to participate. Participants who were recruited prior to adoption 
onto the portfolio make up the additional participants. Informa-
tion on recruitment rates prior to adoption was not collected 
and there is no information on reasons for non-participation. 
A total of 1535 questionnaires were returned, reduced to 1470 
and include:
• Nasal blockage/obstruction/congestion and/or nasal 
discharge (anterior/posterior nasal drip) and
• Either facial pain/pressure and/or reduction or loss of smell
and additionally:
• Endoscopic signs of: polyps and/or mucopurulent dischar-
ge primarily from middle meatus and/or; oedema/mucosal 
obstruction primarily in middle meatus and/or
• CT changes: mucosal changes within the ostiomeatal com-
plex and/or sinuses
Any patients with nasal polyps placed in the AFRS category 
met the Bent and Kuhn criteria (16) or the St Paul’s Sinus Centre 
modification of this (17). 
Patients and controls included were all adult.
Exclusion criteria:
• Patients unable to comprehend written English.
For the control group:
• Patients with active sinonasal disease - e.g. acute or chronic 
forms of rhinitis/rhinosinusitis (as determined by patient 
history or SNOT-22 score of 10 or more
• No chronic medical conditions being actively treated or
• hospitalisation within the last 12 months
Controls included family and friends of those attending ENT out-
patient clinics and hospital staff.
Variables and data sources
The study questionnaire was designed with the input of the 
East of England Research Design Service and included study 
specific questions relating to socio-economic, environmental 
and medical co-morbid variables as well as the validated Short 
Form 36 Quality of Life (QoL) measure (SF-36) (18) measure and 
the Sino-Nasal Outcome Test questionnaire (SNOT-22) (19). 
Socioeconomic variables
Respondents were asked to enter data for occupation, highest 
academic qualification, rural/urban location, duration of resi-
dency, proximity to crops, postcode, annual income, ethnicity 
and household occupancy. Social class based on the National 
Statistics Socio-economic Classification (NS-SEC) (20) and the 
Index of Multiple Deprivation (21) were calculated and used to 
assess socio-economic differences. Participants were also asked 
about tobacco and alcohol consumption.
Medical co-morbidities
Data requested under this category included information on 
psychiatric disorders, frequency of common respiratory illnes-
ses, past medical and surgical history, drug history, known and 
suspected allergies and sensitivities to aspirin and foods high in 
salicylate content.
Figure 1. Participant flow. 
 
Total questionnaires distributed after 
NIHR adoption  
1295 
Total questionnaires returned prior to 
adoption  
680 
Not 
returned  
440 
Returned  
855 
Total returned 
1535 
Duplicates, or paucity of 
entries to questionnaire 
so unusable  
65 
Total after data 
cleaned 
1470 
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eligible after checking for duplicates and missing information. 
See Figure 1 for participant flow.
Descriptive and outcome data
The 1470 participants included 709 males and 606 females (155 
undeclared); 44% had CRSsNP and 56% had CRSwNP or AFRS. As 
demonstrated in Figure 2, the geographic distribution of study 
participants includes a wide range of rural and urban areas 
of the country and in 3 out of the 4 devolved nations. Table 1 
shows detailed demographic information for each of the inclu-
ded subgroups. The full amount of data available was used for 
each relevant analysis; for example, if SNOT-22 was completed 
but not SF-36, participants were included in SNOT-22 analysis 
but not SF-36. Similarly, for all socioeconomic factors all parti-
cipants who completed the relevant question were included in 
that particular analysis, to maximize use of the available data.
Main results
Socio-economic outcomes
Social class is an individual-level assessment based on self-
reported occupation: 1350 respondents (91.8%) provided this 
information. Due to the small number of individuals in some 
categories, classes 1.1 and 1.2 were combined, 4 and 5 were 
combined, and 7 and 8 were combined to assess differences. 
There was a significant association between social class and CRS 
status (p=0.002); however when adjusted for age and sex the 
difference was no longer statistical significant (p=0.0684) and 
there was no specific direction of association.
The index of multiple deprivation (IMD) was also calculated as 
a measure of socioeconomic status (21). This is an area-based 
deprivation measure based on postcode. IMD scores for each 
postcode are based on government statistics measuring relative 
levels of deprivation in small areas of England called Lower 
Layer Super Output Areas (LSOAs). Domains include income, 
employment, health and disability, education, skills and training, 
barriers to housing and services, living environment and crime. 
Most of the indicators used in these statistics are from 2008. The-
re were no significant differences between those with CRS and 
controls (p=0.115); nor did any appear after adjusting for age 
and sex (mean difference -1.36, 95% CI: -3.00 to 0.29, p=0.107).
The number of occupants in the household of the participant 
was also considered; households of controls tended to have 
more occupants than households of those with CRS (p=0.003), 
however this was not significant after adjusting for age and sex 
(p=0.275). Household income (according to the participant) was 
intended to be used as a further socioeconomic measure but 
only two thirds of respondents provided information although 
no significant differences were found. Mean income was 
£41,118.63 for controls and £42,800.02 for those with CRS. This 
highest educational qualification achieved by the participant 
showed no significant differences between controls and those 
with CRS (p=0.599).
Quality of Life
Quality of life was measured using the SF-36 and SNOT-22. There 
was a statistically significant association between SNOT-22 and 
social class, but only a weak correlation was detected (Spearman 
rho = 0.0935, p=0.001). There was no correlation between SNOT-
22 score and IMD, number of household occupants or educati-
onal attainment. There were statistically significant associations 
between three socioeconomic variables and SF-36 but all 
correlations were weak. Results are shown in table 2. There were 
significant differences in mean scores between controls and 
those with CRS for both the SF-36 and SNOT-22, before and after 
adjustment for age and gender differences. Controls had better 
scores for both scales as illustrated in table 3. A further detailed 
analysis of the SNOT-22 subscales and differences between CRS 
subtypes will be reported separately.
Co-morbidities
Several co-morbidities were higher amongst those with CRS 
than controls, including psychiatric problems (p=0.001) and 
respiratory issues.
CRS and mood disturbances
Chi-squared test showed significant differences between partici-
pant subgroups for both depression p=0.03 and anxiety p=0.04 
and between mental health domain scores on SF-36 (p=0.05). 
This will be published in detail at a later date.
Table 1. Demographic information for each of the included subgroups.
Controls CRSsNP CRSwNP AFRS
Participants 221 553 651 45
Females 143 (68.4%)
259 
(53.1%)
185 
(32.2%)
19 
(43.2%)
Mean Age (SD) 47.3 (14.9)
51.8
(15.3)
56.0 
(14.6)
56.1
(12.7)
Range 19-82 18-84 17-102 20-76
Table 2. Quality of life and socioeconomic variables.
NOT-22 (Spearman rho, 
p-value)
SF-36 (Spearman rho, 
p-value)
Social Class 0.0935;  p = 0.001 -0.1545; p < 0.0001
IMD -0.0131; p = 0.6449 -0.0035; p = 0.9006
Household 
occupancy 0.0017; p = 0.9518 0.0695; p = 0.0092
Educational 
attainment -0.0473; p = 0.1359 0.1010; p = 0.0012
138
Erskine et al. 
Allergies
Those with CRS were more likely to report respiratory tract 
sensitivity to aspirin (p= 0.003), wine (p<0.001), fruits (0.034) and 
nuts (0.026), but not to spicy food, drinks or vegetables. Further 
analysis is required for the free text answers regarding inhalant 
allergies and will be reported elsewhere.
Respiratory
Asthma had a strong association with CRS (<0.001) with those 
in the AFRS subgroup most frequently affected. Those with CRS 
were more likely to report suffering from upper respiratory tract 
infections (URTIs) ‘often’ OR=7.39 (95% Confidence interval [CI]: 
3.31-16.51) or ‘frequently’ 30.25 (95% CI 9.77, 93.63).
Burden of surgery
Amongst all CRS patients, 45% had undergone some form of si-
nonasal surgery previously (defined as one or more of polypec-
tomy, endoscopic sinus surgery (ESS), septoplasty, turbinate 
surgery, rhinoplasty) including 325 (26%) who had received at 
least one nasal polypectomy and 169 (14%) who had undergone 
at least one instance of ESS (separately or concurrently). The 
mean number of previous surgeries per patient in those had un-
dergone multiple procedures was 3.3 (range 2–30) and a mean 
duration of time of 10 years since the last procedure. A detailed 
analysis of the surgical data is reported elsewhere (22).
Lifestyle and environmental exposure
There were no significant differences in smoking or alcohol 
consumption between controls and those with CRS. Nor were 
there significant differences in proportions of those living near 
crops between those with CRS and controls. Data on air pol-
lution for all recruitment sites is currently being sought and will 
be reported separately.
 
Discussion
Key results
Sufficient data on socioeconomic status were collected to 
enable the primary objectives to be determined. There were no 
significant differences in socio-economic variables as measured 
by social class, IMD or household occupancy between those 
with and without CRS. There have been few previous studies in-
vestigating the association between CRS and different measures 
of socioeconomic status, particularly in the UK. A similar sized 
epidemiological study of residents of Sao Paulo also found no 
statistically significant differences in CRS prevalence according 
to number of household residents, educational achievement or 
income of head of household, but did find a significant associ-
ation between presence of CRS and belonging to a low-income 
group (23), although it is noted that social structure in Sao Paulo 
is different to the UK. Another study of 127 patients found that 
lower family income was related to worse self-reported sinus 
disease (although there was no difference in objective sinus 
disease based on Lund-Mackay score) (24). A study considering 
markers of disease severity amongst 93 patients with AFRS in 
North Carolina, found that bone erosion and orbitocranial invol-
vement were associated with lower income, rural counties, poor 
housing quality, and less health care access (25). Some studies 
have found that comparable chronic diseases such as asthma 
have a strong association between poverty and disease severity 
(10) but this is controversial (9). Our study found no differences in 
education attainment between cases and controls. 
There were weak but statistically significant associations 
between SNOT-22 score and social class, and SF-36 score and 
social class, household occupancy and educational attainment. 
Although there is sparse literature investigating such associati-
ons amongst those with CRS, Kilty et al found that those with a 
lower educational level scored more highly on a sinus symptom 
score (24). 
Highly significant differences were seen in generic and disease-
specific QoL scores between cases and controls, with cases 
having less favourable scores on both SF-36 and SNOT-22, 
emphasising that CRS patients have a significant impairment 
of their QoL. This is supported by several previous studies (26). 
Potential explanations for the association between socioecono-
mic variables and disease severity are likely to be multi-factorial, 
reflecting the wide range of influencing aetiological factors in 
CRS as well as individuals’ perceptions of symptoms. Several co-
morbidities were significantly more likely to be found amongst 
those with CRS than controls, including psychiatric problems 
including mood disturbances and asthma. Studies considering 
the biopathophysiological mechanisms which could be involved 
in the association between socioeconomic status and the deve-
lopment of asthma have proposed family stress and endotoxin 
exposure in low-income households as a factor in development 
and experience of symptoms (10). For example, caregiver stress 
in early life has been associated with increased levels of TNF-a 
Table 3. Quality of life and diagnosis.
CRS Controls Unadjusted p-value Age and gender adjusted p-value
SF-36 67.8 (20.5) 80.8 (15.1) -12.97 (-15.81,-10.12) <0.001 -14.32 (-17.34,-11.30) <0.001
SNOT-22 45.0 (21.4) 12.1 (13.9) 32.85 (29.78,35.92) <0.001 36.40 (33.16,39.64) <0.001
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in infants, which is known to be a pro-inflammatory cytokine in 
asthma (27).
The proportion of those reporting allergies including aspirin, 
wine, fruits and nuts was higher amongst cases than controls. 
This is supported by several previous studies (28).
There were no significant differences in smoking habits or 
alcohol intake between cases and controls. Existing literature 
varies as to the nature of any association with CRS. Despite 
being known to reduce mucociliary clearance time, the associ-
ation between smoking and CRS varies between studies (28, 29). 
A large epidemiological study of over 73,000 Canadians found 
no association between self-reported smoking and CRS; our 
study supports this finding (11). Similarly no association between 
alcohol intake and CRS was found (11). Smoking is associated with 
poorer postoperative outcomes (30).
Strengths and limitations
This study includes a varied population from across the United 
Kingdom. It is the largest study of CRS in the UK to date. Adop-
tion onto the NIHR portfolio facilitated recruitment and many si-
tes had excellent participation rates. Participants were recruited 
regardless of previous and subsequent management so there 
was no bias towards surgical or medical treatment. There should 
be no difference or bias regarding reporting of socioeconomic 
factors between controls and those with CRS.
The study design had some limitations; it was a self-reported 
study which predisposes to recall bias. Only those in secondary 
or tertiary care were included, although many of those with 
CRS are exclusively treated in primary care. There were large 
amounts of missing data for some socioeconomic parameters. 
If the study was redesigned, controls may have been recruited 
from a wider pool than just from within hospital staff or from 
amongst non-CRS ENT patients/relatives, to increase recruit-
ment particularly amongst males. An online version of the 
questionnaire would have also produced a less labour-intensive 
data processing period at the end of the study.
The study did not intend and cannot provide information about 
prevalence of CRS in the general population.
Generalisability
Given the scope of the study incorporating a mixture of different 
sized academic, tertiary and secondary care sites with partici-
pants from a range of urban and rural locations around the UK, 
we believe the study findings are applicable to the wider popu-
lation of CRS sufferers presenting to ENT departments. However, 
given an even larger burden of CRS patients is managed in a 
primary care setting, the results may not necessarily apply to the 
whole of the CRS-affected population.
Conclusion
Our study is the first study to assess socioeconomic influen-
ces in CRS in the UK and found no socioeconomic differences 
between those with CRS and controls. This finding is significant 
in furthering our understanding of the epidemiology of CRS. We 
identified significant differences in health-related QoL reflecting 
the substantial negative effect of CRS. This increased morbidity 
leads to the increased health care utilisation by patients with 
CRS, for both nasal and non-nasal symptoms, and within both 
primary and secondary care. Additionally those with CRS were 
found to have higher respiratory and psychological co-mor-
bidities. The disease burden associated with CRS needs to be 
considered in both individual patients’ management and when 
undertaking clinical and epidemiological research into CRS, and 
in the context of planning future guidelines. 
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Abstract	  
Background	  
Chronic	   rhinosinusitis	   (CRS)	   is	   a	   common	   respiratory	   tract	   disorder	   and	   is	   known	   to	   be	  
associated	   with	   other	   respiratory	   tract	   diseases	   such	   as	   asthma.	   Inhalant	   allergy	   is	   also	  
commonly	   found	   in	   CRS	  patients.	  However,	   the	   prevalence	  of	   these	   co-­‐morbidities	   varies	  
considerably	   in	   the	   existing	   medical	   literature	   and	   according	   to	   the	   phenotype	   of	   CRS	  
studied.	   This	   study	   looks	   at	   data	  derived	   from	  a	   large	  national	   case-­‐control	   study	   for	   risk	  
factors	  for	  CRS.	  
Objectives	  
•   To	   identify	   the	   prevalence	   of	   asthma,	   inhalant	   allergy	   and	   aspirin	   sensitivity	   in	   CRS	  
patients	  referred	  to	  secondary	  care.	  
•   To	  establish	  any	  differences	  between	  CRS	  phenotypes	  and	  compared	  to	  control	  subjects	  
without	  CRS.	  
Methods	  
All	  CRS	  participants	  were	  diagnosed	  in	  secondary	  care	  according	  to	  international	  guidelines.	  
Participants	   were	   invited	   to	   complete	   a	   study-­‐specific	   questionnaire	   including	   detailed	  
questions	  on	  co-­‐morbidities	  and	  allergies.	  Participants	   included	  CRS	  patients	  both	  without	  
(CRSsNPs)	   and	   with	   polyps	   (CRSwNPs)	   and	   the	   subgroup	   of	   allergic	   fungal	   rhinosinusitis	  
(AFRS).	   Data	   were	   analysed	   for	   differences	   between	   controls	   and	   CRS	   participants	   and	  
between	  subgroups	  using	  chi-­‐squared	  tests.	  
Results	  
From	  a	   total	  of	  1470	  study	  participants,	  221	  controls,	  553	  CRSsNPs,	  651	  CRSwNPs	  and	  45	  
AFRS	  were	  included	  in	  the	  final	  analysis.	  The	  prevalence	  of	  prevalence	  of	  asthma	  was	  9.95%,	  
21.16%,	   46.9%	   and	   73.3%	   respectively.	   The	   prevalence	   of	   confirmed	   inhalant	   allergy	  was	  
13.1%,	  20.3%,	  31.0%	  and	  33.3%	  respectively.	  Finally	  the	  prevalence	  of	  self-­‐	  reported	  aspirin	  
sensitivity	  was	  2.26%	   in	   controls,	   3.25%	   in	  CRSsNPs,	  9.61%	   in	  CRSwNPs	  and	  40%	   in	  AFRS.	  
The	  Odds	  ratio	  for	  aspirin	  sensitivity	  amongst	  those	  with	  AFRS	  28.8	  (9.9,	  83.8)	  p<0.000.	  
Conclusions	  
The	   prevalence	   of	   asthma	   and	   allergy	   in	   CRS	   varies	   by	   phenoytype	   with	   polypoid	  
phenotypes	   having	   a	   stronger	   association	   with	   both.	   Aspirin	   sensitivity	   has	   a	   highly	  
significant	  association	  with	  AFRS.	  All	  of	  these	  comorbidities	  are	  significantly	  more	  prevalent	  
than	   in	   non-­‐CRS	   controls	   and	   strengthen	   the	   need	   for	   a	   combined	   airways	   approach	   to	  
inflammatory	  respiratory	  tract	  disease.	  
  
Background  
Chronic	  rhinosinusitis	  (CRS)	  is	  the	  term	  used	  to	  denote	  a	  common	  symptom	  set	  lasting	  for	  
more	   than	   12	   weeks	   and	   requires	   endoscopic	   or	   radiological	   confirmation	   (1).	   Such	  
symptoms	   include	   nasal	   blockage,	   rhinorrhea,	   facial	   pain	   and	   loss	   of	   sense	   of	   smell.	   CRS	  
affects	   a	   significant	   proportion	   of	   the	   adult	   population	   with	   a	   recent	   European	   study	  
suggesting	  a	  prevalence	  of	  11%	  (2).	  The	  pathophysiology	  for	  CRS	  is	  not	  yet	  fully	  understood	  
but	   it	   is	   currently	  accepted	   to	   roughly	  divide	  cases	   into	   two	  common	  phenotypes	  –	   those	  
with	  polyps and	  those	  without	  nasal	  polyps	  (CRSwNP	  and	  CRSsNPs	  respectively).	  There	  are	  
many	   proposed	   aetiological	   factors;	   viruses,	   bacteria	   and	   fungi	   alongside	   host	   and	  
environmental	  factors	  have	  all	  been	  implicated	  with	  the	  likelihood	  of	  an	  array	  of	  underlying	  
endotypes.	  	  
Allergic	   fungal	   rhinosinusitis	   (AFRS)	   is	   an	   increasingly	   recognised	   distinct	   subtype	   of	  
CRSwNPs	   that	   represents	   a	   therapeutically	   more	   challenging	   variety.	   AFRS	   was	   first	  
described	  in	  1976	  (3)	  and	  1983(4),	  resected	  nasal	  mucosa	  from	  group	  of	  young	  adults	  with	  a	  
history	  of	  asthma	  and	  chronic	  nasal	  polyps	  was	  found	  to	  contain	  similar	  histological	  features	  
including	  a	  distinct	  mucinous	  material	  containing	  eosinophils,	  Charcot-­‐Leyden	  crystals,	  and	  
fungal	   hyphae.	   The	  most	   commonly	   used	   classification	   today	   is	   that	   defined	   by	   Bent	   and	  
Kuhn	  in	  1994	  (5)	  which	  states	  that	  AFRS	  is	  a	  condition	  associated	  with	  five	  major	  criteria;	  1)	  
evidence	   of	   type	   I	   hypersensitivity	   (IgE	   mediated),	   2)	   nasal	   polyposis,	   3)	   characteristic	  
computed	  tomography	  findings,	  4)	  eosinophilic	  mucus,	  and	  5)	  positive	  fungal	  smear,	  and	  six	  
associated	  criteria;	  1)	  asthma,	  2)	  unilateral	  predominance,	  3)	  radiographic	  bone	  erosion,	  4)	  
fungal	  culture,	  5)	  Charcot-­‐Leyden	  crystals,	  and	  6)	  serum	  eosinophilia.	  	  
In	   addition	   to	   the	   potential	   causative	   factors	   already	   described,	   aspirin	   is	   also	   known	   to	  
exacerbate	   nasal	   symptoms.	   In	   some	   patients,	   this	   is	   as	   part	   of	   aspirin	   exacerbated	  
respiratory	   disease	   (AERD)(6).	   This	   was	   first	   described	   in	   1922	   by	  Widal	   (7)	   as	   a	   triad	   of	  
symptoms	  including	  aspirin	  sensitivity,	  asthma,	  and	  nasal	  polyposis,	  more	  commonly	  known	  
as	   Samter’s	   triad	   (8).	    AERD	   initially	   includes	   upper	   airway	   symptoms	   such	   as	   nasal	  
obstruction/congestion	   and	   rhinorrhoea,	   and	   progresses	   over	   months	   and	   years	   to	  
development	  of	  lower	  airway	  symptoms,	  including	  shortness	  of	  breath,	  which	  can	  develop	  
into	  life-­‐threatening	  asthma(9).	  	  	  
The	   role	   of	   atopy	   in	   CRS	   is	   widely	   debated	   in	   the	   medical	   literature	   but	   it	   is	   generally	  
accepted	   that	   it	   is	   not	   a	   definitive	   aetiological	   factor.	   The	   reports	   of	   the	   prevalence	   of	  
allergic	   in	   CRS	   vary	   wildly,	   ranging	   from	   as	   low	   as	   10%	   to	   as	   high	   as	   84%	   (10-­‐15),	   with	  
phenotype	   cases	   included	   in	   the	   relevant	   studies	   likely	   to	   be	   an	   influential	   factor.	   The	  
European	  Position	  Paper	  on	  Rhinosinusitis	  and	  Nasal	  Polyps	  suggests	  that	  a	  selection	  bias	  in	  
these	  studies	  by	  physicians	  with	  an	  interest	  in	  allergy,	  has	  led	  to	  artificially	  high	  reporting	  of	  
inhalant	  allergy	  in	  CRS	  (16-­‐20).	  	  
The	  association	  of	  CRS	  with	  asthma	  is	  commonly	  recognised	  (21,	  22)	  and	  yet	  the	  interaction	  
is	  yet	  to	  be	  fully	  understood	  (23),	  although	  some	  recent	  early	  biomarker	  research	  suggests	  
that	  higher	  serum	  periostin	  levels	  denote	  cases	  of	  CRSwNPs	  with	  comorbid	  asthma	  (24).	  It	  is	  
certainly	  clear	  that	  both	  severity	  and	  duration	  of	  CRS	  are	  associated	  with	  increasing	  levels	  of	  
comorbid	  asthma	   (25,	  26),	   suggesting	  poor	  control	  of	  CRS	  heralds	  more	   lower	   respiratory	  
tract	  disease.	  Again	   the	  prevalence	  of	  asthma	  varies	   in	   the	   literature,	   ranging	   from	  4%	   to	  
44%	  (25,	  27-­‐33),	  influenced	  by	  study	  design	  and	  phenotypes.	  	  
The	   overarching	   aims	   of	   the	   Chronic	   Rhinosinusitis	   Epidemiology	   Study	   (CRES)	   were	   to	  
identify	   any	   difference	   in	   socio-­‐economic	   variables,	   medical	   co-­‐morbidities	   and	  
environmental	  exposures	  between	  patients	  with	  CRS	  and	  healthy	  controls.	  The	  aim	  of	  this	  
specific	   analysis	   was	   to	   identify	   the	   prevalence	   of	   asthma,	   inhalant	   allergy	   and	   aspirin	  
sensitivity	   in	  CRS	  patients	  referred	  to	  secondary	  care	  and	  also	  to	  establish	  any	  differences	  
between	  CRS	  phenotypes	  and	  compared	  to	  control	  subjects	  without	  CRS.	  This	  data	  can	  help	  
to	  inform	  NHS	  policy	  makers	  and	  clinical	  commissioning	  groups	  regarding	  the	  potential	  for	  
airway	  comorbidities.	  
Methods  
The	  CRES	  was	  approved	  by	  the	  Oxford	  C	  Research	  Ethics	  Committee	  (Ref:	  07/H0606/100),	  
sponsored	   by	   the	   University	   of	   East	   Anglia	   (UEA)	   and	   funded	   by	   the	   Anthony	   Long	   and	  
Bernice	  Bibby	  Trusts.	  Details	  of	  the	  full	  methods	  used	  for	  the	  whole	  study	  can	  be	  seen	  in	  the	  
overview	  publication	  (34).	  
Study Design  
The	   study	   was	   conducted	   between	   October	   2007	   and	   September	   2013	   as	   a	   prospective	  
case-­‐control	   multi-­‐centre	   questionnaire	   study.	   The	   study	   specific	   questionnaire	   was	  
anonymous	   and	   therefore	   no	   consent	   was	   taken	   but	   implied	   through	   participation.	  
Participant	   information	   leaflets	   were	   provided.	   	   Questionnaires	   were	   either	   completed	  
before	   leaving	   the	   clinic	   or	   taken	  home	  and	   returned	  by	  post	   in	   Freepost	   envelopes.	   The	  
returned	  questionnaires	  were	  then	  scanned	  into	  a	  database	  electronically	  but	  the	  electronic	  
records	  were	  then	  checked	  by	  two	  members	  of	  the	  research	  team	  for	  accurate	  correlation	  
with	  the	  paper	  questionnaire	  and	  for	  missing	  data.	  	  
Setting 
A	  total	  of	  30	  secondary/tertiary	  care	  sites	  across	  the	  UK	  including	  the	  devolved	  nations	  of	  
Wales	   and	   Scotland	   participated	   in	   the	   study	   where	   general	   otorhinolaryngology	   or	  
subspecialist	  rhinology	  clinics	  managed	  patients	  referred	  from	  primary	  care.	  
Participants 
Patients	   were	   recruited	   at	   the	   point	   of	   referral	   to	   secondary	   care,	   regardless	   of	   prior	  
management	   in	   either	   primary	   or	   secondary	   care	   and	   regardless	   of	   prior	   surgical	  
intervention.	   They	  were	   classified	  by	   sub	  group	  of	  CRS	   (CRSsNPs,	  CRSwNPs	  or	  AFRS)	  by	   a	  
clinician	   on	   the	   basis	   of	   the	   endoscopic	   and/or	   CT	   findings,	   prior	   to	   completion	   of	   the	  
questionnaire.	   Controls	   who	   had	   no	   diagnosis	   of	   nose	   or	   sinus	   problems	   were	   recruited	  
from	   amongst	   family	   and	   friends	   of	   those	   attending	   ENT	   outpatient	   clinics	   (regardless	   of	  
cause)	  and	  from	  amongst	  hospital	  staff,	  provided	  they	  met	  the	  criteria	  below.	  
Inclusion criteria: 
Criteria	   for	   diagnosis	   of	   chronic	   rhinosinusitis	   (CRS)	   with	   or	   without	   polyps	   (EPOS	  
guidelines)(1):	  
Symptoms	  must	  be	  present	  for	  at	  least	  12	  weeks	  and	  include:	  
•   nasal	   blockage/obstruction/congestion	   and/or	   nasal	   discharge	   (anterior/posterior	  
nasal	  drip)	  
•   and	  either	  facial	  pain/pressure	  and/or	  reduction	  or	  loss	  of	  smell	  
and	  additionally:	  
•   endoscopic	   signs	   of:	   polyps	   and/or	  mucopurulent	   discharge	   primarily	   from	  middle	  
meatus	  and/or;	  oedema/mucosal	  obstruction	  primarily	  in	  middle	  meatus	  
•   and/or	  CT	  changes:	  mucosal	  changes	  within	  the	  ostiomeatal	  complex	  and/or	  sinuses	  
Patients	  classified	  as	  AFRS	  adhered	  to	  either	  the	  Bent	  and	  Kuhn	  criteria	  (see	  above)	  or	  the	  
modified	  Vancouver	  criteria	  (35).	  
	  
Exclusion criteria: 
•   Patients	  unable	  to	  comprehend	  written	  English.	  
•   Patients	  under	  the	  age	  of	  18	  years.	  
For the control group: 
•   patients	  with	  active	  sinonasal	  disease	  -­‐	  e.g.	  ARS,	  CRS,	  rhinitis	  
•   no	  medical	  co-­‐morbidity	  being	  actively	  treated	  
•   hospitalisation	  within	  the	  last	  12	  months	  
Variables and data sources 
The	   study	   questionnaire	   included	   various	   specific	   questions	   for	   allergy	   and	   asthma	   as	  
follows:	  
“Do	  you	  have	  any	  known	  confirmed	  allergies	   (on	  a	  skin	  prick	  or	  blood	  test)	  e.g	  house	  dust	  
mite?	  Yes/No”	  followed	  by	  a	  free	  text	  box	  asking	  participants	  to	  state	  any	  allergies.	  	  
“Do	  you	  have	  any	  suspected	  allergies?	  Yes/No”,	  also	  followed	  by	  a	  free	  text	  box.	  	  
“Have	  you	  ever	  experienced	  any	  allergy	  symptoms	  such	  as	  wheezing,	  runny	  nose	  or	  itchy	  skin	  
when	  taking	  aspirin?	  Yes/No”.	  	  
And	  under	   the	   topic	  of	  medical	   comorbidities,	  “Do	  you	  have	  any	  of	   the	   following	  medical	  
problems?:	  Asthma…”	  
Bias 
All	  of	  the	  comorbid	  conditions	  assessed	  were	  based	  on	  self-­‐reporting	  but	  the	  questionnaire	  
design	  and	  subsequent	  analysis	  was	   such	   that	   the	   impact	  of	   this	  has	  been	  minimized	  and	  
will	   be	   equal	   across	   all	   groups.	   Aspirin	   sensitivity	   was	   determined	   by	   asking	   specifically	  
about	   responses	   to	   aspirin	   that	   affect	   respiratory	   mucosa,	   such	   as	   wheezing	   and	  
rhinorrhoea,	   so	   that	   those	   with	   only	   gastrointestinal	   intolerance	   should	   not	   define	  
themselves	  as	  aspirin	  allergic	   for	   the	  purposes	  of	   this	  questionnaire.	  NSAID	   (non-­‐steroidal	  
anti-­‐inflammatory	  drug)	  allergy	  was	  not	  specifically	  enquired	  about	  but	  a	  free	  text	  box	  was	  
included	   for	   any	   additional	   allergies.	   Both	   asthma	   diagnosis	   and	   aspirin	   sensitivity	   are	  
therefore	   self-­‐reported,	   but	   the	   former	  was	   additionally	   correlated	  with	   reported	   asthma	  
medication.	  
 
Sample size calculation 
The	  sample	  size	  calculation	  was	  based	  on	  the	  primary	  outcome	  of	  the	  study	  which	  was	  to	  
look	   for	   common	  associations	  between	  socioeconomic	   factors	  and	  CRS.	  This	   is	  detailed	   in	  
the	  overview	  publication	  of	  the	  study	  (34).	  
	  
Statistical analysis 
For	   the	  purposes	   of	   these	   analyses	  we	  have	  used	  descriptive	   statistics;	   differences	   in	   the	  
rates	  of	  medication	  use	  between	  groups	  were	  assessed	  by	  Chi-­‐Squared	  tests	  and	  odds	  ratios	  
calculated. 
 
Results 
Participant flow and missing data 
Only	  participants	  with	  self-­‐reported	  confirmed	  or	  suspected	  allergies	  were	  included	  in	  this	  
analysis.	  
	  
Descriptive data 
A	   total	   of	   1,470	   participants’	   questionnaires	   were	   available	   for	   analysis;	   1249	   with	   CRS	  
(CRSsNP	   553,	   CRSwNP	   651,	   AFRS	   45)	   and	   221	   controls.	   The	   age	   range	  was	   17-­‐102	   years	  
(mean	  52)	  with	  54%	  reported	  as	  male.	  	  
	  
Main results 
Asthma 
Those	   with	   CRS	   were	  more	   likely	   to	   suffer	   from	   asthma,	   with	   those	   with	  more	   polypoid	  
subtypes	  even	  more	  likely	  to	  report	  asthma	  including	  the	  majority	  of	  those	  with	  AFRS	  (see	  
table	  1).	  
Aspirin 
Those	  with	  CRS	  were	  more	  likely	  to	  report	  aspirin	  sensitivity.	  In	  a	  similar	  manner	  to	  asthma,	  
those	  with	  increasing	  polypoid	  disease	  were	  increasingly	  likely	  to	  report	  aspirin	  sensitivity.	  
The	  odd	  ratio	  for	  aspirin	  sensitivity	  after	  adjustment	  for	  asthma	  diagnosis	  showed	  that	  only	  
those	  with	  AFRS	  were	  significantly	  more	  likely	  to	  report	  aspirin	  sensitivity	  (OR	  9.6,	  p<0.001).	  
There	  was	  no	  significant	   interaction	  between	  CRS	  type	  and	  asthma	  on	  the	  odds	  of	  aspirin	  
sensitivity;	   this	   indicates	   that	   aspirin	   sensitivity	   status	   is	   influenced	   by	   both	   asthma	  
diagnosis	   and	   CRS	   group	   independently.	   There	   were	   no	   significant	   differences	   between	  
males	  and	  females.	  
	  
Inhalant	  allergy	  
Those	  with	  CRS	  were	  also	  more	  likely	  to	  report	  having	  a	  confirmed	  inhalant	  allergy	  (via	  skin	  
prick	   test	  or	  RAST),	  with	   the	  pattern	  being	   the	   same	  as	   for	   asthma	  and	  aspirin	   sensitivity	  
above	  with	  significant	  differences	  compared	  to	  controls	  and	  with	  1	  in	  5	  CRSsNPs	  and	  1	  in	  3	  
polypoid	  CRS	  cases	  (table	  2).	  The	  most	  commonly	  confirmed	  allergen	  was	  house	  dust	  mite	  
followed	   by	   grass	   pollen	   (table	   3,	   figure	   2).	   An	   additional	   255	   participants	   reported	  
suspected	  allergy	  of	  which	  137	  reported	  sensitivity	  to	   inhalant	  allergens	  (118	  with	  CRS,	  19	  
controls).	  
	  
Discussion 
 
Key Results 
Our	  study	  has	  shown	  a	  significantly	  higher	  prevalence	  of	  both	  asthma	  and	  aspirin	  sensitivity	  
within	  the	  polypoid	  phenotypes	  of	  CRS.	  This	  reflects	  the	  substantial	  interaction	  between	  the	  
lower	  and	  upper	  airways	  and	  in	  particular	  between	  the	  underlying	  aetiological	  mechanisms	  
of	   airways	   pathology.	   Similar	   interaction	   is	   also	   found	   in	   those	   with	   allergic	   rhinitis	  
(ARIA)(36).	   	  Those	   in	   the	  AFRS	  subgroup	  have	  a	  very	  high	  prevalence	  of	  both	  asthma	  and	  
aspirin	  sensitivity	  that	  could	  indicate	  an	  overlap	  between	  AFRS	  and	  what	  may	  be	  AERD.	  	  The	  
prevalence	   of	   allergy	  within	   this	   large	   national	   sample	   of	   CRS	   patients	   at	   26%	   of	   all	   CRS	  
cases	   is	   towards	   the	   lower	   end	   of	   the	   range	   of	   allergy	   reported	   in	   the	   literature	   as	  
mentioned	  above,	   lending	  weight	   to	  allergy	  as	  an	  associative	   factor	   in	  CRS	  rather	   than	  an	  
aetiological	  factor.	  	  
Strengths and Limitations 
The	   study	   is	   a	   large	   cross-­‐sectional	   study	   including	   a	   varied	   population	   from	   across	   the	  
United	  Kingdom.	  It	  is	  the	  largest	  research	  study	  of	  CRS	  in	  the	  UK	  to	  date.	  In	  contrast	  to	  other	  
epidemiological	   studies	   in	   CRS,	   patients	   recruited	   were	   diagnosed	   by	   an	  
otorhinolaryngologist	   according	   to	   international	   guidelines.	   According	   to	   Asthma	   UK,	   the	  
prevalence	  of	  asthma	  in	  adults	  in	  the	  UK	  is	  1	  in	  12	  or	  8.3%,	  a	  similar	  number	  to	  our	  control	  
population.	  	  
A	   weakness	   of	   the	   study	   is	   that,	   with	   the	   exception	   of	   the	   diagnosis	   of	   CRS,	   it	   relies	   on	  
participants’	   self-­‐reported	   information.	  The	  questionnaire	  was	  worded	   to	  be	  as	  explicit	  as	  
possible	  so	  that	  participants	  were	  likely	  to	  pick	  the	  most	  accurate	  option,	  for	  example,	  the	  
question	   regarding	   aspirin	   allergy	   is	   phrased	   so	   as	   to	   identify	   respiratory	   and	   nasal-­‐type	  
allergy	   symptoms	   rather	   than	   gastrointestinal	   disturbances.	   Any	   potential	   error	   in	   self-­‐
reporting	  or	  recall	  should	  be	  equal	  across	  CRS	  groups	  so	  should	  not	  bias	  the	  results	  as	  far	  as	  
comparison	   between	   subgroups.	   It	   is	   not	   intended	   that	   these	   results	   be	   used	   as	   a	  
prevalence	  study	   for	  either	  condition	  amongst	   the	  general	  population,	  but	   they	  can	  show	  
prevalence	  of	  both	  aspirin	  allergy	  and	  asthma	  in	  a	  large	  cohort	  of	  CRS	  patients.	  	  
Despite	  clear	  criteria	  for	  the	  diagnosis	  of	  AFRS,	  some	  patients	  with	  nasal	  polyps	  who	  have	  
Samter’s	  triad	  could	  have	  been	  erroneously	  categorised	  in	  the	  AFRS	  group	  rather	  than	  the	  
CRSwNP	   group	   by	   clinicians.	   Controls	   had	   no	   self-­‐reported	   nasal	   symptoms	   but	   did	   not	  
undergo	   nasal	   examination.	   Conversely,	   diagnosis	   of	   AFRS	   requires	   vigilance	   and	   careful	  
investigation	   by	   clinicians	   (37),	   but	   is	   also	   limited	   by	   local	   laboratory	   facilities,	   so	   in	   this	  
multicentre	   study	   it	   is	   likely	   that	   some	  patients	   in	   the	  CRSwNPs	  category	  will	   in	   fact	  have	  
undiagnosed	   AFRS.	   Consequently,	   the	   association	   between	   AFRS	   and	   aspirin	  
sensitivity/asthma	  may	  be	  even	  stronger	  than	  has	  so	  far	  been	  described.	  
Interpretation 
CRS	   is	   known	   to	   be	   a	   complex	   spectrum	   of	   disease	   associated	   with	   respiratory	   co-­‐
morbidities.	  Basic	  phenotypes	  are	  currently	   recognized	  and	  we	  have	  shown	  their	  differing	  
associations	  with	  asthma	  and	  allergies;	  such	  phenotypes	  are	   likely	  to	  be	  refined	  over	  time	  
with	  new	  definitions	  that	  may	  reflect	  these	  results	  and	  include	  the	  presence	  or	  absence	  of	  
concomitant	  allergy	  or	  allergic	  response.	  	  
Those	   with	   AFRS	   were	   most	   likely	   to	   report	   sensitivity	   to	   aspirin.	   In	   AERD,	   the	  
pathophysiology	   includes	   changes	   in	   the	   metabolism	   of	   arachidonic	   acid,	   release	   of	  
inflammatory	   mediators	   and	   cytokines,	   and	   involvement	   of	   microorganisms	   including	  
bacteria	  and	  viruses	   (38).	  Abnormal	  metabolism	  of	  arachidonic	  acid	   is	  characterized	  by	  an	  
imbalance	   between	   cyclooxygenase	   (COX)	   and	   lipoxygenase	   pathways	   that	   results	   in	   an	  
overactive	   lipoxygenase	   pathway.	   This	   is	   accentuated	  with	   aspirin	   and	   non-­‐steroidal	   drug	  
ingestion	   in	   susceptible	   patients,	   leading	   to	   increased	   production	   of	   leukotrienes	   and	  
intensification	  of	  airway	  inflammation.	  A	  similar	  inflammatory	  mechanism	  might	  explain	  the	  
increased	   sensitivity	   to	   aspirin	   experienced	   by	   those	   with	   AFRS.	   Elevated	   release	   of	  
inflammatory	  mediators,	  such	  as	  histamine,	  have	  also	  been	  found	  to	  be	  elevated	   in	   those	  
suffering	   from	   CRSwNPs	   and	   aspirin	   The	   majority	   of	   patients	   with	   AERD	   are	   thought	   to	  
develop	   nasal	   polyps	   during	   the	   course	   of	   their	   disease	   (38).	   Their	   polyposis	   tends	   to	   be	  
more	  extensive	  and	  difficult	  to	  treat	  medically,	  as	  well	  as	  presenting	  with	  higher	  recurrence	  
rates	  after	  surgery,	   in	  a	  similar	  manner	  to	  those	  with	  AFRS	  (9),	  crossover	  of	  diagnoses	  are	  
therefore	  a	  strong	  possibility.	  Nasal	  tissue	  biopsy	  specimens	  from	  patients	  with	  AERD	  have	  
shown	  infiltration	  of	  eosinophils	  and	  degranulated	  mast	  cells.	  	  AERD	  is	  an	  acquired	  disorder	  
and	   aspirin	   hypersensitivity	   can	   occur	   in	   patients	   who	   already	   have	   chronic	   or	   allergic	  
rhinitis	  and	  asthma.	  
It	   is	   likely	   that	   some	  of	   those	  with	  CRS	  and	   inhalant	  or	   aspirin	   allergies	   are	  also	   suffering	  
with	  allergic	   rhinitis.	  Allergic	   rhinitis	   (AR)	   is	  clinically	  defined	  as	  a	  symptomatic	  disorder	  of	  
the	  nose	  induced	  after	  allergen	  exposure	  by	  an	  IgE-­‐mediated	  inflammation	  (39).	  Symptoms	  
themselves	   can	   be	   very	   similar	   to	   CRS,	   but	   the	   chronicity	   and	   pattern	   of	   symptoms	  may	  
differ,	   clinically	   the	   diagnoses	   often	   overlap.	   AR	   is	   very	   prevalent,	   and	   increasing,	   to	   the	  
extent	  that	  an	  international	  taskforce,	  ARIA	  (Allergic	  Rhinitis	  and	  its	  Impact	  on	  Asthma)	  was	  
set	  up	   to	   review	  epidemiology	  and	  management	  of	  AR.	  Both	  outdoor	   (pollen/spores)	  and	  
indoor	   (cats/dogs/house	   dust	   mite)	   allergens	   are	   implicated	   in	   AR	   and	   studies	   using	   the	  
ARIA	  classification	  show	  that	  over	  50%	  of	  patients	  sensitised	  to	  pollen	  suffer	  from	  persistent	  
rhinitis;	  this	  could	  include	  some	  of	  our	  cohort.	  The	  prevalence	  of	  IgE	  sensitisation	  to	  indoor	  
allergens	   is	   positively	   correlated	   with	   the	   frequency	   of	   asthma	   and	   its	   severity.	   Fungal	  
spores	  such	  as	  Alternaria	  have	  also	  been	  found	  to	  be	  associated	  with	  asthma	  as	  well	  as	  with	  
rhinitis	   (39).	   Local	   knowledge	   of	   environmental	   allergen	   patterns	   may	   alert	   clinicians	   to	  
likely	  causes	  of	  AR.	  
The	   evidence	  presented	  here	   supports	   that	   from	  a	   smaller	   study	   of	   51	   patients	   from	   the	  
Mayo	  clinic	  in	  1994	  (40),	  with	  our	  reported	  prevalence	  of	  both	  asthma	  and	  aspirin	  sensitivity	  
of	   58.8%	   and	   29.0%	   in	   the	   AFRS	   cohort	   comparable	   with	   their	   results	   of	   54%	   and	   27%	  
respectively.	  A	  much	  smaller	  Malaysian	  study	  reported	  a	  prevalence	  of	  asthma	  and	  aspirin	  
sensitivity	   as	   37.5%	   and	   25%	   respectively	   (41).	   Our	   study	   is	   the	   largest	   to	   consider	   a	  
spectrum	  of	  CRS	  disorders	  as	  well	  aspirin	  sensitivity	  and	  asthma	  diagnoses.	  AERD	  has	  been	  
found	   to	  affect	  0.3-­‐2.5%	  of	   the	  general	  population	   (38),	  a	   similar	   figure	   to	   the	  number	  of	  
participants	  who	  reported	  aspirin	  sensitivity	  amongst	  our	  control	  and	  CRSsNPs	  groups	  (3%	  
and	  4.2%	   respectively).	   This	   increased	  prevalence	  of	  aspirin	   sensitivity	   combined	  with	   the	  
presence	  of	  more	  severe	  sino-­‐nasal	  disease	  amongst	  those	  with	  AFRS	  may	  therefore	  reflect	  
a	  more	  complex	  pathophysiological	  process	  leading	  to	  its	  development	  (42).	  	  
Generalisability 
Polypoid	   types	   of	   CRS	  were	   associated	  with	   an	   increased	   prevalence	   of	   aspirin	   sensitivity	  
and	  inhalant	  allergies,	  and	  therefore	  we	  hypothesise	  that,	  clinically,	  this	  consideration	  may	  
be	  helpful	   in	   the	   early	   identification	  of	   patients	  who	  are	  more	   likely	   to	   suffer	   from	  more	  
severe	  sinus	  disease,	  both	   in	  primary	  and	  secondary	  care.	  The	  diagnosis	  of	  concurrent	  AR	  
should	   also	   be	   considered	   in	   all	   patients	   with	   CRS,	   carefully	   history	   taking	   should	   alert	  
clinicians	  to	  the	  need	  for	   formal	  allergy	  testing.	  Treatment	  of	   rhinitis	   is	   thought	  to	  reduce	  
asthma	  severity,	  so	  prompt	  treatment	  has	  an	   impact	  on	  both	  upper	  and	  lower	  respiratory	  
tract	  symptoms	  (43).	  Patients	  themselves	  report	  experiencing	  upper	  and	  lower	  respiratory	  
symptoms	  which	  exacerbate	  each	  other.	  Care,	  however,	   is	  normally	  very	  divided	  between	  
ENT	  and	  Respiratory	  medicine	  with	   separate	   clinic	   teams	   for	  upper	   and	   lower	   respiratory	  
symptoms.	   In	   the	  UK,	  dedicated	  allergists	  are	  still	  only	   few	   in	  number,	  and	  many	  patients	  
with	   allergies	   will	   never	   consult	   directly	   with	   an	   allergist.	   Patients	   report	   difficulty	   in	  
accessing	  care	  which	  takes	  both	  upper	  and	   lower	  respiratory	  symptoms	   into	  account,	  and	  
this	   should	   be	   considered,	   with	   combined	   clinics	   or	   close	   working	   relationships	   likely	   to	  
improve	  quality	  and	  efficiency	  of	  care	  (44).	  Patients	  with	  asthma	  and/or	  allergies	  have	  been	  
found	   to	   be	  more	   likely	   to	   experience	  delayed	   surgical	   intervention,	   and	  delayed	   surgical	  
intervention	   itself	   has	   been	   found	   to	   lead	   to	   less	   improvement	   in	   symptoms	   than	   early	  
surgery	   (38).	   Patients	  with	   asthma	  and	  aspirin	  or	   inhalant	   allergies	  may	   therefore	  benefit	  
from	  more	  aggressive	  treatment	  including	  timelier	  referral	  to	  specialist	  services	  and	  united	  
approach	  from	  the	  clinicians	  involved.	  	  
Patients	   with	   AERD	   are	   more	   likely	   to	   suffer	   from	   allergies	   in	   general	   (9),	   it	   may	   be	  
important	   to	   consider	   testing	   for	   such	   allergies	   more	   comprehensively.	   Desensitisation	  
should	   always	   been	   considered	   in	   patients	   with	   severe	   aspirin	   or	   inhaled	   allergies.	   The	  
current	  diagnostic	  criteria	  for	  AFRS	  (5)	  do	  not	  include	  aspirin	  sensitivity	  as	  a	  minor	  criterion,	  
but	   our	   results	   suggest	   that	   as	   aspirin	   sensitivity	   occurs	   in	   40%	   of	   patients	   with	   AFRS,	  
consideration	   should	   be	   given	   to	   including	   it	   amongst	   the	   additional	   factors	   along	   with	  
asthma	  ,	  Charcot-­‐Leyden	  crystals	  and	  	  peripheral	  eosinophilia.	  
Conclusion 
The	   prevalence	   of	   asthma	   and	   allergy	   in	   CRS	   varies	   by	   phenoytype	   with	   polypoid	  
phenotypes	  having	  a	  stronger	  association	  with	  both.	  Aspirin	  exacerbated	  respiratory	  disease	  
has	   a	   large	   overlap	   with	   allergic	   fungal	   rhinosinusitis	   suggesting	   some	   common	  
pathophysiology.	  All	  of	  these	  comorbidities	  are	  significantly	  more	  prevalent	  than	  in	  non-­‐CRS	  
controls	   and	   strengthen	   the	   need	   for	   a	   combined	   airways	   approach	   to	   inflammatory	  
respiratory	   tract	   disease	   with	   particular	   attention	   to	   assessment	   of	   allergy	   status.	   Large-­‐
scale	  studies	  with	  objective	  assessment	  of	  allergy	  status	  would	  help	  to	  unravel	  any	  shared	  
pathophysiology	  between	  these	  diseases	  and	  could	  guide	  more	  efficient	  management.	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  Table 1. Asthma and aspirin sensitivity 
 
	     Factor   Total	  
number  
Asthma	  
(%)	  
Frequency	  
of	  Aspirin	  
Sensitivity	  
(%)  
Odds	  Ratio	  
for	  aspirin	  
sensitivity	  
(95%	  CI)  
p-­‐
value	  
for	  OR  
OR	  for	  
aspirin	  
sensitivity,	  
adjusted	  
for	  asthma	  
diagnosis  
p-­‐
value	  
for	  OR  
Group   Control   221   22	  
(9.95)	  
5	  (2.26)   1   	     1   	    
CRSsNP   553   117	  
(21.16)	  
18	  (3.25)   1.45  
(0.53,	  3.96)  
0.465   1.03	    
(0.37,	  2.88)  
0.948  
CRSwNP   651   303	  
(46.90)	  
62	  (9.61)   4.59	    
(1.82,	  
11.58)  
<0.001   2.00	    
(0.76,	  5.25)  
0.158  
AFRS   45   33	  
(73.33)	  
18	  (40.0)   28.8	    
(9.89,	  83.8)  
<0.001   9.6	  	  	  	  	  	    
(3.12,	  
29.63)  
<0.001  
Asthma   No   968   	  	   21	  (2.12)   	     	     	     	    
Yes   392	     	  	   82	  (17.3)   9.64  
(5.89,15.79)  
<0.001   	     	    
 
Table 2: Inhalant allergy by subgroup 
	  	   Frequency	  of	  
confirmed	  
inhalant	  
allergy	  
%	   Percentage	  
difference	  
compared	  to	  
controls	  
Confidence	  
interval	  
	  	  
p-­‐value	  
Control	   29	   13.1	   	  N/A	   	  N/A	  
	  	  
N/A	  
CRSsNPs	   112	   20.3	   7.2	   1.0756	  to	  12.6
934	  
P	  =	  0.0192	  
CRSwNPs	   202	   31.0	   17.9	   11.6327	  to	  23.
4675	  
P	  <	  0.0001	  
AFRS	   15	   33.3	   19.9	   5.6506	  to	  36.0
499	  
P	  =	  0.0011	  
	  
 
 
 
  
Table 3: Confirmed inhalant allergens 
Allergen	   Frequency	  
House	  dust	  mite	   163	  
Grass	  pollen	   113	  
Other	  pollens	   38	  
Cat	   87	  
Dog	   50	  
	  
  
Figure 1: Participant Flow 
 
 
 
 	  
1470 
questionnaires 
returned
360 Reported "yes" 
for confirmed 
allergy
339 Completed free 
text box
273 inhalant 
allergies
66 non-inhalant 
allergies
21 didn't complete 
free text box or 
gave non-specific 
response
1110 Reported "no" 
for confirmed 
allergy
255 reported "yes" 
for suspected 
allergy
137 suspect 
inhalant allergy
1249 CRS
221 controls
Figure 2: Frequency of confirmed inhalant allergy in CRS participants 
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Abstract	  
Background	  
International	   guidelines	   exist	   for	   the	   medical	   management	   of	   patients	   with	   chronic	  
rhinosinusitis	   (CRS)	   in	   both	   primary	   and	   secondary	   care.	   Patients	   being	   referred	   to	  
secondary	  care	  should	  have	  failed	  primary	  medical	  treatment	  with	  nasal	  douching	  (ND)	  and	  
intranasal	  corticosteroids	  (INCS)	  to	  qualify	  for	  referral.	  
Objectives	  
•   To	   identify	   the	   rate	  of	   specific	   concurrent	  medical	   therapy	   in	  CRS	  patients	   referred	   to	  
secondary	  care.	  
•   To	   establish	   any	   differences	   in	   medication	   use,	   for	   both	   CRS	   and	   general	   medical	  
problems,	  between	  CRS	  patients	  and	  controls	  and	  between	  CRS	  phenotypes.	  
	  
Methods	  
Participant-­‐reported	   study-­‐specific	   questionnaire	   capturing	   free	   text	   data	   on	   current	  
medication	  use	  at	  the	  time	  of	  study	  entry.	  Participants	  included	  CRS	  patients	  both	  without	  
(CRSsNPs)	   and	   with	   polyps	   (CRSwNPs)	   and	   the	   subgroup	   of	   allergic	   fungal	   rhinosinusitis	  
(AFRS).	  Qualitative	   interviews	  with	  21	  patients	  with	  CRS	  also	  explored	   their	  experience	  of	  
CRS	  and	  its	  management.	  
Results	  
From	  a	  total	  of	  1470	  study	  participants,	  1243	  CRS	  patients	  and	  221	  controls	  were	  included	  
in	  the	  final	  analysis.	  INCS	  were	  being	  used	  by	  18%	  of	  participants	  with	  CRSwNPs	  and	  12%	  of	  
those	  with	  CRSsNPs;	  ND	  was	  being	  performed	  by	  1%	  of	  all	  CRS	  participants.	  Bronchodilators	  
and	   inhaled	   corticosteroids	   were	   being	   used	   by	   16%	   and	   20%	   of	   CRSwNPs	   participants	  
respectively	   as	   compared	   to	   only	   8%	   and	   9%	   of	   CRSsNPs	   participants	   (p	   <	   0.0001).	  
Antidepressants	  were	   being	   taken	  by	   14%	  of	   CRSsNPs	   participants	   as	   compared	   to	   7%	  of	  
CRSwNPs	   participants	   (p	   <	   0.0002).	   Other	   trends	   in	   relation	   to	   antihypertensives	   and	  
analgesics	  were	  identified.	  
Conclusions	  
Despite	   the	   existence	   of	   guidelines	   for	   the	  medical	  management	   of	   CRS	   in	   primary	   care,	  
uptake	   of	   this	   appears	   to	   be	   very	   low.	   This	   is	   likely	   to	   represent	   a	   combination	   of	   poor	  
patient	   compliance	   and	   a	   lack	   of	   familiarity	   with	   current	   guidelines	   amongst	   general	  
practitioners.	  Work	   is	  needed	  to	  disseminate	  guidelines	  to	  all	  practitioners	   involved	   in	  the	  
care	  of	  CRS	  patients	  to	  reduce	  unnecessary	  burden	  on	  existing	  healthcare	  resources	  for	  this	  
common	  condition.	  
	   	  
Background  
Chronic	   rhinosinusitis	   (CRS)	   affects	   a	   significant	  proportion	  of	   the	  adult	  population	  with	  a	  
recent	  European	  study	  suggesting	  a	  prevalence	  of	  11%	  in	  the	  UK	  1.	  Longitudinal	  data	  from	  
the	  Clinical	  Practice	  Research	  Datalink	  (CPRD)	  shows	  that	  1%	  these	  affected	  adults	  receive	  
treatment	   from	   their	   GP	   each	   year	   with	   an	   average	   of	   4	   GP	   visits	   and	   additionally	   this	  
includes	  prescription	  of	  multiple	  medications	  with	  91%	  receiving	  an	  antibiotic	  prescription	  2.	  
There	  are	  no	  NICE	  guidelines	   and	  although	   international	   guidelines	  exist	   3	  4	   the	  uptake	  of	  
them	  is	  not	  quantified.	  These	  guidelines	  recommend	  both	  intranasal	  corticosteroids	  (INCS)	  
and	  saline	  irrigation/nasal	  douching	  (ND),	  for	  which	  there	  are	  strong	  recommendations	  for	  
use,	  based	  on	  recent	  Cochrane	  reviews	  5-­‐7.	  Hospital	  Episode	  Statistics	  (HES)	  Data	  shows	  that	  
approximately	   40,000	   sinus	   operations	   are	   performed	   in	   England	   and	   Wales	   each	   year,	  
which	  is	  the	  progression	  of	  management	  when	  medical	  treatment	  in	  isolation	  has	  failed	  8.	  A	  
recent	   ENT-­‐UK	   commissioning	   guideline	   underpins	   the	   need	   for	   adequate	   medical	  
management	   before	   referral	   to	   secondary	   care	   and	   possible	   surgical	   intervention	   9.	   In	   a	  
recent	  Canadian	  study	  it	  was	  demonstrated	  that	  only	  20%	  of	  patients	  with	  established	  CRS	  
were	  taking	  their	  INCS,	  thus	  identifying	  a	  gap	  in	  the	  quality	  of	  care	  10.	  Given	  that	  there	  are	  
an	  estimated	  120,000	  outpatient	  encounters	  for	  CRS	  per	  year	  in	  England	  and	  Wales	  11,	  this	  
could	  represent	  an	  inappropriate	  referral	  rate	  of	  80%	  at	  a	  cost	  of	  over	  £15	  million.	  
The	  aim	  of	   this	   specific	   analysis	  of	   the	  data	   from	   the	  Chronic	  Rhinosinusitis	   Epidemiology	  
Study	   (CRES)	   was	   to	   quantify	   the	   use	   of	   medications	   specific	   to	   CRS	   and	   for	   other	   co-­‐
morbidities	   at	   the	   point	   of	   referral	   to	   secondary	   care	   and	   thus	   determine	   the	   degree	   of	  
compliance	  with	  medical	  management	  of	  CRS	  in	  primary	  care.	  The	  expected	  gold	  standard	  is	  
that	  all	  patients	  referred	  to	  secondary	  care	  should	  be	  compliant	  with	  ND	  and	  INCS	  use.	  
Methods  
The	   CRES	   was	   approved	   by	   the	   Oxford	   C	   Research	   Ethics	   Committee,	   sponsored	   by	   the	  
University	  of	  East	  Anglia	  (UEA)	  and	  funded	  by	  the	  Anthony	  Long	  and	  Bernice	  Bibby	  Trusts.	  
The	   study	  was	   conducted	   as	   a	   prospective	   case-­‐control	  multi-­‐centre	   study	   across	   the	  UK	  
involving	   30	   sites.	   Any	   patients	   presenting	   to	   secondary	   care	   ENT	   outpatient	   clinics	   and	  
diagnosed	  with	  CRS	   as	   defined	  by	   the	   criteria	   laid	  out	   in	   the	   European	  Position	  Paper	  on	  
Rhinosinusitis	  and	  Nasal	  Polyps	  4	  by	  an	  Otorhinolaryngologist,	  were	  invited	  to	  participate	  in	  
the	  study	  regardless	  of	  symptom	  or	  disease	  severity	  or	  duration,	  and	  regardless	  of	  any	  prior	  
interventions.	   Control	   subjects	   were	   also	   recruited	   but	   do	   not	   form	   part	   of	   this	   specific	  
analysis.	  
The	  study	  specific	  questionnaire	  was	  anonymous	  and	  therefore	  no	  consent	  was	  taken	  but	  
implied	  through	  participation.	  Participant	  information	  leaflets	  were	  provided.	  	  Patients	  were	  
classified	  by	  sub	  group	  of	  CRS	  (CRSsNPs,	  CRSwNPs	  or	  allergic	  fungal	  rhinosinusitis	  (AFRS)	  by	  
a	  clinician	  prior	  to	  completion	  of	  the	  questionnaire.	  Questionnaires	  were	  either	  completed	  
before	   leaving	   the	   clinic	   or	   taken	  home	  and	   returned	  by	  post	   in	   Freepost	   envelopes.	   The	  
returned	  questionnaires	  were	  then	  scanned	  into	  a	  database	  electronically	  but	  the	  electronic	  
records	  were	  then	  checked	  by	  two	  members	  of	  the	  research	  team	  for	  accurate	  correlation	  
with	  the	  paper	  questionnaire	  and	  for	  missing	  data.	  	  
The	   study	   questionnaire	   included	   the	   question	   “Do	   you	   have	   any	   regular	   medications?	  
Yes/No”	  followed	  by	  a	  free	  text	  box	  asking	  participants	  to	  list	  any	  current	  medication	  use.	  	  
The	   qualitative	   arm	   of	   the	   study	   was	   undertaken	   in	   2012.	   This	   consisted	   of	   qualitative	  
interviews	   with	   21	   patients	   with	   CRS	   to	   explore	   their	   experiences	   of	   CRS	   and	   its	  
management.	   These	   patients	   were	   all	   recruited	   via	   the	   Rhinology	   clinic	   at	   James	   Paget	  
University	  Hospital,	  Great	  Yarmouth.	  Results	  from	  this	  study	  are	  published	  in	  full	  separately	  
12	  13	  but	  results	  relevant	  to	  this	  analysis	  are	  considered	  here.	  	  
	  
Sample size calculation 
	  
The	  sample	  size	  calculation	  was	  based	  on	  the	  primary	  outcome	  of	  the	  study,	  which	  was	  to	  
look	   for	   common	  associations	  between	  socioeconomic	   factors	  and	  CRS.	  This	   is	  detailed	   in	  
the	  overview	  publication	  of	  the	  study	  14.	  For	  the	  purposes	  of	  these	  analyses	  we	  have	  used	  
descriptive	   statistics;	   differences	   in	   the	   rates	   of	   medication	   use	   between	   groups	   were	  
assessed	  by	  Chi-­‐Squared	  tests.	  
	  
Results 
A	  total	  of	  1,470	  participants’	  questionnaires	  were	  available	  for	  analysis;	  1249	  with	  CRS	  and	  
221	  controls.	  The	  age	  range	  was	  17-­‐102	  years	  (mean	  52)	  with	  54%	  reported	  as	  male.	  	  
	  
Participant flow 
As	  detailed	  in	  figure	  1,	  6	  participants	  had	  incomplete	  information	  in	  the	  medication	  section	  
of	   the	  questionnaire,	   leaving	  1243	  participants.	  A	   total	  of	  899	  had	  answered	  positively	   to	  
taking	  medications	  with	  a	  respective	  850	  having	  recorded	  details	  of	  medications	  taken.	  As	  
the	  AFRS	  group	  was	  small,	  we	  have	  merged	   it	  with	  the	  CRSwNPs	  group	  and	  analysed	  only	  
the	  two	  main	  CRS	  phenotypic	  groups	  and	  the	  controls. 
	  
Missing data 
Subjects	  identified	  in	  figure	  1	  with	  missing	  data	  were	  excluded	  from	  the	  analysis	  in	  keeping	  
with	  the	  primary	  aim	  of	  this	  analysis.	  Table	  1	  shows	  further	  details	  of	  the	  excluded	  cases	  on	  
the	  basis	  of	  the	  text	  box	  entries.	  
	  
Baseline therapy for CRS 
Only	   1%	  of	   CRS	  participants	   reported	   the	  use	   of	  ND	   and	  only	   15%	  of	   all	   CRS	  participants	  
reported	  using	   INCS	  with	  a	  significantly	  higher	  uptake	   in	  the	  CRSwNPs	  group	  (18.4%)	  than	  
the	  CRSsNPs	  group	  (11.8%)	  (p=0.002).	  Oral	  corticosteroid	  and	  antibiotic	  use	  at	  the	  time	  of	  
participants	  completing	  the	  questionnaire	  was	  low	  (1-­‐3%).	  	  
Asthma-related medications 
Table	  3	  shows	  the	  use	  of	  asthma-­‐related	  inhalers	  that	  are	  found	  to	  be	  significantly	  higher	  in	  
the	   CRSwNPs	   group	   (16%	   and	   20%	   versus	   8%	   and	   9%	   for	   non-­‐steroidal	   and	   steroidal	  
inhalers).	  This	  is	  however	  much	  lower	  than	  the	  reported	  rates	  of	  asthma	  in	  the	  two	  groups	  
(21%	  and	  51%).	  
Non-CRS medications 
Analysis	  of	  the	  remaining	  therapeutic	  groups	  noted	  some	  key	  differences	  between	  the	  two	  
phenotypic	   groups	   as	   charted	   in	   table	   4.	   ACE-­‐inhibitors	   and	   α-­‐blockers	   were	   significantly	  
more	  prevalent	  in	  CRSwNPs	  and	  β-­‐blockers,	  NSAIDs	  and	  opiate	  analgesics	  significantly	  more	  
prevalent	  in	  CRSsNPs.	  
CRS and Mood disturbances 
The	  rates	  of	  depression	  and	  anxiety	  in	  CRS	  have	  been	  reported	  elsewhere	  15	  16,	  however	  it	  is	  
pertinent	   to	   note	   that	   despite	   reporting	   much	   higher	   rates	   of	   depression,	   the	   use	   of	  
antidepressants	  are	  much	  lower	  with	  the	  highest	  uptake	  in	  the	  CRSsNPs	  group.	  
Qualitative study 
The	  qualitative	  sub-­‐study	  found	  that	  patients	  reported	  issues	  with	  prescribed	  treatment	  in	  
primary	  care	   13.	  Most	  participants	  described	  several	   courses	  of	  different,	  often	   ineffective	  
treatments,	  which	  were	  not	  always	  reviewed.	   	   It	  was	  clear	  that	  referral	   to	  secondary	  care	  
based	  on	  a	  lack	  of	  symptomatic	  response	  to	  3	  months	  of	  topical	  treatment	  did	  not	  always	  
occur	  for	  our	  participants	  due	  to	  both	  patient	  and	  clinician	  preferences.	  
‘On	  and	  off	  I’ve	  used	  nasal	  sprays,	  it	  was	  a	  sort	  of	  a	  bit	  hit	  and	  miss	  really	  I	  might	  think	  ‘oh	  
it’s	  a	  bit	  bad	  I’ll	  go	  to	  the	  chemist	  and	  get	  something’’.	  
“I’ve	  now	  obviously	  got	  to	  do	  (a	  nasal	  spray)	  (after	  being	  seen	  in	  secondary	  care)	  but	  I’ve	  
only	  ever	  had	  that	  once…	  a	  lot	  of	  the	  time.	  I	  would	  have	  antibiotics	  and	  that	  would	  clear	  it	  
very	  briefly’	  
Most  described  several  courses  of  different,  often  ineffective  treatments,  which  were  
not  always  reviewed.  
‘Everything  I  tried  was  so  random.’  Patient  17  
‘I  was  put  onto  Betnesol  nasal  drops,  remained  on  them  until  last  year  [without  
significant  benefit.  Patient  had  been  on  this  treatment  for  40  years].  Patient  8  
There  were  negative  views  and  misconceptions  about  topical  medications.  
‘The  nasal  sprays  they  make  it  a  lot  worse... it  irritates  my  eyes  and  stuff  to  the  point  
where  I’m  sneezing  100  times  and  you  know  it  just  comes  out  and  I  can’t  keep  it  in’  
‘If  that  cost  £10,000  for  an  operation  that’s  £2,000  for  drugs  they  go  cheap  route.’  
Discussion 
 
Strengths and Limitations 
The	   study	   is	   a	   large	   cross-­‐sectional	   study	   including	   a	   varied	   population	   from	   across	   the	  
United	  Kingdom.	   It	   is	   the	   largest	  research	  study	  of	  CRS	   in	  UK	  to	  date.	   In	  contrast	  to	  other	  
epidemiological	   studies	   in	   CRS,	   patients	   recruited	   were	   diagnosed	   by	   an	  
otorhinolaryngologist	   according	   to	   international	   guidelines.	   The	   study	   design	   had	   some	  
imitations,	   it	  was	  a	  self-­‐reported	  study	  which	  predisposes	   to	   recall	  bias.	   It	   is	  possible	   that	  
some	   patients	   may	   not	   have	   considered	   intranasal	   medications	   when	   asked	   about	  
medication	  use,	  however	  they	  have	  reported	  inhalers	  so	  we	  expect	  that	  the	  impact	  of	  this	  
on	   the	   study	   findings	   is	   small.	   They	   may	   have	   also	   not	   considered	   ND	   as	   a	   regular	  
medication,	  however	  both	  our	  qualitative	  work	  and	  anecdotal	  evidence	  from	  GP	  meetings	  
suggests	   that	   advice	   regarding	  ND	   in	  primary	   care	   is	   scarce	   and	   steam	   inhalation	   is	  more	  
often	  recommended	  to	  patients.	  From	  qualitative	  interviews	  we	  know	  that	  some	  it	  difficult	  
to	  integrate	  ND	  into	  the	  daily	  routine,	  but	  others	  find	  it	  tolerable	  or	  helpful	  17.	  
The	  low	  prevalence	  of	  use	  of	  CRS	  medication	  may	  reflect	  poor	  prescribing,	  poor	  adherence	  
to	  the	  prescription	  or	  poor	  recall.	  It	  may	  also	  reflect	  the	  fact	  that	  sprays	  and	  rinses	  are	  more	  
burdensome	   to	   use	   than	   taking	   tablets,	   as	   described	   in	   our	   qualitative	   interviews	   or	   that	  
they	  are	  not	  seen	  as	  ‘proper’	  medications	  since	  they	  are	  sprays	  not	  tablets	  15	  18.	  
Looking	  at	   the	  wider	  picture,	  one	   international	  study	  demonstrated	  that	  one	   in	   three	  CRS	  
patients	   in	  primary	   care	  have	  poorly	   controlled	   symptoms	   19	  which	   is	   in	   keeping	  with	   the	  
feedback	   from	   our	   participants	   in	   the	   qualitative	   sub-­‐study.	   The	   rhinosinusitis	  
commissioning	   guidelines	   produced	   by	   ENT	   UK	   in	   conjunction	   with	   the	   Royal	   College	   of	  
Surgeons	  of	  England	  recommend	  that	  CRS	  patients	  have	  received	  ND	  and	  INCS	  for	  3	  months	  
before	   referral	   to	   secondary	   care	   20	   and	   this	   is	   based	   on	   the	   European	   position	   paper	   of	  
which	   there	   is	  a	   summary	  version	   for	  GPs	   21.	  However	   this	  poor	  compliance	  with	  primary	  
medical	  treatment	  is	  not	  unique	  to	  the	  UK	  as	  shown	  by	  the	  recent	  Canadian	  study	  showing	  
the	  same	  rate	  of	  INCS	  uptake	  (20%)	  and	  with	  large	  geographical	  variations	  10.	  another	  study	  
of	  60	  patients	  following	  endoscopic	  sinus	  surgery	  found	  that	  	  overall,	  57.4%	  of	  patients	  were	  
non-­‐adherent	  to	  their	  prescribed	  nasal	  medication	  regime	  22.	  
With	   regards	   to	   non-­‐CRS	  medications,	   use	   of	   steroid	   and	  non-­‐steroid	   inhalers	  was	   higher	  
amongst	   those	   with	   CRSsNPs.	   	   This	   was	   likely	   to	   be	   due	   to	   their	   higher	   prevalence	   of	  
asthma.	  Use	  of	  β-blockers	  and	  NSAIDs	  were	  lower	  in	  this	  group,	  which	  was	  also	  likely	  to	  be	  
due	   to	   a	   higher	   prevalence	   of	   asthma	   (contra-­‐indicated).	   Use	   of	   α-­‐blockers	   was	   higher	  
amongst	  CRSwNPs	  and	  since	  it	  is	  mostly	  used	  for	  prostatic	  hypertrophy,	  the	  difference	  may	  
be	   due	   to	   a	   male	   preponderance	   in	   this	   group.	   It	   is	   harder	   to	   explain	   the	   difference	   in	  
antidepressant	  use,	  but	   it	  correlates	  with	  findings	  that	  mood	  and	  emotional	  wellbeing	  are	  
poorer	   in	   those	  without	   polyps	   and	   is	   discussed	  with	   the	   qualitative	   results	   (Erskine	   and	  
Philpott	  2014,	  Erskine,	  Hopkins	  et	  al.	  2016).	  
Non-­‐compliance	   is	   an	   important	   issue,	   particularly	   in	   the	   management	   of	   chronic	  
conditions.	   These	   findings	   are	   consistent	  with	   a	  World	  Health	  Organization	   report,	  which	  
stated	  that,	  on	  average,	  50%	  of	  patients	  are	  not	  adherent	  to	  long-­‐term	  therapy	  for	  chronic	  
illnesses.	   They	   stated	   that	   poor	   adherence	   is	   the	   primary	   reason	   for	   suboptimal	   clinical	  
benefit	  in	  chronic	  diseases,	  causing	  medical	  and	  psychosocial	  complications	  of	  the	  disease,	  
reducing	  quality	  of	  life,	  and	  wasting	  health	  care	  resources	  23.	  Careful	  patient	  education	  may	  
help	  improve	  this	  situation.	  	  
	  
Conclusion 
Despite	   the	   existence	   of	   national,	   European	   and	   International	   guidelines	   for	   the	  medical	  
management	  of	  CRS	  in	  primary	  care,	  uptake	  of	  this	  appears	  to	  be	  very	  low.	  This	  is	  likely	  to	  
represent	  a	  combination	  of	  poor	  patient	  compliance	  and	  a	   lack	  of	   familiarity	  with	  current	  
guidelines	   amongst	   general	   practitioners.	   Work	   is	   needed	   to	   understand	   any	   barriers	   to	  
implementing	  guidelines	  including	  disseminate	  them	  to	  all	  practitioners	  involved	  in	  the	  care	  
of	  CRS	  patients	  and	  to	  encourage	  good	  compliance	  with	  treatment.	  Improvement	  of	  medical	  
management	  may	  serve	  to	  reduce	  unnecessary	  burden	  on	  existing	  healthcare	  resources	  for	  
this	  common	  condition.	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Table 1: Medications reported by subgroup 
	  
	  
*Other	   included	  any	  medication	  which	  did	  not	   fit	   into	  any	  particular	   group.	   Examples	   include	  eye	  
drops,	  skin	  creams.	  
**Reasons	   for	   exclusion	   included:	  Unknown	  medication,	   condition	   stated	   rather	   than	  medication,	  
insufficient	  information.	  	  
 
  
Medication   CRSwNPs  (n=651)   CRSsNPs  (n=553)  
Antihistamines   64  (9.83%)   46  (8.32%)  
Hormone  Replacement  Therapy   6  (0.92%)   12  (2.17%)  
Antihypertensive  (Unspecified)   18  (2.76%)   13  (2.35%)  
ACE  Inhibitor   45  (6.91%)   23  (4.16%)  
Antihypertensive    
(Other  –  Including  Bendrofluazide)  
66  (10.14%)   47  (8.50%)  
Steroid  (Oral)   12  (1.84%)   16  (2.89%)  
Analgesic  (Unspecified)   3  (0.46%)   1  (0.18%)  
Opiate  Analgesic   20  (3.07%)   35  (6.33%)  
Non-­Opiate  Analgesic   11  (1.69%)   18  (3.25%)  
Statin   88  (13.52%)   65  (11.75%)  
Thyroid  Hormone   24  (3.69%)   28  (5.06%)  
Nasal  Spray  (Unspecified)   8  (1.23%)   14  (2.53%)  
Steroid  Nasal  Spray   120  (18.43%)   65  (11.75%)  
Non-­Steroid  Nasal  Spray   4  (0.61%)   4  (0.72%)  
Inhaler  (Unspecified)   42  (6.45%)   13  (2.35%)  
Steroid  Inhaler   141  (21.66%)   51  (9.22%)  
Non-­Steroid  Inhaler   105  (16.13%)   42  (7.59%)  
Antiplatelet/Anticoagulant  (Inc.  Aspirin)   48  (7.37%)   41  (7.41%)  
Anticonvulsant   13  (2.00%)   16  (2.89%)  
Proton  Pump  Inhibitor   63  (9.68%)   60  (10.85%)  
Vitamin/Mineral  Replacement   28  (4.30%)   23  (4.16%)  
Laxative   2  (0.31%)   2  (0.36%)  
Diuretic  (Exc.  Bendrofluazide)   7  (1.08%)   5  (0.90%)  
Antidepressant   46  (7.07%)   75  (13.56%)  
NSAID  (Exc.  Aspirin)   11  (1.69%)   27  (4.88%)  
Antibiotic   10  (1.54%)   16  (2.89%)  
Sinus  Rinse   9  (1.38%)   5  (0.90%)  
Alpha  Blocker  (Inc.  Doxazosin)   31  (4.76%)   13  (2.35%)  
Beta  Blocker   17  (2.61%)   32  (5.79%)  
DMARD/Biologic  Agent    
(Inc.  Methotrexate)  
6  (0.92%)   4  (0.72%)  
Other*   156  (23.96%)   102  (18.44%)  
Excluded**   23  (3.53%)   21  (3.80%)  
Table 2: CRS-related medication use 
Medication	   CRSwNPs	  (n=651)	   CRSsNPs	  (n=553)	   p	  
INCS	   122	  (18.74%)	   67	  (12.12%)	   0.002	  
Antihistamines	   64	  (9.83%)	   46	  (8.32%)	   0.363	  
Nasal	  Spray	  (Unspecified)	   23	  (3.53%)	   14	  (2.53%)	   0.317	  
Steroid	  (Oral)	   12	  (1.84%)	   16	  (2.89%)	   0.2360	  
Antibiotic	   10	  (1.54%)	   16	  (2.89%)	   0.107	  
Sinus	  Rinse	  	   11	  (1.69%)	   5	  (0.9%)	   0.234	  
 
Table 3: Asthma-related medication use 
Medication	   CRSwNPs	  (n=651)	   CRSsNPs	  (n=553)	   p-­‐value	  
Steroid	  Inhaler	   132	  (20.28%)	   48	  (8.68%)	   <0.0001	  
Non-­‐Steroid	  
Inhaler	  
105	  (16.13%)	   42	  (7.59%)	   <0.0001	  
Inhaler	  
(Unspecified)	  
42	  (6.45%)	   13	  (2.35%)	   0.0007	  
 
Table 4: Other medications with noticeable subgroup variations 
Medication	   CRSwNPs	  (n=651)	   CRSsNPs	  (n=553)	   p-­‐value	  
ACE	  Inhibitor	   45	   6.91	   23	   4.16	   0.040	  
Alpha	  Blocker	  	  
(Inc.	  Doxazosin)	  
31	   4.76	   13	   2.35	   0.026	  
Opiate	  Analgesic	   20	   3.07	   35	   6.33	   0.007	  
Beta	  Blocker	   17	   2.61	   32	   5.79	   0.005	  
NSAID	  (Exc.	  Aspirin)	   11	   1.69	   27	   4.88	   0.002	  
 
Table 5: Comparative reports of depression and antidepressant use 
 Consultation	  with	  GP	  for	  
depression	  (%)	  
Antidepressant	  use	  (%)	  
Controls	   15.3	   6.3	  
CRSsNP	   24.6	   13.6	  
CRSwNP	   20.0	   7.1	  
 
  
Figure 1: Participant Flow 
 
	  
Total usable 
questionnaires 
returned 1470
CRS participants 
1243
No medications 
taken 344
Medications taken 
899
Medications 
recorded 850
Excluded 44
No entry in free text 
box 49
Incomplete section on 
medications in 6 CRS cases;
Controls 221
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Objectives: To explore the experience of CRS and its
management from the perspective of patients with CRS. To
our knowledge, this is the first qualitative study exploring
sinus disease.
Design: Semi-structured qualitative interviews.
Setting: ENT outpatient clinic.
Participants: Twenty-one adult patients with CRS: 11
male, 10 female. Patients suffered from a range of types of
CRS (including polyps and fungal disease) and differing
durations of symptoms (1.5–47 years). Participants were
purposively selected. Thematic analysis was used.
Outcome measures: Patient experience of CRS and its
management.
Results: Patients had concerns regarding management of
their symptoms by both healthcare professionals and
themselves, including delays to referral and repeated med-
ications. They reported reduced quality of life and high
financial and psychosocial costs associated with living with
CRS.
Conclusions: Despite guidelines for CRS treatment, out-
comes remain variable leading to dissatisfaction with
treatment. Adherence to existing guidelines may result in
fewer repeated consultations in primary care and earlier
referrals to secondary care.
Background
Rhinosinusitis is one of the most common health problems
in the Western world1 with a recent European study
estimating the prevalence of chronic rhinosinusitis (CRS)
at 11%.2 It is defined as inflammation of the nose and
paranasal sinuses characterised by symptoms of nasal
blockage and/or nasal discharge and may include facial pain
and loss of smell according to the diagnostic criteria of the
European position paper on Rhinosinusitis and Nasal
Polyps.3 Chronic disease is distinguished from acute by the
persistence of symptoms for at least 12 weeks.4
Morbidity is considerable, reaching into physical, social
and emotional indices of health. In addition to nasal
symptoms, patients with CRS consistently report lower
health-related quality of life with adverse effects on olfaction,
sleep quality, sexual function, work productivity and mental
health;5 these have been reported to be worse than in patients
with other chronic illnesses frequently seen in primary care
such as COPD, back pain and heart failure.6 The direct and
indirect costs are consequently large, although as yet not
quantified in a British setting.
Themajority of CRS is diagnosed andmanaged in primary
care7 and is usually made on the basis of nasal symptoms
alone. In secondary and tertiary care, anterior rhinoscopy,
nasal endoscopy and CT scanning can be employed to
confirm the diagnosis of CRS. Evidence-based treatment
options for chronic rhinosinusitis include nasal irrigation
with saline, intranasal or oral steroids, and oral antibiotics.3,8
The use of guideline-based treatment has been shown to
improve quality of life and reduce symptoms in comparison
with free-choice treatment,9 and guidelines for the manage-
ment of CRS have been recently updated3,4,10–12 including
guidance documents specifically for primary care.11 Despite
such guidelines, uptake and utilisation in primary and
secondary care in the United Kingdom is not consistent.13
Treatment therefore remains variable with neither primary
care physicians or patients satisfied with management of
sinus disease.14,15
Optimum management of patients with chronic condi-
tions is usually achieved through therapeutic partnerships
with health professionals.16 ‘Management’ in the context of
chronic disease includes a patient’s whole experience of an
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illness and treatment and is consequently often investigated
through qualitative interviews allowing detailed exploration
of relevant issues. It is seen as an increasingly important
aspect of primary care. Yet in contrast to a wealth of
qualitative literature regarding chronic conditions such as
asthma17 and diabetes, this study, to the best of our
knowledge, is the first study to explore the experience of
CRS and its management from patients’ perspectives. Some
previous work has looked at the impact of allergic rhinitis;
one US study found approximately 30% of physicians
underestimated the severity of allergic rhinitis and its effect
on work and social activities.4 The EPOS3 guidelines have
also suggested that more work is needed to explore the
impact of CRS.
Methods
Semi-structured interviews with 21 purposively selected
patients attending a specialist rhinology clinic were under-
taken. Patients were selected to include a range of duration
andmanagement (surgical andmedical) ofCRSanddifferent
subtypes of disease. They were identified from the senior
author’s tertiary rhinology clinic to include both new and
follow-up patients. Only one patient approached declined
interview as hewas unable to attendduring the timeperiodof
the study, March to June 2012.Whilst only patients who had
beenreferredtosecondarycareweresampledfor this study,all
had had to pass through primary care to be referred.
This study was reviewed and approved by Oxford ‘C’
Ethics Committee. Participants were refunded for travel and
parking and given a £20 shopping voucher for participation.
An interview template was produced; this was designed by
the interviewer (SE), a qualitative researcher (CN) and the
senior author to ensure that it included the broad range of
concerns raised in clinic by patients. Potential concerns were
identified by the senior author and from quality-of-life
studies including patients with CRS as well as similar
research including patients with asthma, as well as allowing
scope for patients to raise their own concerns. The template
was piloted on a patient with CRS who agreed to participate
and give feedback. In line with qualitative research method-
ology, novel issues that came to light during early interviews
were included in the template for subsequent interviews.18
The patients selected and the interview designwere chosen
to maximise the likelihood of including the greatest range of
issues known as ‘maximum variation sampling’, and to
achieve saturation of themes during subsequent analysis.19
Patients were selected to include adult males and females
across a spread of ages with different types of CRS. The exact
numbers of interviews required vary greatly in qualitative
research; an acceptable number of patients were included for
a study of this type to saturate themes and enablemeaningful
analysis. The number of participants was agreed prior to the
start of recruitment; this is in excess of the twelve which are
generally thought to be required to achieve saturation of
themes,19 but it was intended to include a heterogeneousmix
of patients with CRS, so a larger number was selected
according to qualitative research principles19–21 which allow
flexibility to suit the type of participants, interviews and
objectives of the study.
Once the study had been explained, patients could choose
when to participate in the qualitative interview. Interviews
were carried out in a separate room adjacent to the rhinology
clinic by a clinician trained and experienced in qualitative
research methods and lasted between 50 and 90 minutes.
Participants could decide to have the interview on the day of
their clinic appointment or come back at another time more
convenient to them. This clinician undertaking the inter-
views was not involved directly in participants’ clinical care.
Interviews were recorded and transcribed.
Thematic analysis of the transcripts was undertaken;
interviews were transcribed precisely as spoken and checked
against recordings for accuracy. Both frequently occurring
and important themes were highlighted, considered and
coded.15,22 To our knowledge, there is no similar qualitative
studyofpatientswith any formof sinusdisease. The aimsof this
analysis were therefore exploratory, to generate novel themes. It
wascarriedoutusingNVIVO10,a softwarepackage fororganising
the analysis of qualitative research. All transcriptswere analysed
by one researcher with two other researchers analysing selected
transcripts to ensure consistency and reduce researcher bias.
The scope of the overall themes identified was too great in
breadth to be considered with sufficient detail in one paper
(see Table 1). This analysis reports the factors perceived as
relevant to patient care both formanagement in primary care
and referral to secondary care. Many participants had
considerable frustrations with an aspect of CRS manage-
ment, so the themes contributing most to this feeling have
been included here. Themes such as perceived trigger factors
were considered as a separate issue by most participants and
so will be considered in a following paper. The interaction
between CRS symptoms and other respiratory problems was
an important issue, and whilst relevant to the overarching
‘management’ theme, it was an issue for specific participants
only and is related to the aetiology of their symptoms; it will
therefore also be considered separately.23
Results
Participants
The age range of participants was 24–75 years with 10
females and 11 males. Patients suffered from different types
of CRS (established from clinical information and according
Chronic rhinosinusitis: patient experiences 9
© 2015 John Wiley & Sons Ltd  Clinical Otolaryngology 41, 8–14
to EPOS 2012 criteria)3 as follows: CRS without nasal polyps
(CRSsNP) 6, CRS with nasal polyps (CRSwNPs) 10 and
allergic fungal rhinosinusitis (AFRS) 5. Patient estimated
duration of symptoms was 1.5–47 years with a mean of 19.7
and median 14.5 years.
Table 1 shows themes and subthemes identified from
analysis of all interviews. Themes in bold are considered in
this analysis.
Those themes including topics relevant to access to care
(bold) are discussed in more detail as follows.
Symptom and duration of symptoms. Patients described a
wide range of physical symptoms.
‘I was just producing a lot of mucus. . ... I’m constantly
blowingmy nose and I’ve lostmy sense of smell.’ Patient 9
(Male, 55, AFRS)
‘I get horrible yellow catarrh, . . .just you know all the
time.’ Patient 2 (Female, 62, CRSwNP)
The onset of symptoms also varied greatly. Many patients
felt their symptoms had had an insidious onset, and others
said they could name a triggering incident or time period
where symptoms had begun.
‘I found that I was getting cold-like symptoms every
winter and year by year they seemed to be lasting longer’.
Patient 9 (Male, 55, AFRS)
Treatment seeking and referral. Treatment-seeking behav-
iour varied greatly. Some patients had treated themselves for
many years prior to seeking further treatment. Others visited
their GP/several GPs and tried a range of topical and systemic
treatments. Some felt this was acceptable; others wanted a
prompt referral to secondary care when treatment or
investigation was unsatisfactory.
‘My one thing would be I’ve had them [symptoms] now
for quite a few years. . . if it turns out that it is something
[sinister] I’ll be pretty miffed that I wasn’t referred that
long ago.’ Patient 11 (Male, 34, CRSsNP)
Referral (or lack of referral) to secondary care was
prompted both by GP suggestion and by patient request.
Reasons for onward referral included failed treatment and
patient concern.
‘He never referred me because I didn’t consider it a really
big problem.’ Patient 2(Female, 62, CRSwNP)
Problems with treatment. Treatment neither in primary nor
in secondary care was entirely satisfactory to some patients.
Sometimes this was due to unsatisfactory consultations;
others felt their symptoms were not taken seriously.
‘I mean it’s just annoying that you’ve got to stop work go
and queue up at the GP’s sit there to be told well they can’t
find anything.’ Patient 4 (Male, 53, CRSsNP)
‘No one (primary care) ever looked up my nose really to
see if there was anything there.’ Patient 5 (Male, 53,
CRSwNP)
It was not only in primary care where patients were met
with frustrations. Some of the patients found repeated
consultations in an ENT clinic did not improve their
problems.
‘I did go on [the internet] and it did say you know if you
have a good consultant they will do the allergy test, the
camera and a CT scan. I never got that far so I was a little
bit upset about that.’ Patient 13 (Female, 58, CRSsNP)
Most described several courses of different, often ineffec-
tive treatments, which were not always reviewed.
‘Everything I tried was so random.’ Patient 17 (Female,
47, AFRS)
‘I was put onto Betnesol nasal drops, remained on them
until last year [without significant benefit. Patient had
been on this treatment for 40 years]. Patient 8 (Female,
73, CRSwNP)
Others did experience improvement, but found it was not
sustained.
Table 1. Themes raised
Themes raised
Perceived triggering factors Impact on daily living
Environmental Sleep
Dietary Anosmia
Family history Work and social
functions
Symptoms Relationships
Duration of symptoms Interaction with other
illnesses
Treatment seeking Asthma
Self-treatment Need for integrated
management with other
specialties (allergy,
respiratory)
Delayed referral
Problems with treatment Financial burden
Repeated or unsuccessful
medical
Cost of treatment
treatments, often costly Missed work
Continuity of care
Lifelong treatment
Side-effects and limitations
of surgery
10 S.E. Erskine et al.
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‘The combination of antibiotics and steroids was very,
very effective, very quickly, but it didn’t last; it would just
be for the time that I was taking the tablets.’ Patient 17
(Female, 47, AFRS)
As expected, surgery often bought about more immediate
benefits, although some patients were disappointed at the
short-lived benefits of treatment.
‘I’ve had polyps removed twice but you know it brings
about marginal improvement for a while but it doesn’t
change the condition noticeably’ Patient 9 (Male, 55,
AFRS)
Many wished that they had been able to access more
effective treatment more quickly.
‘Actually you realise after you’ve had something like this
[comprehensive sinus surgery] done how different you
feel and to know that I’ve spent years of my life not really
100%, well is a bit annoying.’ Patient 17 (Female, 47,
AFRS)
Interaction with other illnesses. Reported elsewhere.23
Another issue reported was interaction with other
illnesses, and this may also mask diagnosis.
‘My GP kept saying oh well you’ve got a touch of
bronchitis and all kinds of things like that . . . I was
referred to the chest clinic. . . then the consultant at the
chest clinic said well whilst your nose is so congested your
chest will never be free so I suggest you go and see an ENT
consultant.’ Patient 8 (Female, 73, CRSwNP)
Impact on daily living. Impact on daily life ranged hugely.
CRS is an inflammatory process very rarely associated with
life-threatening problems, but despite this, symptoms were
troublesome enough to worry many patients that they had a
sinister underlying pathology.
‘You start worrying about various things like you know
with obviously like cancer . . . that does play on my mind
um quite a bit at times and obviously that’s a lot of the
reason why I did go back to the GP. ‘ Patient 11 (Male, 34,
CRSsNP)
Some participants did not feel their symptoms were very
problematic, whilst others described a bleak outlook influ-
encing every sphere of their life.
‘You get to the point where. . .you’re quite toler-
ant. . .you’ll put up (with) an awful lot as a human being,
you’ll just cope, but then you start to think what if I didn’t
have to, how would I feel, what would my life be like?’
Patient 17 (Female, 47, AFRS)
‘I think I was about 14 I tried to commit suicide because it
got so bad it really you know it seemed like no one was
helping me [although] I was going to my doctors
explaining everything to him.’ Patient 7 (Male, 24,
CRSsNP)
Work and social functioning were also impaired.
‘If I’m getting majorly congested my over the telephone it
is awkward people ask me to repeat myself.’ Patient 1
(Female, 56, CRSwNP)
Financial burden. The financial impact was discussed. This
related to seeking alternative treatments when conventional
NHS care proved unsatisfactory.
‘He’s a chiropractor. . . I was seeing him every six weeks
and his charges were pretty high. . . 4 to 5 thousand
pounds. . . but it’s something I’m passionate about Iwant,
as does everyone really, want to find the root cause.’
Patient 20 (Male, 35, AFRS)
In addition to the cost of over-the-counter medications
and prescriptions:
‘Your GP should give you the whole twelve weeks in one
prescription. . . you could have a prescription for a period
of time and you’ll get like seven days’ worth and you’re
back ‘I’ll give you another twoweeks’ and then there’s two
things, it adds up and that’s extortionate.’ Patient 11
(Male, 34, CRSsNP)
Discussion
Key findings
CRS is extremely common and associated with significant
morbidity, but several participants felt symptoms were
not necessarily taken seriously. Although treatments are
available, these interviews highlight areas in which
outcomes are clearly not yet satisfactory and with costs
to both the individual and the economy. Diagnosis and
treatment of CRS is dependent on a patient presenting,
usually to their GP. This may be preceded by years of
occasional medication use and recurring symptoms;
patients with CRS frequently self-medicate with both
over-the-counter (OTC) remedies and complementary
medicines, evident in both the interviews and in larger
quantitative studies.24–26 This may underlie why most
patients present in middle age; they have an insidious
onset with gradually worsening symptoms. Some partic-
ipants were frustrated by repeated ineffective medications
and a lack of systematic management, and others were
not sure how to use topical nasal products. Many
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participants alluded to the fact that there is often no one
‘cure’; better explanation by clinicians as to the nature of
CRS may make ongoing medical treatment more under-
standable and acceptable. The degree of morbidity
experienced varies widely from feeling congested to
feeling suicidal. Patients had often shouldered significant
financial burden in managing their CRS, not only through
missing work due to poorly controlled symptoms but also
when trying alternative therapies (with little evidence
base) or looking for private health advice when they felt
their NHS care had not been adequate.
Strengths and limitations
Involvement of patients in their own health care is increas-
ingly recognised as important; these interviews are unique in
allowing patients to raise their own concerns regarding
management of CRS in a research setting. The themes are
likely to resonate strongly with many clinicians’ clinical
experiences. The wide range of participants ensures that
themes associated with experience of CRS and management
are as broad as possible although results are not necessarily
generalisable to a wider population. Participants were asked
whether they would like to participate in the study following
their consultation about their CRS; they may have felt
obliged to participate, and the risk of this was minimised as
the person conducting the studies was not directly involved
in the participants’ care.
Comparison with other studies
Few studies have directly addressed concerns of patients
with CRS; this study allowed patients to discuss any issues
surrounding CRS and its management which they felt are
important. Our study reflects current literature in the great
variation of experience of diagnostic tests and treatment in
both primary and secondary care, with geographic varia-
tion as well as variation between clinicians in the same
centre.7,9,27
The existing literature paints a discordant picture
between management of CRS recommended by specialists
and reality. Few studies have directly addressed this issue,
but the causes appear to be multilevel: patient concerns
and expectations, variations in clinical practice, physician
and patient education and health infrastructure may all
feed into patterns of behaviour that contribute to subop-
timal outcomes with current management of this disease.
A cross-sectional European survey of 2966 patients
suggested that patients with allergic rhinitis tended to
either self-medicate or present to the GP in order to
request a specific treatment, rather than to have a two-way
discussion about appropriate management28 presenting the
first of several obstacles to successful treatment. One
clinical series in California found use of complementary
and alternative medicine in as many as 43% of patients
with a diagnosis of CRS, including dietary modifications,
herbal therapy, acupuncture, homoeopathy and chiroprac-
tic practice.24 Whilst such strategies may prove effective for
some, a lack of good quality advice or guidance from
healthcare professionals may mean patients suffer unnec-
essarily or turn to alternative medical therapies with little
or no foundations in evidence.11,29
Other potential problems include short consultation
times, lack of postgraduate training in ENT and/or allergy,
lack of access to or lack of expertise in diagnostic tests, and
uncertainty over when to refer to secondary or tertiary
care.30 One study of 188 GPs with an interest in allergy and
respiratory disorders found that only 0.6% instigated
appropriate management of treatment for allergic rhini-
tis.17 Additionally, there may be a discrepancy between
physician and patient attitudes towards the severity of
disease and treatment options.4 For example, intranasal
corticosteroids (INCs) have become established as first-line
agents in the management of CRS. Whilst concerns over
the side-effects of oral steroids initially limited their
widespread use, a multitude of randomised controlled
trials has demonstrated the safety and efficacy of intranasal
steroids. Both GPs and ENT surgeons frequently prescribe
INCs, but recent studies suggest significant concerns still
exist amongst patients regarding INCs and damage to the
nose, systemic side-effects and addiction.31 Lifestyle factors
are poorly understood; they will be further investigated by
this study group as part of a large multicentre question-
naire study, the Chronic Rhinosinusitis Epidemiology
Study (CRES).
Many patients interviewed were frustrated with short
courses of antibiotic or other treatment which had nil,
or no sustained effect. GP prescribing of antibiotics was
found to reach 74% in ‘sinus’ type complaints in one
Dutch study30 with higher rates of prescribing associated
with lower GP knowledge of respiratory tract infections,
lower perceived time available for consultation and with
longer duration of the GP’s practice. A similar picture is
likely to be found amongst GPs in the United Kingdom,
despite neither BSACI guidelines12 nor EPOS guidelines
recommending antibiotics use by GPs for CRS.10 Vari-
ation in surgical management was similarly great;
analysis of Hospital Episode Statistic (HES) data to
encapsulate the picture at Primary Care Trust (PCT)
level in the NHS shows greater than fivefold variation in
maximum and minimum surgical intervention rates,
after standardisation by age and gender, ranging between
2.5 sinonasal procedures per 100 000 population per
annum in London and 13.5 in Devon and Cornwall.32
12 S.E. Erskine et al.
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Implications for research and/or practice
Adherence to the EPOS guidelines would streamline
management; commissioning guidelines from ENT-UK
show clear treatment and referral pathways from primary
care.33 Correct treatment can only follow a correct
diagnosis; it is known that nasal endoscopy improves the
accuracy of a diagnosis of sinusitis, but it is acknowl-
edged that widespread use in primary care would not be
feasible.8 Thus, it is more important that referral to
secondary care is undertaken if there is no symptomatic
response to 3 months of topical treatment; this did not
always occur for our participants due to both patient
and clinician preferences. One participant mentioned
that no one had looked in his nose prior to referral to
secondary care; basic anterior rhinoscopy may be feasible
and helpful in primary care settings.
The likely duration of treatment should be discussed and
include the possibility of the need for treatment to be
lifelong, to helpmanage both expectations of the outcome of
treatment and to aid management of the financial burden of
medication. Time should be taken to explain how to use
topical treatments to maximise their effect.
The formal synthesis of patients’ views highlights the need
for research to better understand CRS and its management.
Given the popularity of self-medication, this may include
alteration of service provision away from the clinician
towards community pharmacy and non-clinicians. It will
become increasingly important to quantify the financial
burden of CRS both to the individuals and to the NHS.
Efficient care is needed and is likely to be improved by better
use of current guidelines.3,34 Research is also needed to
clarify our understanding of the epidemiology of CRS to
enable development of more effective medical and surgical
treatments; these data support such research proposals.
Our study underlines the wide range of morbidity
associated with CRS as well as potential weaknesses in
management pathways. Reflecting on such concerns and
considering them when managing patients with CRS will
improve care for such individuals.
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Managing chronic rhinosinusitis and respiratory disease: a qualitative
study of triggers and interactions
Sally E. Erskine, MB ChB, BMedSci (hons), MClinRes, MRCS, Caitlin Notley, BSc (hons), PhD,
Andrew M. Wilson, MB ChB, MRCP (UK), and Carl M. Philpott, MB ChB, DLO, FRCS (ORL-HNS), MD, PGCME
Norwich Medical School, Norwich Research Park, University of East Anglia, Norwich, UK
Abstract
Objective: The aim of this analysis is to explore views of patients with chronic rhinosinusitis
(CRS) about of the aetiology of their respiratory symptoms and the relationship between upper
and lower respiratory symptoms. Methods: This study is part of a larger mixed methods study
investigating the epidemiology of CRS, which comprises a questionnaire study of patients with
CRS and controls and a qualitative study of 21 patients with CRS. Semi structured qualitative
interviews were undertaken with these patients; 11 males and 10 females. Twelve patients
had asthma. Patients were recruited with a tertiary outpatient rhinology clinic. Interviews
were transcribed verbatim and analysed using thematic analysis, using Nvivo software (QSR
International, Melbourne, Australia). Several important and recurring themes were highlighted.
Results: Patients described many perceived triggering factors and an interaction between upper
and lower respiratory tract symptoms. They felt that their symptoms could be managed more
holistically. Conclusions: Concerns about triggers of respiratory symptoms and interactions
between upper and lower respiratory symptoms are of significant concern to patients. These
should be appropriately managed and acknowledged in formal treatment pathways, for
example, through the use of combined ENT/respiratory clinics.
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Introduction
Rhinosinusitis is inflammation of the lining of the nose and
sinuses. Symptoms include a blocked and/or runny nose, a poor
sense of smell and a feeling of pressure or pain across the face.
It is one of the most common health problems in the Western
world [1,2]. Chronic disease is distinguished from acute by the
persistence of symptoms for 12 weeks or longer [3]. Morbidity
in chronic rhinosinusitis (CRS) is significant; in addition to
nasal symptoms, patients report low health-related quality of
life with adverse effects on olfaction, sleep quality, sexual
function, work productivity and mental health [4]. Such indices
have been reported to be worse than in patients with chronic
obstructive pulmonary disease (COPD), back pain and heart
failure [5]. Asthma prevalence in the UK is also high, with
estimates ranging from 5 to 16% [6,7]. Morbidity associated
with asthma is similarly high [8], and in some cases, it can also
be associated with significant mortality [9].
Evaluation of the epidemiology of upper airways path-
ology is particularly difficult since there are many forms of
rhinitis and rhinosinusitis with differing aetiologies and
clinical courses. Definitions vary from asking whether a
physician has ever given a diagnosis of rhinitis, to use of a
symptom severity score [10]. Despite this difficulty, a large
number of studies have shown a high proportion of those with
asthma appear to suffer from ‘‘rhinitis’’ and vice versa [6,10]
and the concept of the ‘‘united airway’’, the idea that upper
and lower respiratory tract symptoms being manifestations of
the same disease processes, has long been recognised [10].
For example, a French study of 1623 adult patients with
asthma in respiratory clinics found 67.1% had some form of
rhinopathy (allergic rhinitis in 66.2% of participants and nasal
polyposis in 10.1%) [6]. The proportion of asthmatics with
rhinitis may be even higher – a Greek study of 27 patients and
10 controls showed the presence of nasal mucosa eosinophilia
in those with asthma, despite the absence of rhinitis symp-
toms, even in the absence of atopy [11].
It is known that asthma control is worse in those with
allergic rhinitis [12] and that such patients seek healthcare
more frequently [13]. In addition, whilst both sinus disease
and asthma are very costly to individuals, the NHS and wider
society [14], the combined effect of having rhinitis and
asthma has a particularly large impact on both morbidity and
cost [13]; maximising the efficiency of treatment of both
conditions is therefore important.
Management of both diseases usually begins in Primary
Care and both have treatment guidelines. Treatment for
CRS should follow gradual escalation using evidence-based
Correspondence: Sally E. Erskine, c/o Carl M. Philpott, Norwich
Medical School, Norwich Research Park, University of East Anglia,
Norwich NR4 7TJ, UK. Tel: 07941611330. E-mail: sally.erskine@
doctors.org.uk
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treatment options including nasal irrigation with saline and
intranasal steroids. Treatment is often initiated on the basis
of history alone, with anterior rhinoscopy, nasal endoscopy
and CT scanning utilised after referral to secondary care. Oral
corticosteroids and oral antibiotics should be reserved for
secondary care once endoscopy and/or CT scanning has
been performed. Surgery is only indicated for cases that fail to
respond to maximum medical therapy [3,15]. Despite these
guidelines, investigation and treatment of CRS varies widely
[16]. Treatment for asthma in the UK tends to follow
the SIGN guidance [17] with stepwise escalation in care. The
British Society of Allergy and Clinical Immunology have
produced a comprehensive document discussing the impact
of allergic rhinitis on asthma and the challenges it poses to
management, and CRS is also considered within this [18].
Recent treatment recommendations, in addition to those for
allergic rhinitis and asthma as separate conditions, include
the use or inhaled glucocorticosteroids over oral leukotriene
receptor antagonists and consideration of the use of allergen-
specific immunotherapy [19].
This study was conducted as a sub-study of the Chronic
Rhinosinusitis Epidemiology Study (CRES), which was
designed to aid better understanding of medical and non-
medical factors contributing to development or worsening of
CRS. This qualitative interview-based sub-study was designed
to complement the quantitative data collected from the main
study questionnaires. Qualitative interviews are often used to
evaluate patients’ experiences, but there is a paucity of work
regarding CRS highlighted in the European Position Paper on
Sinusitis [3]. The aim of these interviews was to explore
patients’ subjective experiences of CRS. Preliminary thematic
analysis highlighted several broad ranging important and
recurring themes. These included the perceptions of the
causes of respiratory problems and the interaction between
upper and lower respiratory symptoms; the purpose of this
analysis is therefore to consider patients ideas and experiences
of the causes, interactions and treatment of their upper and
lower respiratory symptoms. Other themes will be reported
separately elsewhere.
Materials and methods
This study was approved by the Oxford C Research Ethics
Committee. Semi-structured interviews with 21 purposively
selected patients attending a specialist rhinology clinic were
undertaken. Informed consent was taken from each partici-
pant prior to entering this study. The same interview questions
were asked of each participant with additional questions asked
in later interviews if a previous participant had raised a new
issue, as is standard practice in qualitative research. This
study was piloted on one participant. One patient approached
declined interview (unable to attend interview during the time
period of this study).
Participants were selected to include adult males and
females across a spread of ages with different types of CRS.
This purposive selection is standard practice in qualitative
research [20]; rather than to select a representative sample of
the general population of patients with CRS, the participants
were chosen to optimise diversity of both patient and disease
characteristics and to include as broad a range of experiences
as possible. This should increase the likelihood of saturating
themes during analysis. Patients were attending a mixture
of new and follow up appointments. Once the study had been
explained, patients could choose when to participate.
Interviews were carried out in a private consulting room
adjacent to the rhinology clinic by a female clinician (ENT
SpR) trained in qualitative research methods who had not
previously met participants and lasted between 20 and 90
minutes. Interviews were recorded and transcribed verbatim.
Thematic analysis of the transcripts was undertaken;
interviews were transcribed precisely as spoken and checked
against recordings for accuracy. Both frequently occurring
and important themes [21] were highlighted, considered and
coded [21,22].The aims of this analysis therefore were
exploratory to generate novel themes. Analysis was carried
out using Nvivo 10 (QSR International, Melbourne,
Australia), a software package for organising the analysis of
qualitative research. All transcripts were analysed by one
researcher with two other researchers analysing selected
transcripts to ensure consistency.
The questionnaire study consisted of a study-specific
questionnaire of patients with CRS and controls including
demographic, socioeconomic, environmental and health
details, SNOT-22 and a standard quality of life tool. It will
be reported elsewhere in full detail.
Results
The age range of participants was 24–75 years with 10
females and 11 males. Patients suffered from different
types of CRS (established from clinical information): 6 had
CRS without polyps, 10 had CRS with nasal polyps and 5 had
allergic fungal rhinosinusitis (AFRS). Patient estimated
duration of symptoms was 1.5–47 years with a mean of
19.7 and median 14.5 years. Only 6 of 21 patients did not
believe they had any allergies. A diagnosis of asthma
was cited by 12 of the patients. This information is shown
in the context of the full CRES data listed in Table 1. It must
be remembered that the interview participants were selected
to include a broad range of views, the inclusion of a large
number of patients with AFRS included is therefore inevitable
since these patients tend to have the most extreme experiences
of chronic sinus disease.
The main themes are listed in Table 2. The scope of the
issues raised was very wide-reaching and too broad for one
paper. This article therefore considers patients underlying
beliefs about the causes of their symptoms and how different
symptoms interact. These broad themes were strongly
associated with each other by participants.
Table 1. CRS sub type, allergies and asthma.
n (%) Qualitative study CRES questionnaire
CRSsNP 6 (28.6) 575 (37.6)
CRSwNP 10 (47.6) 659 (43.1)
AFRS 5 (23.8) 57 (3.7)
Control – 236 (15.4)
Allergies 15 (71.4) 342 (26.5% of patients,
excluding controls)
Asthma 12/21 (57.1) 464 (35.8% of patients,
excluding controls)
Age range (years) 24–75 18–101
2 S. E. Erskine et al. J Asthma, Early Online: 1–6
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Perceived triggering factors: environmental
Many participants strongly felt that they knew what triggered
their symptoms, and that this may be beneficial to their
management. Triggering factors varied widely, not only
between individuals but also over time. Factors that
aggravated some were helpful to others. Climate was a
frequently mentioned factor and often related to environmen-
tal triggers as well as temperature. Participants were split
between those who found ‘‘hayfever season’’ the worst and
those whose symptoms were worse in the winter. Some found
no real variation with climate or environment.
It tends to be the very early spring or summer time or
October time where the asthma has really been exacerbated
very badly. Patient 17
I’ve been on holidays and you always feel better when
you’re somewhere sunny and the climate is nicer. Patient 10
Definitely pollen and that sort of mist when it’s been really
hot and you get the rain [makes it worse]. . . like the damp
sort of feeling. Patient 7
I’ve worked all over the country I’ve worked abroad and
I’ve been on holiday abroad and it doesn’t matter if I’ve
been in the Caribbean or been on the continent it’s exactly
the same. Patient 18
Moving house seemed to trigger a change in symptoms for
many patients. This was sometimes associated with a change
from an urban to a rural area or vice versa – again the
direction of association varied between patients.
One of the reasons [my parents] moved [to seaside town]
was because me and my brother have got asthma and cos
we were living right next to a factory and they said that the
fresh air from the sea would help . . . . Since I’ve moved up
here [I’ve] been a lot worse . . . so it might be less pollution
but whatever it is in the atmosphere has made it worse.
Patient 7
I do suffer more if I go into big smoggy cities so for
example if I go into London or if I go to Manchester or
somewhere like that. Patient 17
Not only a wider environmental change but also just
moving within the same village or area seemed to trigger
symptoms which persisted. Several participants mentioned
the presence of a black mould within their new house, which
they felt could be to blame.
I mean the house I’ve moved to is only probably two or three
miles from the house I was living in before, the wider
environment isn’t hugely different . . . but I can trace a real
change in the level of the symptoms [since moving] Patient 9
We moved house in and it was kind of from that moment
forward . . . we changed all the carpets it was all either
wood or tile downstairs . . . .we didn’t have pets . . . I tried
to use anti-allergy sheets, mattress protectors and every-
thing . . . to combat what I thought was a house move that
has caused this . . . we now live in a new build and it hasn’t
gone away. Patient 20
Perceived triggering factors: dietary
Other trigger factors that were widely discussed included food
and drink.
I might not be allergic to dairy products but without a
doubt they are mucus forming . . . as soon as I’ve drunk it
[milk] within no time at all I’d be having problems
breathing [through my nose] Patient 21
I really did have to stop drinking wine . . . having finished a
glass of wine slowly over a couple of hours it [inside nose]
would just gradually swell and tighten and become really
really uncomfortable Patient 17
Some participants had no suggestions as to the cause of
their symptoms.
There’s not a known sort of thing that’s triggered off any of
this, nothing like that at all. Patient 2
Symptoms
The course of disease varied greatly with some participants
able to identify a start date and others noticing symptoms
more insidiously, this was true for both CRS and asthma.
I’ve had hay fever and like since the age of 11 . . . so I’ve
had like runny noses since then really and then I get cold
symptoms twice a month even in the summer. Patient 12
19 years ago I was diagnosed then with asthma (as an
adult) . . . as a child I’d had bronchitis um but my doctor
thinks it was most probably asthma. Patient 1
Subsequent management also varied. Some patients self-
managed with a variety of over the counter preparations, whilst
others tried courses of topical or systemic treatments, often
repeatedly and ineffectively prior to referral to secondary care.
I always have a nasal spray and I’m doing the nasal
douches . . . I haven’t had any bad headaches [since then]
but my nose [still] seems really blocked. Patient 1
Table 2. Themes raised (those in bold are explored in this paper).
Perceived triggering factors Impact on daily living
Environmental Sleep
Dietary Anosmia
Family history Work and social functions
Symptoms Relationships
Duration of symptoms Interaction with other illnesses
Treatment seeking Asthma
Self-treatment
Delayed referral
Need for integrated management
with other specialties (allergy
and respiratory)
Financial burden
Problems with treatment Cost of treatment
Repeated or unsuccessful
medical treatments,
Missed work
often costly
Continuity of care
Lifelong treatment
Side effects and limitations
of surgery
DOI: 10.3109/02770903.2014.995308 Managing chronic rhinosinusitis and respiratory disease 3
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Interaction with other illnesses
Participants frequently reported the interaction of their nasal
symptoms with other illnesses, a problem which also delayed
or masked diagnosis.
My GP kept saying oh well you’ve got a touch of bronchitis
and all kinds of things like that . . . I was referred to the
chest clinic . . . then the consultant said well whilst your
nose is so congested your chest will never be free, so I
suggest you go and see an ENT consultant. Patient 8.
Upper and lower respiratory symptoms frequently trig-
gered or worsened each other.
I’d usually get a sort of sinus infection first and then a chest
infection afterwards. Patient 14
I think I got a chest infection via the rubbish going down.
Patient 19
Participants felt that care for such symptoms was very
disjointed.
They [respiratory team] say to you breathe through your
nose oh god you say I’ve got chronic rhinosinusitis . . . they
just don’t take much notice it’s ‘breathe through your
nose’ . . . they don’t seem to understand because they’re
used to telling people you must breathe through your nose.
Patient 21
Impact on daily life ranged hugely, but the impact of a
combination of upper and lower respiratory symptoms
seemed particularly problematic.
I have a mild asthma which is linked to allergies and yes if
my nose is playing up then it’s kind of inter linked . . . it can
really kind of bung you up and generally makes you feel a
bit down. Patient 20
Quite apart from anything else it’s about the amount of
time that it actually interferes with your life . . . cos it does
quite seriously you know . . . and especially if you get to the
point where you’re not sleeping and there’s all kind of
other knock on effects. Patient 17
Treating both together was often challenging – particularly
since neither involves only tablet medication. Some were
confused as to why separate nasal and oral inhalers using the
same ingredients were prescribed.
It gets too much trying to sort out all these different things
[inhalers for asthma and sprays for CRS]. Patient 19
Because of the performance with this douching . . . I didn’t
take my asthma inhalers. Patient 20
Problems with nocturnal breathing were particularly
significant.
Somebody else might think oh it’s not too bad but it’s the
headaches and the pain in your nose and at the moment
it’s the dryness in your throat as well at night times
[from breathing through the mouth], and at the moment
my mouth is so dry that at night I feel quite miserable.
Patient 16
My poor husband sometimes has to go in the spare room
because of my snoring which I feel very embarrassed
about. Patient 1
Discussion
Main findings
A vast range of experiences of both symptoms and manage-
ment as well as a variety of perceived triggers were described
by those interviewed, with no one particular common theme.
Allergies and triggers are clearly an important concern for
patients and should be explored and investigated as part of
management. Both CRS and asthma have a multifactorial
aetiology including environmental, emotional and dietary
factors, and these were identified by many participants
[19,23]. Formal testing as well as a detailed history is
therefore important [19]. Participants sometimes found it
difficult to pinpoint the exact onset of symptoms or found
medical staff had difficult in identifying or appreciating these
symptoms. They sometimes felt that treatment was poorly
streamlined with reluctance by clinicians to escalate care and
that subsequent care was not always well integrated with other
services when necessary.
Interpretation of findings in relation to previously
published work
Patients’ CRS symptoms often began insidiously and were
consequently dismissed as harmless or insignificant by
both the patients themselves and clinicians, making
initiating correct management challenging. A systematic
review of a large number of studies concerned with
differing perceptions of symptoms by patients and clin-
icians supports this finding [24]. A study of 188 GPs with
an interest in allergy and respiratory disorders found that
only 0.6% instigated appropriate management of treatment
for allergic rhinitis [25]. Asthma, with its capacity to
quickly become life-threatening, and well-recognised man-
agement pathways may be recognised and managed more
promptly; however, there are problems with existing
guidelines including the lack of consideration for co-
morbid conditions [26].
Patients feel that integrated care of CRS and asthma is
particularly important, a view supported by several scientific
studies [10] and underpinned by the concept of the ‘‘united
airway’’. Despite this, the most widely used guidelines for
CRS and asthma in the UK pay little attention to the
interaction. The European Position Paper on Rhinosinusitis
and Nasal Polyps (EPOS) mentions consideration of asthma
during diagnosis but there are no clear suggestion for
integrated management. Likewise, in SIGN 101 (the major
asthma guideline), the only management algorithm that
mentions rhinitis concerns work-related asthma [17]. Since
both conditions are frequently managed in primary care, early
recognition is particularly important and is suggested in a
review of asthma consultations in primary care [6]. Given the
4 S. E. Erskine et al. J Asthma, Early Online: 1–6
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large burden of disease made up by a combination of these
two diagnoses, more effective use of primary care resources
including GPs with a relevant special interest may be
increasingly important [27]. Identification of those with
rhinitis in the care of respiratory physicians and vice versa
could also be helpful, and questionnaires have been shown
to help this process [28]. Specific management measures
such as the use of concomitant intranasal corticosteroid
medications have be shown to improve some asthma-specific
outcome measures in patients with both allergic rhinitis
and asthma [20].
Implications for future research, policy and practice
Optimum management of patients with any chronic condition
is best achieved via strong therapeutic partnerships between
health professionals [29]. Sinus disease is not always managed
systematically, and neither GPs nor patients are satisfied
with current treatment [30]. Adherence to asthma guidelines
by both clinicians and patients is also likely to be variable,
and the need for more patient-centred guidelines has been
proposed [26]. ‘‘Management’’ must be holistic so as to
consider the limitations imposed on patients’ daily lives
and any subsequent physical and psychosocial sequelae.
Involvement of patients in their own healthcare is increas-
ingly recognised as important; these interviews are to our
knowledge unique in CRS. The formal synthesis of such
information highlights the need for research to improve
understanding of the epidemiology of CRS and to better
quantify the burden of CRS in patients with other respiratory
diseases, as well as the need for more integrated treatment
pathways.
Strengths and limitations of this study
A limitation of this type of research occurs since patients were
purposefully selected, but results are not designed to be used
to quantify and generalise views; participants represent a
selection of patients coming to secondary/tertiary care,
and the variety of ages, durations of symptoms and types of
CRS ensures that as wide a range as possible of potential
experiences have been considered. Recall bias may also occur,
particularly since some patients have had symptoms over
many years.
Conclusion
Patients with CRS have many ideas regarding the aetiology of
their symptoms and have concerns regarding their investiga-
tion. They have particular concerns regarding management
when suffering from an additional respiratory problem such as
asthma. Such issues are likely to resonate strongly with many
clinicians’ clinical experiences, but may require further study
and in depth analysis to be verified, perhaps in a different
clinical setting.
Patients have clear ideas as to the causes of their
symptoms, but it may take years for such concerns to be
investigated, if ever. The concept of a ‘‘united airway’’ is
widely accepted, but the traditional segregation of the airway
into ENT and respiratory specialties, as well as separate
allergy services, may be a further barrier to providing holistic
care. Nationally, guidelines for management of both rhinitis
and asthma should include clear guidance to investigate the
presence of the alternate disease.
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Abstract 
Objective 
There are large numbers of patients with olfactory disturbance in the UK and shortfalls in 
assessment and support amongst mainstream ENT practice. The aim of this analysis is to 
identify the main concerns for such patients and to identify key areas for research and service 
improvement. 
Study Design 
Qualitative analysis of written patient accounts  
Methods 
This qualitative study utilized unstructured written patient accounts from consenting patients 
experiencing olfactory disturbances received by the Smell and Taste clinic at a tertiary referral 
centre in the UK. Framework analysis was performed using Nvivo 10 software. 
 
Results 
Accounts submitted by 71 participants were included in the analysis; age range 31-80 years, 
45 females, 26 males. Themes identified include negative emotional impact, feelings of 
isolation, impaired relationships and daily functioning, impact on physical health and the 
difficulty and financial burden of seeking help. 
 
Conclusions 
Olfactory disturbances have a wide-ranging impact on the lives of sufferers, compounded by 
a lack of knowledge of the disorder amongst clinicians. There is a role for further support and 
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education both for sufferers and clinicians, as well as a need to improve our understanding of 
olfactory disturbance. 
Key words: 
Olfaction 
Anosmia/hyposmia 
Quality of life 
Level of evidence: 
2c – outcomes research 
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Introduction 
 
Currently olfactory disorders are reported to affect significant numbers of the population 
with prevalence estimated between 1-49% 
1-5
; people with anosmia account for 
approximately 5% of the population [7]. Olfactory disturbance presents both increased risk to 
certain physical harms such as smoke or rotten food, as well as decreasing pleasure derived 
from eating, and loss of a dimension in our experience of our environment.  Such symptoms 
have a multitude of causes from local nasal problems to central neural aetiologies with 
sinonasal disease and post-viral olfactory loss being the two most common
6
.  
Olfactory disorders increase in incidence with age, even in an otherwise healthy population, 
in a similar manner to impaired hearing or sight, but whereas hearing and vision are readily 
tested and frequently improved or corrected today 
2, 7, 8
; no such simple solutions are yet 
available for olfaction and our understanding of human olfaction remains relatively poor.  
An apparent increase in collective patient awareness about olfactory problems in the wider 
populous has been demonstrated by growing membership of the patient support charity, 
Fifth Sense (16), as well as an increase in referrals to specialist smell & taste clinics such as 
the tertiary referral unit at the James Paget University Hospital (JPUH), the first Smell and 
Taste Clinic established in the UK. After opening in 2010, the Smell and Taste Clinic received a 
large amount of written correspondence from a pent up body of patients in the UK 
requesting help with their olfactory disorder; this increased rapidly following media articles to 
promote engagement events for Fifth Sense. Many correspondents wrote in great detail 
about their disorder and the way it had impacted on their lives. In order to formally address 
the issues raised the research team proposed to carry out a qualitative analysis of these 
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communications. This study was designed to analyse the written accounts of anosmia 
sufferers and use this information for the following purposes: 
 
 
Primary objective: 
• To determine the key themes which can be identified from the accounts of anosmia 
sufferers 
Secondary objectives: 
• To identify any key areas to target for future research or service development 
• To describe the educational needs for doctors to be better equipped to deal with these 
problems 
 
 
Materials and methods 
The study was given ethical approval by the West of Scotland Research Ethics Committee 4 
and supported by raised awareness through Fifth Sense newsletters, mailshots and the 
website. Patients were approached if they had previously contacted the clinic by e-mail or 
letter or if they attended the clinic during the study period between 01/06/2013 and 
01/12/2014. The following criteria were used for participants: 
Inclusion criteria: 
• Any patient who had suffered a quantitative loss of smell (hyposmia or anosmia) 
• Any patient who had suffered a distortion in their sense of smell (parosmia/phantosmia) 
Exclusion criteria: 
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• Any patient under the age of 16 
 
These patients were then sent an information sheet and consent form, either via e-mail, 
post or in person in the clinic, in order to obtain their written informed consent to 
participate in the study. The accounts of those who agreed to participate were then 
anonymised, removing all identifiable links to the patient (e.g. name, date of birth) and any 
identifiable references to any hospitals or doctors with whom the patients have had prior 
contact. Where existing accounts given were brief, a hint sheet was provided to guide them 
to submit a more detailed account. A framework approach to analysis was undertaken, 
using NVivo qualitative software to manage data analysis. Framework analysis is a five-stage 
process that ultimately allows for sensitive analysis of the relationship between concepts 
and typologies across and within individuals, thus showing variation in experiences across 
participants but also drawing out common themes.   
Qualitative data was stored on password-protected computers at the University of East 
Anglia, with individual participants identified only by unique anonymous study identifiers, 
and all personal contact details destroyed. Accounts were analysed by TB with a sample 
checked by SE in line with qualitative methodology.  
 
Results 
A total of 71 participants submitted accounts that were used in the analysis with an age 
range of 31 to 80 years, including 45 females and 26 males. The analysed data collected 
revealed a large number of themes relating to the experiences of anosmia sufferers shown 
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in table 1. Key issues raised by participants include those of reduced physical wellbeing, 
emotional distress and impairment of social function. 
 
Table 1. Main themes 
 
An overview of these themes and important subthemes were considered. 
 
 
1. PHYSICAL (table 2) 
Diet and Appetite 
Given the integral relationship between olfaction and gustation, it is unsurprising that a large 
number of participants reported that anosmia had a negative impact upon their enjoyment of 
food. As a consequence of the reduced pleasure of eating, some participants reported a 
reduction in their appetite with subsequent weight loss.  
 
Others reported a general decline in the quality of their diet with the reduced perception of 
flavours leading to an increased intake of foods with low nutritional value (particularly those 
high in fat, salt and sugar), with resulting weight-gain.  
 
Hazard Perception 
It is well established that the olfactory system is an important component of hazard 
perception (17). Therefore, people with anosmia are less able to detect the presence of 
substances that are potentially hazardous to health. Key examples include expired food 
products, smoke and gas, with a large number of participants specifically raising these as 
issues that were a cause for concern. In some accounts, altered olfaction was deemed solely 
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responsible for serious ‘near-misses’, some of which had the potential to result in significant 
harm. 
 
Personal Hygiene 
The proper maintenance of personal hygiene was also discussed as an issue complicated by the 
effects of altered olfaction. In addition to the direct health effects of suboptimal hygiene, this issue 
appeared to carry an emotional burden, causing anxiety, worry and embarrassment. 
 
2. EMOTIONAL (table 3) 
As evidenced by the accounts of various participants within this study, the spectrum of 
emotional impact associated with anosmia is vast. A diverse range of negative emotions were 
reported by sufferers’, including but not limited to anger, anxiety, frustration, bereavement, 
boredom, depression, desperation, embarrassment, guilt, isolation, loss of confidence, loss of 
identity, regret and sadness. Defining the relationship between these emotions and the 
experience of anosmia is complicated and seems to involve a multitude of factors. These 
include the loss of enjoyment of activities that were previously important to the individual, 
the perception that anosmia attracts little sympathy or understanding from outsiders, 
difficulty in expressing the impact of symptoms, the status of an/hyposmia as an ‘invisible 
disease’, reduced participation in social activity, poorly established treatment pathways and 
little hope of recovery. Depression and anxiety were frequently described; anger and misery 
were common. Others describe guilt and embarrassment. 
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3. SOCIAL IMPACT (table 4) 
The impact of anosmia upon the social lives of sufferers’ manifests within the home 
environment, with activities of daily living frequently raised as challenging areas. For instance: 
preparing food, childcare tasks, special occasions (such as Christmas, birthdays, restaurant 
meals) as well as general sociable activities with friends and family were all referenced within 
the accounts. In addition, the realms of finance, employment and spirituality were each 
discussed by participants. 
 
Preparation of food 
A theme widely reported by participants was a loss of interest in cooking, or an impairment of 
their cookery skills. Some reported that they were now embarrassed to serve their dishes to 
family members and friends, and this subsequently had an impact upon their social life. 
  
Celebrations 
Some participants reported that they were unable to take pleasure in occasions that would 
usually be a cause for celebration. For sufferers of an/hyposmia, the inability to link smells 
with happy memories may render these events underwhelming experiences. 
 
Childcare 
Various parental tasks were reported as being made more difficult by an/hyposmia. For 
example, parents of young children were unable to detect soiled nappies. Being unable to 
perform such essential tasks led some parents to feel they were failing in their role. 
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Financial/work 
Some participants reported that their olfactory disorder had a financial impact. For example, 
the expense of seeking alternative treatments and the value of lost earnings. Many 
participants reported that their work was directly affected by the symptoms of anosmia.  
 
Spiritual 
Perhaps unsurprisingly, the impact of olfactory disturbance extended beyond physical and 
social activities. One participant reported their lack of smell as impeding upon their ability to 
carry out activities of a spiritual nature. This is a particularly clear demonstration of just how 
far-reaching the impact of anosmia can be. 
 
Memories 
We carry smells with us as memories throughout our lives. Smells link us to people, places, 
good times, bad times and emotional experiences. Without a sense of smell, memories and 
links with the past can be lost. 
 
4. INTERPERSONAL IMPACT (table 5) 
Relationship with partners, friends and family 
Many participants described profound effect on their relationships with other people as a results of 
their olfactory disturbance. These range from not enjoying eating together to more intimate 
relationships, particularly sex. Participants described strain on relationships caused by a lack of 
understanding of the problem. Those with children found bonding with very young children and 
babies difficult. 
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Health care professionals  
Participants often described negative or unhelpful interactions with healthcare professionals both in 
the community and also specialist ENT surgeons, with difficulties in accessing specialist care. 
Participants were concerned by a lack of empathy. Those who had managed to get help and were 
supported were very pleased. Even if nothing could be done about anosmia, participants were very 
grateful for advice and understanding. 
 
Discussion  
Olfactory impairment is known to expose an individual to potential environmental dangers, 
and it impacts negatively on a vast range of daily activities and experiences.  Previous studies 
have explored the negative impact of these disorders through a quantitative approach using 
questionnaires 
9-11
, this study explores these issues in more detail by referring to sufferers’ 
written accounts.  
Our participants accounts have shown the extent and depth of the impact impaired olfaction 
has on daily life. This is not surprising given the extra dimension olfaction gives to the 
enjoyment of food, exploration of our environment and evocation of treasured memories; 
olfaction is both a life-saving and life-enhancing sense as described by our participants. 
Experiences of olfactory disturbance were reported with global and wide-reaching negative 
impacts. In terms of physical health, potential harms discussed included loss of interest in 
food and difficulty identifying expired food products and the inability to detect smoke or gas. 
Emotional negatives were described with great depth of feeling, including embarrassment, 
sadness, depression, worry and bereavement. Every aspect of life was disrupted from 
everyday concerns such as personal hygiene to loss of intimacy and the break-down of 
personal relationships. The financial burden described included the cost of private referral 
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and alternative treatments. The effects were profound for some, especially if their profession 
or safety depends upon it, and clinicians often feel unable to do much to assess or treat the 
problem.  
 
This study also adds to increasing evidence from patients and healthcare professionals that 
suggest that olfactory disorders are often poorly managed (13,14), which in itself appears to 
exacerbate the negative impact upon sufferers
9
.  Sufferers describe a lack of 
acknowledgement of disordered olfaction as a significant problem. A frequently highlighted 
barrier to treatment was the attitude of healthcare workers – several participants had been 
met with disinterest or refused referral.  
; a basic first step healthcare professionals could take would be to listen to sufferers, 
acknowledgement the significant effect on their lives and offer referral to specialist centre to 
help diagnose possible causes and treat where possible.  
 
 
‘Specialists’ should ensure that they have a plan for investigation of such patients. The causes 
of olfactory disturbance contribute to the difficulties in management. On one hand symptoms 
from chronic sinus disease often begin insidiously, and can therefore be dismissed as 
harmless or insignificant by both patients and clinicians (ref our paper), on the other hand, 
olfactory disturbance caused by head trauma can increase distress as the persistent nature of 
the sensory disturbance is a constant reminder of the injury.  Some participants were told 
there was no treatment available and whilst this may sometimes be the case, management 
options in terms of advice, support and information should be offered, particularly in a 
secondary or tertiary are setting. 
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Clearly these accounts illustrate that a wider range of therapeutic options are needed, this 
requires research to improve our understanding of the basic science of olfaction so that 
interventions can begin to match those for the other senses. 
 
Strengths and limitations 
This is the first qualitative study of British subjects affected by olfactory disturbance to 
describe their experiences in their own words. Participants had voluntarily written to the 
Smell & Taste Clinic seeking advice about their disorder, so clearly those who were available 
for inclusion were who felt most affected by their disorder or most motivated to seek 
treatment. However, the intention is to describe the experience of those with olfactory 
disturbance in a qualitative manner not to comment of the prevalence of specific symptoms. 
 
 
Conclusion 
Involvement of patients in their own healthcare is increasingly recognised as important; 
these accounts are unique in allowing participants to voice their concerns regarding 
experience and management of olfactory disturbance. The synthesis of this information 
from a wide range of individuals highlights the need for better education for healthcare 
professionals as well as research to improve understanding of human olfaction and develop 
therapeutic options.  
 
Patients with olfactory disturbance have many concerns regarding the impact their 
symptoms have on their lives and the lack of availability of information or solutions to such 
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symptoms.  A streamlined protocol for investigation of olfactory disturbance could be 
agreed and distributed nationally to help rule out and manage reversible causes, and would 
help ensure that as many patients as possible have a resolution of symptoms. For those who 
remain hyposmic or anosmic, clear information and support should be provided. Such a 
large number and range of negative experiences of olfactory disturbance as described here 
should inspire researchers to further their understanding of human olfaction and supports 
research to investigate therapeutic options.  
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Table 1: Main themes 
 
PHYSICAL IMPACT EMOTIONAL 
IMPACT 
SOCIAL IMPACT FINANCIAL INTERPERSONAL 
RELATIONSHIPS 
Appetite, diet and 
weight 
Anger, irritation, 
frustration 
Activities of 
daily living 
Alternative 
therapies 
Attitudes of 
healthcare 
professional 
Hazard perception 
• Expired food 
products 
• Noxious 
substances 
Anxiety - Celebrations Private 
treatment 
- Disinterest 
Bereavement - Childcare  - Lack of 
knowledge 
Boredom - Cooking  - Lack of support 
Personal hygiene Covering up - Dining out  - No treatment 
offered 
 Depression - General 
interaction 
 - Positive 
experiences 
 Desperation Leisure  - Reluctance to 
refer 
 Embarrassment  Occupation  Attitudes of other 
people 
 Guilt Relationships   
 Isolation - With family   
 Loss of confidence - With friends   
 Loss of identity - With partner   
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 Regret Spiritual   
 Sadness    
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Table 2: Physical Concerns 
Diet and 
appetite 
“The main impact is the inability to smell food cooking and when on the plate, this 
means the digestive juices are not stimulated and generally food tastes like 
cardboard.”  
“All food is bland and pretty tasteless and I only get the textures, crunchy, smooth 
and juicy.”  
 
“Food generally tasted of nothing… I ate little for some months, losing a lot of 
weigh.t”  
“As all food tastes bland there is no incentive to prepare a variety of different meals 
which has resulted in weight gain as I have resorted to eating too many cakes and 
sweet things”  
“I overload my meals with too much salt, but it’s the only way to eat a bland meal”  
Hazard 
Perception 
 
“Eating is another problem as I do not know if the food is fresh and have been 
made sick when eating something which was obviously off”  
“My husband has come home on several occasions to find the house smelling of gas 
as I have perhaps accidentally knocked the switch when cleaning”  
 
Personal 
Hygiene 
 
 “I worry in case I smell, particularly in the hot weather. I carry perfume and sprays 
with me in my bag. I also can’t tell if my feet smell. I worry about my breath 
smelling even though I brush and use mouthwash regularly”  
“Personally I have found it very difficult when around people. I am very strict about 
personal hygiene but still find it embarrassing when anyone mentions smells 
around me, after all how do I know it’s not coming from me?!”  
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Table 3. Emotional Concerns 
Impact of 
anosmia 
“I feel I live in a world behind glass, because I cannot smell and taste anything 
and feel depressed and sad much like being bereaved” 
“The first Xmas I found very difficult – I found the tree no longer smelled and 
embarrassed the young lad putting the tree I bought into my car by crying”  
“This is a hidden disability, which no-one who has not been there can really 
understand”  
“I cannot contribute socially, e.g. ‘taste this, smell this’. This leads to a sense of 
isolation as I cannot contribute to shared experiences. This has a negative effect 
on both mood and emotion”  
Depression and 
anxiety 
“I think that this has affected my whole well-being…. I have struggled to keep 
out of the black hole and there remains a lot of anguish inside me”  
“Having no smell makes me sad, I feel like the edge has gone off my life. I’m 
OK but not quite right, som thing is missing” 
 
Anger and 
misery 
“Generally I would describe life without smell and taste as being utterly 
miserable”  
“Since my problems occurred three years ago my friends tell my wife that my 
personality has changed, I have become withdrawn and quiet not the jolly 
friendly outgoing person that I used to be”  
“It infuriates me sometimes that I still can’t taste an orange, a lime, or a glass of 
red wine or good coffee”  
 “When my family comment on the smell of a meal I just want to cry” 
“The thought of not smelling my children again was/is too distressing to accept” 
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Guilt and 
embarrassment 
“I feel guilty complaining about something that isn’t life-threatening” (BB) 
“I don’t usually tell people that I can’t smell as I am embarrassed about it. If I 
am out and about with people and they say ‘what’s that smell?’ I often just play 
along and try and change the subject as soon as I can” (JP1) 
“I have to check my daughter’s nappies regularly and I worry in case she has 
pooed and people think I am not changing her. My husband has to remind me to 
wash her as sometimes they look clean but they smell.” (JP1) 
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Table 4. Social Impact 
General 
activities 
“I have retreated from the company of family and friends, no longer wanting 
to accept invitations which include food and drink” (MS1) 
 “Although I have a love of the outdoors my enjoyment has been limited by 
not being able to recognize associated smells such as the sea or wild flowers. 
This disappointment is reinforced when friends comment on smells” (EF) 
Preparation of 
food 
 
 
“Cooking has also become a non-event as I feel it pointless to try new recipes 
as I now have to rely on my partner to taste for seasoning etc. It may look 
good but I don’t feel that there is much point in experimenting with new 
foods as all I experience is texture” (CE) 
 “I feel a lifetime interest in cooking and nutrition is over without my sense of 
taste and smell” (MS1) 
 
Celebrations 
 
Having no smell means that I miss out on all the memories that smell can 
evoke, bonfire night, Christmas smells, the smell of a certain perfume or 
food. I have some clothes that belonged to my nana who has died and I miss 
being able to smell her on them.” (JP1) 
Financial and 
work 
“Life was becoming increasingly difficult as I spent a small fortune on 
alternative therapies in an effect to help myself. I tried homeopathy, 
massage of the face, reflexology, and many other treatments” (AS) 
 
“I was an Avon rep for 22 years but as a result of the nasal problems I had to 
give it up as I could not smell the perfume and other products I was selling. I 
loved selling Avon and felt another door was closed in my face” (AS) 
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“I am an engineer and I work in many different environments, the lack of 
ability to smell has affected my diagnostic skills, and on occasion has put me 
in danger” (DT) 
“I am a social worker and my job involves going into people’s homes. I am 
disadvantaged as I can’t smell smoke, pet odours, damp and other smells 
that may be concerning in homes where children are living” (JP) 
 
Spiritual “It affects my ability to conduct my spiritual/ritual practice in the way and 
depth I feel I should. And I feel this holds me back from where I should be in 
development with my practice at this point in my life” (MC) 
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Table 5. interpersonal impact 
  
Relationship 
with 
partners, 
friends and 
family 
 
‘I am sure there was an impact on sex and being close to my husband when he 
did not smell as he normally did. Although our marriage was already in difficulty, 
I believe anosmia helped end it due to the impact on sex, no longer sharing 
enjoyment in food and drink, and probably his not understanding the impact on 
me, and my getting resentful, while not being able to explain it either.’ 
 
‘My libido has diminished; I believe that relates to being unable to smell women.’ 
 
‘One thing that did not feature in the BBC publicity … is the effect of the sense of 
smell on sexual interest. Looking back, that is the thing that has indirectly had 
the most effect on both my and my father's relationships. It's fair to say that if 
we had known about this, both our lives and our relationships would have been 
very different.’ 
 
Children ‘People have their own smells, which we do not even notice normally and my 
children do not smell ‘right’, which was difficult for me.’ 
‘One of my biggest regrets is not being able to smell my babies. I have heard it 
is one of the most amazing smells and bonds you to your children.’ 
‘I had a baby boy born at the age of 45 and I could not smell him and therefore 
felt I could not bond with him like I had with my other four sons.’ 
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Health care 
professionals  
 
‘My GP felt I should get used to it, it just happens.’ 
‘I went to the GP about it, was asked 'is it really a problem then' and I had to 
press to see an ENT consultant at X Hospital. The consultant also seemed to think 
I was making a fuss about nothing and just told me there was nothing that could 
be done and I should just accept it. I had heard about the smell and taste clinic 
and asked to be referred. He said he had never heard of either the clinic or Mr X 
but grudgingly wrote a letter of referral.’ 
 
‘After appointments with two different locally based consultants I felt that the 
condition was not treated seriously and that I was dismissed as a patient with a 
minor non-life threatening condition.  This thought was re-enforced by the fact 
that I was never offered any form of x-ray or scan in an attempt to trace the 
cause of my condition or indeed to check for any damage that may have been 
suffered through the injury.’  
Lack of 
empathy 
‘More understanding and support would have been very welcome! If I had lost 
my sight or hearing, I suspect I would have received a lot more attention. 
I saw a Neurologist who said I could see and hear and would have to be stoic.’ 
 
Support My GP has also been very supportive and has prescribed steroids several times a 
year for holidays etc. to enable me to taste and smell.  He made the referral 
straightaway and has been extremely interested in my progress. 
‘Throughout my dealings with medical professionals concerning my anosmia, I 
have always found them to be willing to listen, sympathetic and keen to help.  
My GP especially showed his level of empathy as when I visited him for unrelated 
matters from time to time, he would ask about my anosmia and if it had 
improved any.’ 
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‘Now taste and smell and I feel wonderful.’  
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A cross sectional analysis of a case-control study about 
quality of life in CRS in the UK; a comparison between CRS 
subtypes*
Abstract 
Background: The Sinonasal Outcome Test (SNOT-22) has been used as a patient reported outcome measure to grade symptom 
severity before and after treatment for chronic rhinosinusitis (CRS). 
Methodology: This analysis uses data from the CRS Epidemiology Study (CRES). The overarching aim of CRES was to determine 
factors that influence the onset and severity of CRS. A study-specific questionnaire including SNOT-22 was distributed to patients 
with CRS attending ENT clinics across 30 centres in the United Kingdom. The aim of this analysis was to compare SNOT-22 scores 
between those with different types of CRS to determine any differences present in the total score or the subdomains and to assess 
whether any differences varied according to gender. 
Results: There were a total of 1249 CRS participants in the following subgroups: CRS without nasal polyps (CRSsNPs) (n=553), CRS 
with nasal polyps (CRSwNPs) (n=651), allergic fungal rhinosinusitis (AFRS) (n=45). Since there were differing gender ratios in each 
subgroup, males and females were analysed separately. The mean and standard deviation for SNOT-22 was: males CRSsNP 41.1 
(21.0), CRSwNP 41.7 (20.5); females CRSsNP 49.6 (19.7), CRSwNP 49.5 (22.9). In the nasal domain, those with CRSwNP scored more 
highly than those with CRSsNP; for males 18.1 (8.1) vs. 15.9 (7.9); for females 19.6 (8.0) vs 16.7 (7.5).
Conclusions: Patients with CRSwNPs report higher symptom scores in the nasal domain of SNOT-22 than those with CRSsNPs 
with women in both subgroups reporting higher total scores than men. 
Key words: quality of life, sinusitis, respiratory symptoms, nasal obstruction, facial pain, olfaction disorders
Sally Erskine1,2, Claire Hopkins3, Nirmal Kumar4, Janet Wilson5, Allan Clark1,  
Alasdair Robertson6, Naveed Kara7, Vishnu Sunkaraneni8, Shahram Anari9, 
Carl Philpott1,2, on behalf of the CRES Group
1 Norwich Medical School, University of East Anglia, Norwich, UK 
2 ENT Department, James Paget University Hospital NHS Foundation Trust, Great Yarmouth, UK 
3 ENT Department, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
4 ENT Department, Writington, Wigan and Lee NHS Foundation Trust, Wigan, UK 
5 Head & Neck Surg. Institute of Health & Society, Newcastle University, Newcastle, UK
6 ENT Department, Southern General Hospital, Glasgow, UK 
7 ENT Department, Darlington Memorial Hospitals NHS Foundation Trust, Darlington, UK 
8 ENT Department, Royal Surrey County Hospital, Surrey, UK 
9 ENT Department, Heart of England NHS Foundation Trust, Birmingham, UK 
Rhinology 54: 311-315, 2016
DOI:10.4193/Rhino15.361
*Received for publication:
December 7, 2015
Accepted: March 31, 2016
311
Introduction
Chronic rhinosinusitis (CRS) affects a significant proportion 
of the population, and as such is a burdensome disease to 
both individual sufferers and to the population as a whole (1). 
There are presently two accepted broad subcategories of CRS; 
CRSwNP, CRSsNPs (2); with the more severe, refractory AFRS 
a subset of CRSwNPs (3). Symptoms and their severity may 
vary widely between patients with CRS. Many questionnaires 
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have been proposed to help quantify and evaluate patients’ 
symptoms. The most widely accepted and best validated patient 
self-report symptom evaluation tool is the SNOT-22, whose 22 
items incorporate both nasal and non-nasal symptoms (4). It 
is a modification of the 31-question Rhinosinusitis Outcome 
Measure (RSOM-31) (5) and an advancement of the SNOT-20 (6). 
When used to monitor response to treatment the minimum 
clinically importance difference (MCID) is 9 points on the SNOT-
22 (7). Factor analysis has identified four principal SNOT subscales 
– nasal, facial, sleep and mood and we have considered these in 
our analysis (6,7-9). 
The overarching aim of the CRS Epidemiology Study (CRES) 
was to aid better understanding of medical and non-medical 
factors contributing to development or worsening of CRS. The 
aim of this analysis is to evaluate qualitative and quantitative 
differences in the SNOT-22 scale among different categories of 
rhinosinusitis in the substantial population of patients studied 
in the CRES.
Materials and methods
Study design and setting
The CRES was approved by the Oxford C Research Ethics Com-
mittee, sponsored by the University of East Anglia (UEA) and 
funded by the Anthony Long and Bernice Bibby Trusts. The 
study was conducted as a case-control questionnaire study and 
recruited from a total of 30 sites from around the UK (including 
the devolved nations of Wales and Scotland), between 2007 and 
2013. The CRES questionnaire included study specific questions 
relating to socio-economic, environmental and medical co-
morbidity variables as well as the validated Short Form 36 (SF-
36)(10) quality of life measure and SNOT-22 (11). Within SNOT-22, 
self-reported symptom severity is graded from 0-5, with 5 being 
a severe problem. Scores for each question are added to pro-
duce an overall score of 0-1 (11). The subdomains used comprise 
the following questions; rhinological symptoms (blowing nose, 
sneezing, runny nose, nasal obstruction, loss of smell/taste), ear 
and facial symptoms (ear fullness, dizziness, ear pain, facial pain/
pressure), sleep function (difficulty falling asleep, waking up at 
night, lack of a good night’s sleep) and psychological issues (fati-
gue, reduced productivity, reduced concentration, frustrate/rest-
less/irritable, sad, embarrassed). The questions regarding cough 
and waking up tired were not included in these four subscales.
Participants and methods
The diagnosis of CRS was confirmed by an Otorhinolaryngolo-
gist according to the criteria below. Patients with CRS presenting 
to secondary/tertiary care ENT outpatient clinics were invited 
to participate in the study, regardless of symptom or disease 
severity or previous treatment, provided they conformed to the 
following criteria:
Inclusion criteria:
CRS with or without polyps as defined by the criteria laid out in 
EPOS 2012(2). Symptoms must be present for at least 12 weeks 
and include:
• nasal blockage/obstruction/congestion and/or nasal 
discharge (anterior/posterior nasal drip)
• and either facial pain/pressure and/or reduction or loss of 
smell
and additionally:
• endoscopic signs of: polyps and/or mucopurulent dischar-
ge primarily from middle meatus and/or; oedema/mucosal 
obstruction primarily in middle meatus
• and/or CT changes: mucosal changes within the ostio-
meatal complex and/or sinuses
Any patients with nasal polyps placed in the AFRS category met 
the Bent and Kuhn criteria (11) or the St Paul’s Sinus Centre modifi-
cation of this (12). 
Patients and controls included were at least 18 years of age.
Exclusion criteria:
• Patients unable to comprehend written English.
All participants were provided with information leaflets but as 
the study specific questionnaire was anonymous, consent was 
implied through participation. Questionnaires were returned by 
participants using a freepost envelope and scanned to a secure 
database using Formic. Two members of the research team chec-
ked the accuracy of electronic scanning of returned questionnai-
res against the original copy. 
Statistical analysis
Since there were differing gender ratios in each subgroup, males 
and females were analysed separately. Descriptive analysis was 
undertaken with the mean and standard deviation reported 
for continuous variables and the number and percentage for 
categorical variables. Due to small numbers in the AFRS group, 
it was decided that those with AFRS would be included in the 
CRSwNPs group. The SNOT-22 score and the principal subscales 
were compared using independent samples t-tests for compare 
the means between individuals with CRSsNPS and CRSwNPS. 
Due to the difference in ages between these groups they were 
always adjusted for age using a linear regression model with age 
as a predictor variable.
Results 
A total of 1249 completed CRES questionnaires from CRS 
patients were available for analysis (Table 1). Detailed descrip-
tion of the geographical distribution of participants has been 
published previously (13). There were no significant differences in 
total SNOT-22 score between disease subtypes amongst either 
males or females (Table 2). There were significant differences in 
nasal symptom domain scores between those with and without 
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polyps, with those with CRSwNPs having the highest scores, 
this difference existed amongst both males and females. For 
the facial and emotional domains, those with CRSsNPs scored 
more highly than those with CRSwNPs and this tended towards 
significance in the facial domain for females.
Whilst the analysis was separated for gender for the reason cited 
above, it is worth noting that women with and without polyps 
scored significantly more highly than males on the SNOT-22: 
mean of 49.6 vs 41.1 for CRSsNP and 49.5 vs 41.7 for CRSwNP. 
Such differences are clinically significant since they are 8.5 and 
8.4 respectively, close to the minimum clinically important dif-
ference of 8.9 points (11).
Discussion
Our study has evaluated SNOT-22 scores across a large and 
diverse population and has found that there are significant 
differences in the nasal domain between those in the two main 
subgroups of CRS. In a disease such as CRS which consists of 
multiple and variable symptoms, SNOT-22 scores enable us to 
assess the global impact of disease on a patient, and if repeated 
at intervals provides a comparator over time which may be used 
to assess response to treatment. These are important consi-
derations when measuring outcomes. In contrast to objective 
measures, such as CT scans, peak nasal inspiratory flow or smell 
testing, which measure only a single symptom or measure of 
nasal function, SNOT-22 provides a more comprehensive assess-
ment of disease burden through global symptoms and quality 
of life impact. By showing differences in CRS symptoms in dif-
ferent subtypes of CRS we may be able to better understand and 
quantify disease severity. 
The SNOT-22 score has already been shown to be a useful pre-
dictor of the improvement in QoL that could be expected after 
sinus surgery for CRS (14,15). Tan et al. found that the frequency 
of individual symptoms varied the likelihood of a CRS diagno-
sis and consequently varied the most effective management 
algorithm to choose (16); a more detailed understanding of SNOT-
22 in different disease subtypes may further inform clinical 
decision making. A study of 126 patients by Banerji et al. using 
‘SNOT-20+1’ found similar differences (17); nasal obstruction and 
hyposmia/anosmia were more prevalent in those with polyps 
and facial pain/pressure/headache were more prevalent in those 
without. Using the Rhinosinusitis Symptom Inventory (RSI), 
Bhattacharyya also found higher scores for nasal symptoms 
in those with polyps and higher scores for facial symptoms in 
those without (18). In a study of 234 patients, Dietz de Loos et al. 
used the Rhinosinusitis Outcome Measure 31 (RSOM 31) and 
found that those with polyps were more likely to score highly on 
nasal symptoms compared to those without polyps (19). This ob-
servation therefore appears consistent regardless of the PROM 
used, and may be due to the physical impact of nasal polyps 
filling the nasal cavity in those with CRSwNPs. Since our study 
was anonymous, it was not possible to correlate our scores with 
Table 1. Summary of participants submitting SNOT-22 questionnaires.
Participants ControlsN=221
CRSsNP
553
CRSwNP
651
AFRS
45
Females 143 (68.4%) 259 (53.1%) 185 (32.2%) 19 (43.2%)
Mean Age 
(SD) 47.3 (14.9) 51.8 (15.3) 56.0 (14.6) 56.1 (12.7)
Range 19-82 18-84 17-102 20-76
Table 2. Total SNOT-22 and domain scores for all subtypes.
CRSsNP CRSwNPs Unadjusted Adjusted for age
Mean difference 
(95% CI) p-value
Mean difference 
(95% CI) p-value
Males only
SNOT-22 41.1 (21.0) 41.7 (20.5) 0.60 (-2.87,4.08) 0.7328 1.23 (-2.28,4.75) 0.490
Nasal 15.9 (7.9) 18.1 (8.1) 2.20 (0.87,3.53) 0.0012 2.43 (1.07,3.79) <0.001
Facial 5.0 (4.5) 4.3 (4.1) -0.73 (-1.44,-0.02) 0.0453 -0.55 (-1.26,0.17) 0.134
Sleep fatigue 5.8 (4.3) 6.1 (4.3) 0.26 (-0.45,0.98) 0.4661 0.32 (-0.41,1.05) 0.387
Emotion 9.7 (7.2) 9.2 (7.1) -0.50 (-1.69,0.69) 0.4055 -0.39 (-1.60,0.81) 0.520
Females only
SNOT-22 49.6 (19.7) 49.5 (22.9) -0.12 (-4.16,3.91) 0.9518 1.03 (-3.07,5.13) 0.622
Nasal 16.7 (7.5) 19.6 (8.0) 2.86 (1.40,4.31) 0.0001 3.19 (1.70,4.67) <0.001
Facial 7.4 (4.9) 6.3 (4.7) -1.09 (-2.01,-0.18) 0.0196 -0.88 (-1.80,0.05) 0.064
Sleep fatigue 7.4 (4.2) 7.5 (4.7) 0.11 (-0.71,0.93) 0.7859 0.19 (-0.65,1.04) 0.656
Emotion 12.7 (7.4) 11.1 (7.9) -1.64 (-3.08,-0.21) 0.0251 -1.10 (-2.55,0.35) 0.137
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any objective measures of severity such as Lund-Mackay score, 
although previous studies have found only a weak association 
between preoperative SNOT-22 scores and Lund-Mackay scores 
(20,21).
Amongst females, the difference in the facial domain between 
those with CRSsNPs and those with CRSwNPs approached 
significance. The reasons behind this difference are equally 
complex but our findings are supported by previous work which 
found that CRSsNPs had more impact on vitality and bodily pain 
than did CRSwNPs (22). We know from our own cohort that rates 
of consultation with a General Practitioner for depression and 
anxiety are higher amongst those with CRSsNPs (23), but the di-
rection of this association is difficult to establish. It may be that 
the underlying autonomic driver behind symptom generation 
is greater in patients with CRSsNPs; both state and trait anxiety 
have been found to be higher amongst those with both allergic 
rhinitis and vasomotor rhinitis than controls (24). Symptom gene-
ration may therefore interact with ANS dysfunction. This reflects 
the wide-ranging impact of CRS on patients over and above 
purely nasal symptoms. Gender differences are to be expected; 
previous literature including the UK Sino nasal audit data (25) sug-
gests that females are more likely to report somatic symptoms 
(26) including nasal symptoms (27). We have shown that in addition 
to higher scores overall, the composition of scores may also be 
different.
Clinical uses
The strength of PROMs such as SNOT-22 lies in the fact that they 
are not subject to individual clinicians’ interpretation and can 
be used by patients to chart the course of their disease between 
primary and secondary care and before and after any interven-
tion. There has been debate as to whether diagnosis according 
to questionnaire adequately correlates to clinical diagnosis by 
a clinician. Lange et al. investigated this dilemma and found 
moderate agreement between the questionnaire and clinician 
based diagnosis (21). So whilst using SNOT-22 in combination 
with traditional clinical assessment including nasendoscopy, as 
in this study, is likely to be the best route to accurate diagnosis, 
SNOT-22 could be a useful tool for General Practitioners when 
making decisions regarding treatment response and/or onward 
referral depending on symptom severity, even in the absence 
of nasendoscopy. This may avoid delays in treatment escalation 
and referral which are known to be harmful for patients when 
they have no benefit from first-line therapies (28). However, the 
SNOT-22 may be challenging to complete in a short GP appoint-
ment; the nasal domain may be useful in this regard as it would 
be quick to administer and repeat. Equally, if General Practitio-
ners using SNOT-22 note that patients score highly in the non-
nasal domains, such as sleep, further questions as to the nature 
of such symptoms may result in more holistic management 
through non-nasal interventions, such as treatment of related 
anxiety and depression (23).
The distribution of scores for those with and without polyps was 
too broad to allow identification of different phenotypes accor-
ding to SNOT-22 score alone, but greater knowledge and use of 
the sub-domains may help guide differentiation between both 
controls and different subgroups, and may allow better corre-
lation with more traditional objective measures. The predictive 
value of the domains requires further evaluation. SNOT-22 score 
could further refine currently used diagnostic criteria to quantify 
subjective interpretations of patients’ symptoms (2). 
Conclusion
Our analysis has found significant differences in symptom 
reporting between CRSsNPs and CRSwNPs. Whilst this principle 
is supported by previous studies, our research has shown for 
the first time that such differences are represented by signifi-
cant differences in the nasal domain of SNOT-22. PROMs are 
increasingly important in clinical care and research; this finding 
aids understanding into the way SNOT-22 score is composed 
amongst patients with different CRS subtypes and may help in 
understanding differing treatment responses for these patient 
groups as quantified by SNOT-22. Our study has also shown dif-
ferences in symptom reporting between males and females and 
is the largest UK study to quantify these differences amongst 
different CRS subtypes. Gender differences therefore should be 
considered when researching and treating CRS. Evaluation of 
symptoms in combination with endoscopic examination and/or 
CT scanning remains the gold standard for diagnosis but SNOT-
22 is important in evaluating patients’ experiences of symptoms 
and changes over time. Future work may include development 
of a utility tool based on the SNOT-22 that may be used more 
effectively in a primary care setting to help select appropriate 
treatment and referral pathways.
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SUMMARY 
 
Background:  
This study is part of the Chronic Rhinosinusitis Epidemiology Study (CRES). The 
overarching aim is to determine factors that influence the onset and severity of chronic 
rhinosinusitis (CRS). The aim of this analysis is to determine whether those with CRS are 
more likely to report psychiatric morbidity and in particular mood disturbance compared 
with healthy controls.  
 
Methods: 
CRES consists of a study-specific questionnaire regarding demographic and 
socioeconomic factors and past medical history as well as a nasal symptom score (SNOT-
22) and SF-36 (QoL - quality of life tool). Both of these tools contain mental health or 
emotional well-being domains. Participants were specifically asked whether they had 
ever consulted with their General Practitioner for anxiety or depression. Questionnaires 
were distributed to patients with CRS attending ENT outpatient clinics at 30 centres 
across the United Kingdom from 2007-2013. Controls were also recruited at these sites. 
Patients were divided into subgroups of CRS according to the absence/presence of polyps 
(CRSsNPs/CRSwNPs) or allergic fungal rhinosinusitis (AFRS). 
 
 
Results:  
Consultations with a family physician for depression or anxiety were higher amongst 
those with CRS than controls, but this was only significant for those with CRSsNPs. 
Odds ratio (OR) for CRSsNPs vs controls, 1.89, p=0.001; OR for CRSwNPs 1.40, 
p=0.078. Patients with CRS showed significantly higher mental health morbidity than 
controls across the mental health and emotional wellbeing domains of the SF-36 and 
SNOT-22.  Mean difference in the mental health domain of SF-36 was 8.3 for CRSsNPs 
and 5.3 for CRSwNPs (p<0.001). For the emotional domain of SNOT-22, differences 
were 7.7 and 6.3 respectively (p<0.001). 
 
Conclusions:  
Depression and anxiety are significantly more common in patients with CRS compared to 
healthy controls, especially in those with CRSsNPs. This added mental health morbidity 
needs consideration when managing these patients in primary and secondary care 
settings. 
 
INTRODUCTION 
 
Chronic rhinosinusitis (CRS) is a common condition with a recent European study 
showing the prevalence of to be 10.9% across Europe which equates to 6.8 million 
Britons affected(Bachert, Van Bruaene et al. 2009).  The recent European Position Paper 
on Rhinosinusitis and Nasal Polyps 2012 (EPOS) (Fokkens, Lund et al. 2012), defines 
rhinosinusitis in adults as ‘inflammation of the nose and the paranasal sinuses 
characterised by two or more symptoms, one of which should be either nasal 
blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip) ± facial 
pain/pressure ± reduction or loss of smell and either endoscopic or CT findings of polyps, 
mucopus or mucosal oedema. Rhinosinusitis is considered ‘chronic’ if symptoms persist 
for > 12 weeks. CRS is currently subdivided into two main types – CRS with and without 
nasal polyps (CRSwNP and CRSsNP respectively), as exemplified by EPOS 2012 
(Fokkens, Lund et al. 2012) to broad phenotypes, with allergic fungal rhinosinusitis 
(AFRS) as a distinct subtype of CRSwNP, which is particularly severe and difficult to 
treat. 
 
Whilst diagnosis and treatment of CRS is largely based on nasal symptoms, it is known 
that CRS has a much wider effect on health. Consultations for CRS both in Primary Care 
and ENT tend to focus on the symptoms used to make a clinical diagnosis (Fokkens, 
Lund et al. 2012) rather than a more holistic evaluation of patient well-being including 
mental health (Galderisi, Heinz et al 2015). A previous study of 158 patients has 
suggested significant morbidity in CRS with quality of life scores worse than amongst 
those with other chronic diseases such as lower back pain (Gliklich and Metson 1995). 
Since CRS primarily affects those aged 40-60 years, the significant effect on an 
individual’s functioning and productivity also has an impact in the workplace. CRS has 
been identified as one of the top ten most costly diseases for US employers (Goetzel, 
Hawkins et al. 2003). Qualitative interviews with patients with CRS have found that 
those affected describe low mood, poor sleep and even suicidal ideation (Erskine, 
Verkerk et al. 2015). EPOS states under the heading ‘Research Needs’ that studies are 
required to ‘investigate the impact of psychological problems such as depression, stress 
exposure and anxiety’ (Fokkens, Lund et al. 2012) .  
 
The overarching aim of the CRS Epidemiology Study (CRES) was to identify differences 
in socio-economic variables between patients with CRS and healthy controls to aid better 
understanding of medical and non-medical factors contributing to the development or 
worsening of CRS. The purpose of this study is to consider the differences in psychiatric 
morbidity between those with different types of CRS and controls using several different 
self-reported measures of mental health and emotional well-being. 
MATERIALS AND METHODS 
 
Study Design and Setting 
CRES was approved by the Oxford C Research Ethics Committee, sponsored by the 
University of East Anglia (UEA) and funded by the Anthony Long and Bernice Bibby 
Trusts. Following a pilot study of the questionnaire in 2006, the study commenced 
recruitment in ENT departments of the East Anglia region (East of England Deanery) of 
the UK in 2007. Following elevation to the National Institute of Health Research Clinical 
Research Network Portfolio in 2012, a total of 30 sites from around the UK (including 
Wales and Scotland) joined the study which ran between 2007 and 2013. The study 
specific questionnaire was anonymous and therefore consent was implied through 
participation. Participant information leaflets were provided.   
 
Participants 
Patients presenting to secondary care outpatient clinics and diagnosed with CRS by an 
ENT surgeon, as defined by the criteria laid out in the European Position Paper on 
Rhinosinusitis and Nasal Polyps (Fokkens, Lund et al. 2012) were invited to participate 
in the study regardless of symptom or disease severity or duration, and regardless of any 
prior interventions. Participants may therefore have been seen by ENT for the first time 
when they were recruited or they could have had treatment previously. Patients were 
classified by sub group of CRS (CRSsNPs, CRSwNPs or allergic fungal rhinosinusitis 
(AFRS) by a clinician prior to completion of the questionnaire using the EPOS 
definitions for with or without polyps (using endoscopic and/or radiological 
confirmation). Patients placed in the AFRS category met the Bent and Kuhn criteria 
(Bent and Kuhn 1994) or the St Paul’s Sinus Centre modification of this (Philpott, Javer 
et al. 2011). Controls included family and friends of those attending ENT outpatient 
clinics and hospital staff who had no diagnosis of nose or sinus problems and had not 
been admitted to hospital in the previous 12 months.  
 
Participants taking part in qualitative interviews were all recruited from one centre. 
Methodology and results of these studies are published elsewhere (Erskine, Notley et al. , 
Erskine, Verkerk et al. 2015) 
 
Variables and data sources 
The study questionnaire was designed with the input of the East of England Research 
Design Service and included study specific questions relating to socio-economic, 
environmental and medical co-morbid variables as well as the validated Short Form 36 
Quality of Life (QoL) measure (SF-36) (18) measure and the Sino-Nasal Outcome Test 
questionnaire (SNOT-22)(19). In this analysis the mental health domain of SF-36 and the 
emotional domain for SNOT-22 were also used. SNOT-22 asks 22 symptoms of CRS, 
both nasal and non-nasal, these are scored from 0 to 5 for severity, so the total is out of 
110. The emotional domain of SNOT-22 includes fatigue, reduced productivity, reduced 
concentration, frustration/restlessness/irritability, sadness and embarrassment. 
Participants were additionally asked whether they had consulted their GP for anxiety or 
depression. 
 
Statistical analysis 
The participant characteristics are described using mean and standard deviation for 
continuous measures and number and percentage for categorical variables. Both disease 
groups are compared to control in terms of proportion with any facial pain, anxiety, 
depression or anxiety and depression using logistic regression, using odds ratios to 
compare the disease groups to control. They were also compared using regression for 
Mental Health SF-36, SNOT-22 emotion, SF-36 total and SNOT-22 total, using the mean 
difference to compare the disease groups to control. Results were firstly unadjusted, then 
adjusted for age and sex. The mean difference was additionally adjusted for consultation 
for anxiety or depression. 
 
 
 
RESULTS 
A total of 1,470 participants were recruited as shown in table 1. The overall recruitment 
was 66% of those invited to participate. Information on reasons for non-participation is 
not available. 
 
Table 1: Demographic information of CRS subgroups 
 
 
1,464 participants included sufficient information to analyse consultations with anxiety 
and depression. All measures of mental well-being are shown in table 2. 
 
 
Table 2: Mental well-being variables by CRS group  
 
 
Differences between those with CRS and controls were found in rates of consultation 
with GP for anxiety and depression. Those with CRSsNPs reported significantly higher 
rates of consultation for both anxiety and depression than controls.  Those with CRSwNP 
reported higher rates of consultation for depression, but this was not significant. 
Differences were found in total and mental health SF-36 score and total and emotional 
domain of SNOT-22 score, with those with CRS scoring more poorly than controls, and 
those with CRSsNPs scoring more poorly than those with CRSwNP in SF-36 and SNOT-
22 overall and in both the mental health and emotional domains and in. Table 3 show 
odds ratios for these variables.  
 
 
Table 3: Differences in psychiatric morbidity between subgroups  
 
Those with CRSsNPs scored significantly more poorly than controls across all measures 
of mental and emotional health. Those with CRSwNPs scored more highly on the 
mental/emotional domains of SF-36 and SNOT-22.  
 Differences in scores for mental health and emotional domains as well as total SF-36 and 
SNOT-22 persist despite adjusting for consultation with GP for anxiety and depression 
(table 4). 
 
Table 4: Differences in SF-36 and SNOT-22 after adjustment for gender, age and 
anxiety/depression 
DISCUSSION 
Key Results 
All measures of anxiety and depression in this cohort were higher amongst those with 
CRSsNPs compared with controls. Mental health and emotional well-being measures 
were higher amongst those with CRSwNP than controls. Those with CRsNPs had scored 
more poorly than those with CRSwNPs. Differences in mental health and well-being 
persisted despite adjusting for consultation with GP for anxiety and depression. 
 
Strengths and limitations 
The study is self-reported, although there is no reason for any subgroup to over-report 
symptoms compared to any other. 
 
A strength of the study is the ability to triangulate information about psychiatric 
morbidity from three sources; SF-36, SNOT-22 and GP consultation.  
 
The study has focused on CRS patients in a secondary care setting, however it is 
recognised that the larger burden of CRS is seen in a primary care setting. We do not 
have data on disease severity according to objective measures such as the Lund Mackay 
score or endoscopic grading due to the anonymous self-reported nature of the study. 
These are known to be poor predictors of symptom severity(Hopkins, Browne et al. 
2007) Participants were examined (via endoscopy) to establish subgroup prior to entry 
into the study but no further assessment of clinical disease was taken. We do not know 
whether those who have seen a GP for anxiety or depression have ongoing symptoms. 
  
Interpretation 
Any person with chronic disease is likely to score less favourably for mental health/ 
emotional well-being since they will often need to adjust their lifestyle, hopes and even 
employment to accommodate their illness (Turner and Kelly 2000); given that CRS does 
not give rise to a specific disability, the extent of the morbidity it is associated with may 
be overlooked by clinicians (Erskine, Notley et al. , Erskine, Verkerk et al. 2015), which 
in itself may lead to increased levels of distress. Previous smaller studies of 63 rhinitis 
patients and 143 CRS patients respectively have also found that such patients have 
increased levels of anxiety and depression (Ryden O, Andersson B et al. 2004, Wasan, 
Fernandez et al. 2007). The causal association is not well-understood; depression and 
anxiety may amplify symptoms of CRS or be the consequence of living with CRS, or it 
may be that the co-morbid anxiety and depression are epiphenomena. These results show 
that the psychological co-morbidity associated with CRS is significant. Such co-
morbidities should be taken into account when managing patients. There is good 
evidence from other areas that appropriate treatment of co-morbid mental disorder is 
likely to improve outcomes of physical disorders (Moussavi, Chatterji et al. 2007). 
 
Both state anxiety (defined as fear, tension, and increased arousal induced temporarily by 
specific situations perceived as threatening) and trait anxiety (a predisposition to stress 
and worry) have been found to be higher amongst those with both allergic rhinitis (IgE 
mediated) and vasomotor rhinitis (Vidian nerve hypersensitivity) than controls 
(Addolorato, Ancona et al. 1999) and could reflect autonomic nervous system (ANS) 
dysfunction. The nose has a rich and complex nerve supply which is experienced on a 
routine basis; rhinorrhoea in cold weather or when eating spicy foods. The ANS has a 
role in altering the nasal airway during postural change(Ko, Kuo et al. 2008)  but the 
relevance of ANS dysfunction in the generation of nasal symptoms remains little studied. 
It has been evaluated in few previous series totalling fewer than 30 patients (Ishman, 
Martin et al. 2007). The main differences between patients and controls were that 
sudomotor, cardiovagal and adrenergic subscores were all significantly more abnormal 
amongst patients than controls, as were overall ANS scores.  
 
Personality traits, in particular ‘type A’ personality and anxiety are implicated in the 
development of cardiovascular disease, this may be explained by abnormal sympathetic 
nervous activity in response to stressors (Schroeder, Narkiewicz et al. 2000). Similar 
mechanisms may occur in the nasal airway, meaning that those who are more anxious 
already may be more likely to experience nasal symptoms such as congestion and 
rhinorrhoea. Fatigue is also a frequent concomitant symptom of ANS dysfunction and is 
regularly found in CRS patients.  ANS dysfunction may therefore contribute to the 
several components of CRS symptom generation, including: 
 1. Predisposing factors - Personality and or other factors which set ‘baseline’ ANS 
activity in an individual 
 2. Precipitating factors – Responses to environmental triggers and state anxiety 
 3. Perpetuating factors – ANS dysfunction may feed into low mood, anxiety and 
fatigue  
   
Stress and infections are independently associated with asthma development and 
exacerbation. There is evidence that stress hormones can alter immune processes, induce 
inflammation, and increase susceptibility to infection in those with asthma; T-Helper 
cells have particularly been implicated. Additionally, prolonged psychological stress is 
thought to predispose to respiratory infections in asthmatics (Trueba and Ritz 2013). CRS 
has a very complex aetiology, with bacteria, viruses, fungi, immune dysfunction, atopy 
and genetic predisposition all implicated; similar interactions with infection and stress 
may also apply. 
 
The differences between those who have CRS with and without polyps are perhaps more 
complex to understand. Our results show that those without polyps are more likely to 
consult with their GP and also tend to score more poorly on the mental and emotional 
scales, as well as total SF-36 and SNOT-22. Clinically, those with nasal polyps and in 
particular those with AFRS (where nasal polyps are also present) are often considered to 
have more severe disease with more obvious pathology. CRS is often considered to be a 
spectrum of disease from CRSsNP to AFRS. It could be logical to think therefore that 
patients with nasal polyps would experience more significant negative impact on their 
emotional well-being as a consequence of the physical manifestations of polyps, but this 
is not apparent in our data. Mental health scores in those with CRS have been found to 
correlate with subjective symptom scores (Nanayakkara, Igwe et al. 2013). Data from 
CRES found that when using total SNOT-22 scores, those with polyps scored more 
highly for nasal symptoms than those without (A cross sectional cohort study of Quality 
of life in CRS in the UK; a comparison between CRS subtypes, Rhinology journal – 
under review(Philpott, Erskine et al. 2016), although it is well known that measurements 
of individual objective parameters of disease such as peak nasal inspiratory flow rates or 
scoring the severity of CT scans (Lund Mackay score) do not correlate well with patients’ 
own self-reported symptom scores (Hopkins, Browne et al. 2007). Our results find that 
emotional well-being is worse amongst those without nasal polyps. One explanation 
could be that patients with polyps may have an expectation that these can be removed 
facilitating a ‘cure’. Some ‘sinonasal’ symptoms such as facial pain and headache have a 
vast possible aetiology and are well known to be associated with anxiety states; they are 
also found more frequently in patients with CRSsNPs than in those with polyps (found in 
our own study) (Durr, Desrosiers et al. 2001).  
 
It has been suggested that certain clinical variables such as age, culture, expectations and 
mental and physical health may influence patient’s reporting of their symptoms and 
consequently modify disease severity (Wilson and Cleary 1995). CRS patients with 
depression are known to report significantly worse pain and energy levels, and difficulty 
with daily activities when compared with a control group of CRS patients without 
depression (Brandsted and Sindwani 2007). Symptoms such as fatigue are also more 
likely to be reported in patients with depression. Studies have found dynamic changes in 
mu-opioid neurotransmission in response to an experimentally induced negative affective 
state which support a physiological basis for somatic amplification in patients with mood 
disturbance (Zubieta, Ketter et al. 2003, Wasan, Fernandez et al. 2007, Wasan, Fernandez 
et al. 2007). Pre-existing or concurrent psychiatric comorbidity may therefore affect 
symptom reporting, with those with psychiatric co-morbidities known to report elevated 
symptom scores (Wasan, Fernandez et al. 2007). In our study, differences in mental 
health and well-being persisted, despite adjusting for consultation with GP for anxiety 
and depression, with those with CRS scoring significantly more poorly than controls. So 
even those with no diagnosis of depression or anxiety are still reporting decreased mental 
health and emotional well-being. This should be taken into consideration when managing 
patients with mood disturbance and CRS.  
 
Clinically, the association between mood disturbance and CRS is important for many 
reasons. Depression or anxiety symptoms may decrease motivation to seek medical help 
or adhere to treatment plans (Turner and Kelly 2000). Many treatments for CRS involve 
nasal douching or application of nasal sprays or drops which can be time-consuming and 
inconvenient (Erskine, Notley et al.) and may be more challenging to stick to than simply 
taking a tablet. Oral steroids are frequently used in the management of nasal polyps and 
are known to affect mood in many ways; clinicians should be careful to discuss these 
mood-altering effects in those who may already have a mood disturbance. It may be 
necessary to screen those whose symptoms are particularly bothersome for anxiety or 
depression diagnoses, for example the Hospital Anxiety and Depression Score (HADS), 
to see whether such symptoms require treatment over and above management of nasal 
symptoms. Simply taking note of a patient’s symptoms may be beneficial (Erskine, 
Notley et al. , Erskine, Verkerk et al. 2015). Other simpler measure such as writing down 
experiences have been found to bring about measurable physiological improvements in 
patients with comparable chronic conditions such as asthma (Smyth, Stone et al. 1999).  
 
Conclusion 
Our study has shown that those with CRS experience poorer mental well-being than 
healthy controls. Additionally, those with CRSsNPs score worse than those with polypoid 
disease. This is the largest UK study to show such a difference between these phenotypes, 
although anecdotally many clinicians have seen such a phenomenon in clinical practice. 
Our results should influence management strategies for patients with different nasal 
pathologies by highlighting the importance of considering the non-nasal sequelae and 
associated symptoms of CRS particularly amongst those with CRSsNPs.  
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Table 1: Demographic information of CRS subgroups 
 
  Controls CRSsNP CRSwNP AFRS 
Participants 221 553 651 45 
Females 143 (68.4%) 259 (53.1%) 185 (32.2%) 19 (43.2%) 
Mean Age 
(s.d) 
47.3 (14.9) 51.8 (15.3) 56.0 (14.6) 56.1 (12.7) 
Range 19-82 18-84 17-102 20-76 
 
Table 2: Mental well-being variables by CRS group  
 
  Controls   % CRSsNP  % CRSwNP/AFRS  % 
Total  221  551  692  
Consultation 
with GP Anxiety 
35 15.84 128 23.23 112 16.21 
 Depression 32 14.48 139 25.23 139 20.09 
 Anxiety or 
depression 
43 19.46 173 31.40 175 25.29 
Any facial 
pain  
28 13.86 363 70.90 388 57.82 
  Mean S.D Mean  S.D Mean  S.D 
Mental health SF-36 77.91  14.99 69.58 19.82 72.65 18.23 
SNOT-22 (emotional 
domain) 
3.66 5.51 11.37 7.64 9.92 7.46 
SF-36 total 80.75 15.12 65.92 21.41 69.28 19.62 
SNOT-22 total 12.11 13.95 45.67 21.05 44.41 21.62 
 
Table 3: Differences in psychiatric morbidity between subgroups  
 
 CRSsNP vs control 
 
 
 
CRSwNP vs control 
 
 Unadjusted Age-sex adjusted Unadjusted Age-sex adjusted 
 
Odds ratio p-value Odds ratio p-value Odds ratio 
p-
value 
Odds ratio 
p-
value 
Anxiety 
1.61 (1.07,2.43) 0.024 1.83 (1.16,2.88) 0.009 
1.03 
(0.68,1.56) 
0.896 
1.38 
(0.86,2.20) 
0.183 
Depression 
1.99 (1.31,3.04) 0.001 2.25 (1.41,3.57) 0.001 
1.48 
(0.98,2.26) 
0.064 
2.03 
(1.26,3.25) 
0.003 
Anxiety or 
depression 
1.89 (1.30,2.77) 0.001 2.14 (1.41,3.24) <0.001 
1.40 
(0.96,2.04) 
0.078 
1.88 
(1.23,2.87) 
0.004 
Any facial pain 
15.14 (9.73,23.56) <0.001 
27.36 
(16.31,45.90) 
<0.001 
8.52 
(5.56,13.06) 
<0.001 
18.46 
(11.02,30.92) 
<0.001 
 
Mean difference p-value Mean difference p-value 
Mean 
difference 
p-
value 
  
Mental health -8.33 (-11.22,- <0.001 -9.39 (-12.39,- <0.001 -5.26 (-8.06,- <0.001 -8.49 (- <0.001 
SF-36 5.44) 6.39) 2.46) 11.49,-5.48) 
Snot22 
(emotion) 
7.71 (6.53,8.89) <0.001 8.28 (7.06,9.50) <0.001 
6.26 
(5.12,7.40) 
<0.001 
7.50 
(6.28,8.71) 
<0.001 
SF-36 -14.84 (-17.94,-
11.74) 
<0.001 
-15.32 (-18.56,-
12.08) 
<0.001 
-11.48 (-
14.48,-8.48) 
<0.001 
-13.30 (-
16.55,-10.05) 
<0.001 
SNOT-22 33.57 
(30.21,36.92) 
<0.001 
35.99 
(32.50,39.47) 
<0.001 
32.30 
(29.07,35.54) 
<0.001 
36.81 
(33.33,40.30) 
<0.001 
 
 
 
 
 
 
Table 4: Differences in SF-36 and SNOT-22 after adjustment for gender, age and 
anxiety/depression  
 
 CRSsNP vs 
control 
 % 
CRSwNP vs 
control 
 % 
 Mean 
difference 
p-value 
Mean 
difference 
p-value 
Mental health SF-36  
-7.00 (-9.72,-
4.28) 
<0.001 
 
-6.48 (-9.21,-
3.76) 
<0.001 
Snot22 (emotion) 7.50 (6.34,8.66) <0.001 6.86 (5.70,8.01) <0.001 
SF-36 -13.08 (-16.12,-
10.05) 
<0.001 
-11.43 (-14.47,-
8.40) 
<0.001 
SNOT-22 34.45 
(31.05,37.86) 
<0.001 
35.51 
(32.12,38.90) 
<0.001 
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ABSTRACT (250) 
Objectives  
Direct comparison of different diseases allows clinicians and researchers to place the burden of symptoms 
and impact on quality of life of each condition in context. Generic health-related quality of life 
assessment tools allow such analysis, limited data is available for British patients with Chronic 
rhinosinusitis. 
Design 
As part of a larger feasibility study, patients underwent baseline assessment using the SNOT-22, SF-12 
and EQ-5D-5L tools. Data was analysed using Microsoft excel and algorithms available for the analysis 
of the later 2 tools. We plotted EQ-5D-5L VAS and utility scores and SF-12 MCS and PCS scores 
separately against SNOT-22 scores and quantified associations using bivariate ordinary least squares 
regression analysis. 
Setting 
Patients were prospectively recruited from 6 UK outpatient clinics.  
Participants 
Adult patients with chronic rhinosinusitis without nasal polyps (CRSsNPs).  
Main Outcome measures 
Baseline SNOT-22, SF-12 and EQ-5D-5L scores. 
Results 
Fifty-two adults were recruited with a mean age of 55 years, 51% were male. The mean SNOT-22 score 
was 43.82. Mental and physical component scores of the SF-12 were 46.53 and 46 respectively. Mean 
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index score computed form the EQ-5D-5L was 0.75. Worse (higher) SNOT-22 scores were associated 
with lower EQ-5D-5L VAS and utility scores and SF-12 MCS and PCS scores. 
Conclusion 
The EQ-5D-5L suggests that British CRSsNPs patients are negatively impacted with regards to quality of 
life. We found the SF-12 to be less sensitive and conclude that the EQ-5D-5L tool is a quick and 
accessible method for assessing QOL in order it can be compared with other disease states.  
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Introduction 
There is accumulating evidence of the personal and societal impact of chronic rhinosinusitis (CRS) with 
regards to symptom severity 
1
, reduced productivity and absenteeism 
2
. Many studies of patients with 
CRS increasingly using the Sinonasal Outcome Test (SNOT-22) (disease specific, internationally 
validated questionnaire) as an outcome measure 
3
. While this allows for excellent assessment and 
monitoring of the impact of CRS symptoms at an individual level, it does not allow direct comparison 
with other chronic conditions. Generic health-related quality of life (HRQoL) assessment tools allow 
comparison of disease states on both a functional level 
4
 and with regards to and the burden to society 
each condition presents. Such tools include the EuroQoL Five Dimension tool (EQ-5D-3L/5L)
5
,  Health 
Utilities Index 
6
, the Short Form 36 (SF-36) 
7
 and the latter’s shortened versions, the SF-12 and SF-6D.  
Lange et al published health utility assessments from the trans-European GALEN study that showed a 
lower health-related quality of life using the EQ-5D-3L in CRS patients compared to those without CRS 
8
. A recent study in the USA reported a lower health utility value (also generated by the EQ-5D) for 
patients with CRS compared to the general population, the value was similar to that of other chronic 
disease such as mild asthma and migraine 
9
. A large UK epidemiological study recently showed those 
with CRS to have lower QOL using the SF-36, specifically both mental health and emotional domains 
were lower 
10
.   The SF-36 was converted to a shorter form, the SF-12 and validated for use within the UK 
11
. The SF-12 has itself been used for CRS patients outside the UK
12
 and as a short and quicker method of 
assessing HRQoL than the SF36 it is potentially more attractive for future research. Thus, the aim of this 
study is to evaluate the EQ-5D-5L and SF-12 health utility measures in a UK CRS population. In addition 
the data can be seen alongside the widely published disease-specific SNOT-22 questionnaire.     
Methods 
As part of a feasibility study, a prospective cohort of patients were recruited from six UK centres with a 
confirmed diagnosis of CRS without nasal polyps (CRSsNPs) just prior to commencing maximal medical 
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therapy 
13
. The study was ethically approved by the West Midlands Research Ethics Committee (ref: 
12/WM/0359) and included on the UK CRN portfolio (ref: 13417).  Funding was provided by a Royal 
College of Surgeons Pump Priming Grant and supported by the Anthony Long and Bernice Bibby Trusts. 
All patients recruited were diagnosed with CRSsNPs according the EPOS 2012 criteria 
14
 by a rhinologist 
in a specialist clinic and subsequently underwent 2 face-to-face study visits and a third interaction via 
postal correspondence (questionnaires and feedback only). Patients who did not complete all 
questionnaires were excluded from this analysis. Adult patients between 18 and 70 years, with a diagnosis 
of CRSsNPs as per the EPOS guidelines who had not received maximal medical treatment previously 
were included, and although previous surgery was not a reason for exclusion although no patients had 
undergone previous endoscopic sinus surgery.  Patients with CRSwNPs and secondary CRS (eg 
Wegner’s, immunodeficiency) were excluded. Patients received a 12-week course of Clarithromycin 
250mg b.d. alongside b.d. nasal douching and intranasal mometasone, (2 squirts, each nostril b.d.), the 
latter two being continued for a further 12 weeks.  
Measures 
The SNOT-22 is an internationally validated disease-specific questionnaire detailing both disease-specific 
(e.g. blocked nose) and global (e.g. sleep disturbance) domains
3
. Twenty-two items are covered and 
scored on a Likert grading system (0-5). The resulting scores range from 0 – 110, the median score in a 
normal population without CRS ranges between 6.5 and 13 in published studies 
15
. 
The SF-12 questionnaire (a condensed version of the SF-36) is a 12-point assessment tool covering eight 
dimensions of health; two validated scores are produced, the physical component summary (PCS) and the 
mental component summary (MCS) . The scores compare to a norm-based scoring algorithm where 50 is 
the typical adult, a score of over 50 indicates better health than the typical person and less than 50, worse 
health.  
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The EQ-5D-5L is a standardised measure of health status consisting of a visual analogue scale (VAS) to 
assess patient reported health state on the day of completing the survey (0 = worst imaginable health state 
and 100 = best imaginable health state) in addition to a questionnaire with 5 dimensions (mobility, self-
care, usual activities, pain/discomfort and anxiety/depression) (EuroQol 2011) 
16
. Each of the dimensions 
asks for a response that corresponds to a health status level of no problems, slight problems, moderate 
problems, severe problems, and extreme problems that are coded level 1-5 respectively. The levels can 
then converted into a health index score using the website (https://www.ohe.org/publications/valuing-
health-related-quality-life-eq-5d-5l-value-set-england), according to the population setting (in this case 
UK), on a scale where 1 equals perfect health and 0 equals death, and values less than zero represent 
states worse than death.  
All 3 questionnaires were completed by patients at baseline, 12 weeks and 6 months, for the purpose of 
this analysis which aimed to report HRQoL for British CRS patients only baseline data is reported.  
Analysis 
All results were analysed using Microsoft excel. In addition, the EQ-5D-5L was analysed using the 
euroqol website to give an index score.  
We plotted EQ-5D-5L VAS and utility scores and SF-12 MCS and PCS scores separately against SNOT-
22 scores and quantified associations using bivariate ordinary least squares regression analysis, regressing 
each measure separately against SNOT-22 scores.   
 
Results 
Fifty-five patients were recruited over a 13-month period (January 2013-January 2014), the mean age was 
55 years (range 21-81) and 51% were male. Following exclusions 52 patients who completed all 3 
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questionnaires were included in this study. The mean SNOT-22 score was 43.82 (Standard deviation 
22.4).  
SF-12 scores are reported as 2 separate scores, the mental and physical component. The mean MCS was 
46.53 (SD of 11.46) and the mean PCS 46 (SD of 11.46), both lower than the score expected for a ‘typical 
adult’ (e.g. score of 50 or above).  
The EQ-5D has two components, the questionnaire given an index score and the VAS. The mean index 
score of was 0.75 (SD of 0.23).  The questionnaire component is reported as the percentage of patients 
reporting a particular level within each of the 5 dimensions and is represented in table 1. The mean VAS 
score was 73.38. 
Worse (higher) SNOT-22 scores were associated with lower EQ-5D-5L VAS and utility scores and SF-12 
MCS and PCS scores (Figure 1). In all cases the coefficient on SNOT-22 score was statistically 
significant and negative (all four p-values on the SNOT-22 score regression coefficient<0.05).   
Discussion 
Synopsis of key/new findings with comparison with other studies 
This is the first publication of EQ-5D and SF12 scores in UK patients diagnosed with CRSsNPs in 
accordance to the EPOS-2012 guidelines.  The mean SNOT-22 score in this study is comparable to other 
larger published cohorts of patients with CRSsNP undergoing medical treatment in a hospital setting, and 
therefore our results are likely to be generalisable to CRS patients referred for ENT treatment across the 
UK. 
Using the norm-based scoring system published by the developers of the SF-12 (where the mean score in 
the general population is 50 with a standard deviation of 10 in the USA general population) both physical 
(self-care, physical and social activities alongside bodily pain and tiredness) component score (46.53) and 
mental (psychological distress) component summary scores (46) are both reduced. Compared to values 
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for a British population with ‘No reported chronic illness’ (scores of 52.08 (PCS) and 51.60 (MCS) 
17
, the 
scores are notably lower and similar to previously reported CRS studies 46.7 and 45.6 (PCS and MCS 
respectively, USA population) 
18
.  
Overall the SF-12 scores suggest that despite their CRS, patients manage relatively well with regards to 
both physical and mental quality of life components when compared to other chronic diseases (see table 
2). The findings from this study are in contrast with work by Glicklich et al 
19
 and Erskine et al 
10
 who 
used the full SF-36. In the later study overall scores were reduced in CRS patients when compared to non-
CRS controls, with a difference of 11-17 points (p<0.001) for overall quality of life.  In their study, a 
significant difference was also found when looking at the mental and emotional health domains; those 
with CRS scored more negatively than those without, with those with CRSsNPs scoring more poorly than 
those with nasal polyps. Qualitative interviews have also found significant negative quality of life related 
issues . There are several reasons for the discrepancy; it may be that the SF-12 lacks the sensitivity to 
detect the impact of CRS on the HRQoL of the patient, as the tool focuses largely on physical activity and 
mobility. One common problem for patients relating to quality of life is known to be accessing 
appropriate treatment, and the feeling that symptoms are not taken seriously hence there may therefore be 
benefit for the patients in the trial in knowing they are receiving treatment while taking part in a trial. 
Additionally concurrent asthma contributes negatively on quality of life in CRS, at the main recruiting 
site of our study 16% of the 38 patients were found to have asthma compared with 21% in the more 
broadly inclusive CRES study 
20
 which may explain some of the difference in QoL. 
EQ-5D-5L suggests there is a greater impact of CRS as the health index score generated for this group of 
patients was 0.75. We are limited by the lack of UK studies that use the newest version of the EQ-5D (5 
level version as used in this study) when putting this figure into context. Data from the USA shows 
COPD patients to have an index score of 0.79 
21
 and European data showed a score of 0.69 in patients 4 
months after a stroke
22
 Hence our study would suggest that CRS does impact on quality of life and 
perhaps surprisingly to similar scale as that seen in other chronic disease states.  
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Health profile reporting shows that many patients are able to continue about their normal activities of 
daily living with the majority reporting a level 1 response of ‘no problem’ with regards to mobility, self-
care and usual activities. Contrary to this patients were more affected in the domains of pain/discomfort 
and anxiety/depression with a larger percentage reporting a level 2 (slight problems) or 3 (moderate 
problems). This is of interest on two accounts, first similar to the aforementioned studies there appears to 
be a psychological aspect to the disease that is not particularly highlighted with the SF-12. Secondly, that 
pain/discomfort is reported in a significant number of patients in line with previous studies which have 
shown that 70% of patients with CRSsNPs undergoing sinus surgery report facial pain
23
 alongside higher 
rates of anxiety and depression 
10
. 
It is interesting that the health index score for our UK cohort of patients undergoing a trial of medical 
treatment suggests greater disease burden than a US cohort of patients who have already failed medical 
therapy and have been selected for surgery (index value of 0.81)
9
 but may reflect differences in accepted 
maximum medical therapy between the two nations. In our feasibility study, 50% of patients improved 
with maximal medical treatment 
13
, and therefore one would expect those selected for surgery in the US 
study to be a more severely affected subgroup. Of note, surgical intervention rates in the US are 
significantly higher than in the UK and may reflect lower thresholds for surgery in the US. In addition it 
may also reflect differences in primary care treatment, such that only more severely affected patients are 
treated within secondary care in the UK. This highlights the importance of evaluating health utility in a 
UK cohort and puts the disease in perspective as compared to other commonly encountered chronic 
disease states. 
Strengths of this study 
This study data is useful in two ways, firstly it provides a reference generic QOL measurement in UK 
patients with CRS for future researchers. We have shown the mean SNOT-22 scores to be in line with a 
large UK epidemiological study 
24
 and hence the data provided here can be used as a benchmark for 
Page 9 of 21
Clinical Otolaryngology
Clinical Otolaryngology
For Peer Review
future patient cohorts. Additionally they allow comparison of CRSsNPs with other chronic disease states, 
the health index scores obtained from the EQ-5D data indicate it has significant impact on patients.  The 
health index score generated for this group of patients gives a simple value in which to compare other 
CRS cohorts internationally but also allows comparison with other chronic disease states.  
A recent European study found a prevalence of CRS to be at 11% but despite comparable prevalence rates 
to both asthma and diabetes with similar negative impact upon quality of life and economic burden, there 
is a considerable disparity in the research funding and publications rates between the conditions. We 
would hope that the data would support future research into treatments for CRS on par with that for 
chronic respiratory disease and back pain. Making comparisons to other chronic conditions puts the plight 
of CRS patients into perspective.  
The fact that patients included in this study presented to a specific rhinology clinic (rather than a general 
ENT outpatient clinic) is a limitation of the study as it means there may be a bias towards those with more 
severe disease. However, due to the similar SNOT-22 scores to other CRSsNPs patients in larger cohorts 
24 25
 and because the exclusion criteria prevented those who had tried previous maximal medical therapy 
from joining the study (therefore unlikely to have had recalcitrant disease), we believe the patients 
included here to be representative. Other limitations include the small sample size and lack of data from 
patients with CRS with nasal polyposis, which should be performed in the future. 
Clinical applicability of the study 
Index value generated from the EQ-5D questionnaire shows UK patients with CRSsNPs to be negatively 
affected with regards to their HRQoL with scores in line with other chronic disease states. We would 
advise using the EQ-5D-5L questionnaire, as a quick and reliable method of assessing HRQoL in future 
studies using CRS cohorts. The SF-12 has not been shown on this occasion to be particularly useful and 
as such we would not advise it is used in CRS related studies but perhaps replaced by the SF-36 as used in 
other studies.   
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Figure 1a-d. Association between SNOT-22 scores and EQ-5D-5L VAS and utility scores and SF-12 
MCS and PCS scores 
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Table 1: Percentage of patients reporting each level (no problems = level 1, extreme problem = level 5) of 
the 5 dimension components of the EQ-5D 
Table 1 
% of 
patients 
reporting 
Mobility Self-care Usual 
activities 
Pain/discomfort Anxiety/depression 
 level 1 69.23 90.38 60.46 32.69 57.69 
 level 2 11.54 0 15.38 30.77 21.15 
 level 3 9.62 7.69 15.38 25 17.31 
 level 4 9.62 1.92 5.77 9.62 1.92 
 level 5 0 0 0 1.92 1.92 
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Table 2: Physical Component Scores (PCS) and Mental Component Scores (MCS) of the SF12 
Questionnaire.  
 PCS MCS 
Current study 46.53 46 
Benign Prostatic Hypertrophy
17
  44.57 44.08 
Congestive heart failure
17
 31.47 38.36 
Parkinson’s
17
 23.30 29.09 
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Figure 1a. Association between SNOT-22 scores and EQ-5D-5L VAS  
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Figure 1b. Association between SNOT-22 scores and EQ-5D-5L  utility scores  
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Figure 1c. Association between SNOT-22 scores  SF-12 MCS scores  
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Figure 1d. Association between SNOT-22 scores  SF-12 PCS scores  
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Quality-of-life outcomes after sinus surgery in allergic
fungal rhinosinusitis versus nonfungal chronic
rhinosinusitis
Liam Masterson, M.D., Francesco M. Egro, M.D., Jessica Bewick, M.D., Sally E. Erskine, M.D.,
Alan Clark, Ph.D., Amin R. Javer, M.D., and Carl M. Philpott, M.D.
ABSTRACT
Background: Given the differences in pathophysiology between allergic fungal rhinosinusitis (AFRS) and other chronic rhinosinusitis (CRS) subgroups,
it remains unclear about whether these patients respond differently to a combination of surgical and medical treatments.
Objective: To evaluate differences in quality-of-life (QoL) outcomes for a cohort of patients who underwent endoscopic sinus surgery (ESS) for CRS.
Methods: This retrospective review included patients with CRS who underwent ESS between 2010 and 2013. QoL was measured by using the 22-item
Sino-Nasal Outcome Test (SNOT-22). Variables collected included baseline demographics, SNOT-22 scores before ESS and at 1, 3, 6, 9, and 12 months after
ESS. Groups tested were CRS with nasal polyposis, CRS without nasal polyposis (CRSsNP), and patients with AFRS. A linear mixed- effects regression model
was used to calculate the adjusted mean QoL differences.
Results: Among the 250 patients included, 61.6% had CRS with nasal polyposis (n  154), 28.8% had CRSsNP (n  72), and 9.6% had AFRS (n  24).
Significant differences were seen in SNOT-22 scores between pre- and postoperative visits and between the etiologic subgroups (p  0.001). Multivariate
analysis revealed significantly greater improvement in QoL for patients with AFRS in comparison with those with CRSsNP at the 9-month follow-up (change
in SNOT-22 score, 22.6 [95% confidence interval, 1.2–44.1]; p  0.0) and the 12-month follow-up (change in SNOT-22 score, 20.2 [95% confidence interval,
0.5–39.9]; p  0.04).
Conclusions: Patients with AFRS experienced a more-prolonged QoL benefit from surgical and targeted medical intervention compared with those with
CRSsNP, which may reflect the severity of inflammation that they presented with compared with other CRS subtypes.
(Am J Rhinol Allergy 30, e30–e35, 2016; doi: 10.2500/ajra.2016.30.4280)
Chronic rhinosinusitis (CRS) is a debilitating disease that impactsthe quality of life (QoL) and productivity of patients, with
significant financial implications for health care systems.1 According
to a recent analysis of U.S. National Health Interview Survey data,
CRS affects 1 in 10 adults.2 The impact of the disease on QoL, as
measured by Short Form 36 scores, is reportedly worse than other
major disease states, such as congestive heart failure, chronic obstruc-
tive pulmonary disease, and back pain.3
Allergic fungal rhinosinusitis (AFRS) is a severe form of CRS that
was first reported by Safirstein4 and Millar et al.5 in 1976 and 1981,
respectively.4,5 It is believed to be an immunologic reaction to micro-
scopic environmental fungi.6–8 Patients with this condition form nasal
polyps and display thick fungal mucin and debris in the paranasal
sinus cavities. The AFRS cycle indicates that continuous antigenic
exposure, atopy, and inflammation all play key roles in the patho-
physiology of the disease. Addressing each of the above factors,
therefore, will provide the best chance of long-term disease control.
An integrated approach to management usually depends on com-
plete surgical removal of all fungal disease and long-term prevention
of recurrence through either immunomodulation (immunotherapy
and/or corticosteroids) or fungistatic antimicrobials (e.g., itracona-
zole). At present, recurrent disease is a frequent occurrence (espe-
cially if surgical or medical therapy are used in isolation), and, con-
sequently, there is no consensus on the correct medical therapy.9,10
The Bent and Kuhn diagnostic criteria for AFRS requires the fol-
lowing: (a) type I (immunoglobulin E) hypersensitivity reaction to
fungal subtypes (confirmed by history, skin tests, or serology), (b) the
“double density sign” on computed tomography (CT), (c) nasal pol-
yposis, (d) eosinophilic mucus, and (e) positive fungal stain of sinus
contents.11,12 A positive or negative fungal culture does not confirm or
refute the diagnosis of AFRS because clinical laboratories vary in
specimen handling and other capabilities that may significantly in-
fluence the rate of positive fungal cultures.12,13 Furthermore, fungal
disease may proliferate as saprophytic growth in diseased sinuses.
A variety of scoring symptoms have been developed to provide a
quantitative measure of the symptomatology of CRS in studies of
clinical effectiveness. The Sino-Nasal Outcome Test (SNOT-22) is an
internationally validated, disease-specific QoL assessment tool devel-
oped for assessing symptom severity and the impact of rhinosinus-
itis.14,15
Investigating the relationship between patient disease character-
istics and endoscopic sinus surgery (ESS) at postoperative fol-
low-up time points is important for the physician-patient consul-
tation. However, it remains unclear how QoL for different patient
groups may change at these time intervals, especially those with
AFRS versus other CRS groups (CRS with nasal polyposis
[CRSwNP], CRS without nasal polyposis [CRSsNP]). This study,
therefore, aimed to assess the perioperative outcomes in an unse-
lected cohort of patients, with specific emphasis on QoL and other
pertinent clinical factors.
METHODS
Study Population
This retrospective study received approval of the local clinical
research and audit governance committee (James Paget University
Hospital). Patients with CRS (16 years old) who underwent ESS
between March 2010 and December 2013 at a regional tertiary referral
center were included in the analysis. CRS was diagnosed based on the
criteria laid down in the European Position Paper on Rhinosinusitis
and Nasal Polyps in 2012.16 In our institution, we used a modified
version of the “Bent and Kuhn criteria” for AFRS, which replaces
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immunoglobulin E hypersensitivity with immunocompetence.9 L.
Masterson and F.M. Egro contributed equally to this work.
Only patients with preoperative and 1 postoperative available
QoL scores were included in the analysis. No ethical approval was
sought because this study was conducted as an audit of ESS out-
comes. ESS was recommended to patients for whommaximal medical
therapy failed; many patients in the AFRS group who were referred
had previously undergone surgical procedures (15 of 24 patients;
average, 2.13 procedures per patient).
The data recorded included self-reported patient characteristics
(age, sex, race, smoking, allergic rhinitis, asthma, aspirin sensitivity,
previous sinus surgery, preoperative medical therapy), diagnosis,
preoperative CT findings, complications, and revision rates. Disease-
specific health-related QoL was assessed by using a validated QoL
instrument (SNOT-22). Patients in our unit are routinely asked to
complete this questionnaire at pre- and postoperative period visits.
For the purpose of this analysis, the time points considered were the
last preoperative score (after maximum medical therapy) and at 3, 6,
9, and 12 months after surgery. The minimal clinically important
difference for the SNOT-22 score has previously been determined
as 8.9.17
Clinical Management
Preoperative Therapy. All the patients received a course of perioper-
ative prednisolone (40 mg/day) and co-amoxiclav (625 mg/day),
starting 7 days before surgery (unless contraindicated).
Operative Technique. Topical preparation involved buffered Moffat
(cocaine) solution. The standard operative approach included de-
bridement of nasal polyps if required and sinus dissection tailored to
the preoperative CT, which would include (when appropriate) total
uncinectomy and visualization of natural maxillary sinus ostia or
revision of previous antrostomies (by using an angled 30° or 70°
endoscope), total ethmoidectomy, sphenoidotomy, and frontal si-
nusotomy. Sinus cavities were lavaged with saline solution that con-
tained baby shampoo (and with amphotericin B in cases of AFRS). A
solution of Nasacort (Sanofi, Guildford, United Kingdom) and gen-
tamicin was instilled into the maxillary and ethmoidal sinuses, and
also was used to soak bilateral middle meatal spacers left in situ for 1
week.18 An image guidance system (Fusion ENT Navigation System,
Medtronic, MN) was used by the senior author (C. P.) for the majority
of cases from 2011 onward. Any samples taken were sent for histo-
pathology and/or microbiology, culture, and sensitivity with or with-
out fungal stain.
Postoperative Therapy. Prednisolone 40 mg/day was continued for 1
week, with a reducing regime of 5 mg/day thereafter for 7 days.
Co-amoxiclav 625 mg was continued for 1 week. Patients were ad-
vised to perform saline solution nasal douching twice daily. Topical
therapy was commenced on day 7 (after removal of middle meatal
spacers and debridement of debris) in cases of patients with CRSsNP,
Nasonex 2 puffs twice daily (mometasone; Merck & Co, Inc, White-
house Station, NJ), and in patients with CRSwNP and AFRS, Pulmi-
cort nebules (budesonide 0.5 mg per 2 mL; AstraZeneca, Luton,
United Kingdom) were added to the saline solution douches. Sys-
temic itraconazole was given selectively if fungal mucin was seen
during surgery or in the postoperative period.9 A major complication
was defined as the following: (1) epistaxis  500 mL, which required
blood transfusion, placement of intranasal packs, surgical ligation, or
embolization; (2) orbital trauma that required intervention; or (3)
intracranial trauma that required intervention.19
Statistics
All data were analyzed by using IBM SPSS for Windows version
20.0 (SPSS, Inc., Chicago, IL). A p value of 0.05 was considered to be
of statistical significance. First, we compared continuous variables by
using one-way analysis of variance tests, and we used the 2 test to
compare categorical variables. The mean SNOT-22 scores before ESS
and at 1, 3, 6, 9, and 12 months after ESS were calculated and
categorized into the three etiologic groups. The CRSsNP subgroup
was chosen as the reference population to allow comparison of out-
comes with other patient cohorts at the various time points.20 Also, we
carried out a multivariate linear mixed-effects regression model. If a
SNOT-22 score was missing at a certain point, then the rest of the
scores for that same patient were still incorporated in the final anal-
ysis. The model included fixed and random effects analysis to account
for the correlation between repeated SNOT-22 score measures per
patient.
RESULTS
This study included 250 patients with adequately completed
SNOT-22 scores, and who met the inclusion criteria. The mean (stan-
dard deviation) age was 54.1  14.6 years, with a male predominance
(62%). The distribution of CRS subtypes, shown in Fig. 1, includes the
following: CRSwNP, 61.6% (n  154); CRSsNP, 28.8% (n  72); and
AFRS, 9.6% (n  24). A total of 32% patients (n  80) had undergone
previous sinus surgery (range, 1–20; mean, 2.25 procedures). During
the study period, two patients (1%) required a further revision after
initial image-guided sinus surgery; of these two patients, one had a
history of ESS.
There were four patients with major complications (two specific,
two nonspecific); one additional patient had a500 mL blood loss but
required no packing or transfusion (Table 1). These five patients and
one additional patient required an overnight stay, although three of
these six patients were private patients booked as overnight cases.
Two further patients had a breach of the lamina papyracea, but there
were no symptomatic issues for these patients, nor any sequelae.
The prevalence of asthma, aspirin sensitivity, and allergic rhinitis
were significantly higher in the AFRS group. In addition, patients
with AFRS were more likely to have undergone previous ESS surgery
and to have a higher preoperative Lund-Mackay CT score. There
were no significant differences for each etiologic group in terms of
age, race, or smoking. Patients with CRSwNP were more likely to be
men in comparison with the other groups (Table 2).
Analysis of the data for all subtypes revealed a statistically significant
decrease (p  0.01) in scores at the 3-month post-ESS SNOT-22 assess-
ment (mean, 21.7) compared with preoperative assessment (mean, 54.2).
Subgroup analysis showed a similar statistically significant decrease in
SNOT-22 scores (p  0.01): CRSwNP decreased from 53.7 to 20.3,
CRSsNP decreased from 55.5 to 27.2, and AFRS decreased from 53.2 to
16.9. The results are shown in Fig. 2. This trend continued at 6, 9, and 12
months (p 0.01). The mean SNOT-22 scores over time by patients with
CRSwNP, CRSsNP, or AFRS are summarized in Table 3. Among the 250
patients with preoperative SNOT-22 scores, 14% (n  36) were dis-
charged in3months, 50% (n 124) in6months, 58% (n 146) in9
months, and 69% (n  172) in 12 months.
The linear mixed-effects regression models were performed to es-
tablish the differences of the changes in SNOT-22 scores over time
among the AFRS, CRSwNP, and CRSsNP groups, and the results are
shown in Table 4. After adjusting for all clinical factors, compared
Figure 1. Diagnostic categories (in percentages).
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with patients with CRSsNP, there were significantly more improve-
ments in QoL in patients with AFRS from baseline to 9 months
(SNOT-22, 22.6 [95% confidence interval, 1.2–44.1]; p  0.03) and at
the 12-month follow-up (SNOT-22, 20.2 [95% confidence interval,
0.5–39.9]; p  0.04). Increasing age and smoking were retained in the
final model because both factors were significantly associated with
adverse SNOT-22 scores (changing the point estimate of the associa-
tion among AFRS, CRSwNP, or CRSsNP). Other variables not re-
tained in the final model included asthma, race, sex, allergic rhinitis,
aspirin sensitivity, and previous sinus surgery. The SNOT-22 scores
before ESS and at 1, 3, 6, 9, and 12 months after surgery arranged by
the three main subgroups are shown in Fig. 3.
DISCUSSION
This article provides a comprehensive assessment of QoL outcomes
after surgical treatment in patients with CRS, including those with
AFRS. One previous study, published in 2010, looked at surgical
outcomes in patients with AFRS, but this did not provide a correlation
with the other CRS subgroups.21 Analysis of our data inferred that
10% of all the patients with CRS who were treated had a diagnosis
of AFRS. This finding would support epidemiologic data that indi-
cates AFRS is present in 7–10% of patients with nasal polyposis and
can often go undiagnosed.22
Clinical Outcomes
With regard to disease-specific QoL, the AFRS subgroup demon-
strated significant benefit in comparison with the reference group
Figure 2. Summary of pre- and postoperative Sino-Nasal Outcome Test
(SNOT-22) mean score  standard error (*p  0.01).
Table 1 Symptomatic patient complications
Complication No. of
Patients
(a)
No. of
Revision
Case(s)
Permanent
Sequelae
Comment
Bleeding* 2 2 No Discharged next day
Orbital 0 0 0 Not applicable
Intracranial 1 0 No Post-ESS microlaryngoscopy with difficult extubation; the patient presented after
3 days with pneumocephalus but no CSF leak and was managed
conservatively
General 2 1 No TIA, resolved with no residual symptoms; PE, preceding knee surgery 3 months
before ESS
ESS  endoscopic sinus surgery; CSF  cerebrospinal fluid; TIA  transient ischaemic attack; PE  pulmonary embolism.
*Of  500 mL; required transfusion and/or packing.
Table 2 Patient characteristics by etiologic category
Variable CRSsNP CRSwNP AFRS Total p Value
Age, mean (SD), y 50  14.5 56  15 51  14 54  15 0.18
Sex, % men 47.2 65.6 50 58.8 0.02
Lund-Mackay score, mean (SD)* 11.8 4.8 17.2  5 20.2  4.2 16  5.8 0.001
Asthma, % 22.2 47.4 70.8 42.4 0.001
Aspirin sensitivity, % 6.3 6.8 50 11.2 0.001
Allergic rhinitis, % 31.9 36.3 70.8 38.4 0.002
Preoperative SNOT-22 score, mean (SD) 55.0 21 53  22 53.2  21 54  22 0.79
Previous surgery, no. (%) 8 (11.1) 57 (37) 15 (62.5) 80 (32) 0.001
No. operations, mean  SE 1.2  0.2 2.4  0.4 2.1  0.2 2.2  0.3 0.53
White, no. (%) 71 (98.7) 149 (96.7) 24 (100) 244 (97.6) 0.50
Black, no. (%) 1 (1.3) 1 (0.6) 0 (0) 2 (0.8) 0.63
Asian, no. (%) 0 (0) 4 (2.6) 0 (0) 4 (1.6) 0.28
Never smoker, no. (%) 39 (54.1) 86 (55.8) 17 (70.8) 142 (56.8) 0.33
Ex-smoker, no. (%) 14 (19.4) 41 (26.6) 4 (16.7) 59 (23.6) 0.35
Current smoker, no. (%) 15 (20.8) 21 (13.6) 3 (12.5) 39 (15.6) 0.34
Total 72 154 24 250 —
CRSsNP  chronic rhinosinusitis without nasal polyposis; CRSwNP  chronic rhinosinusitis with nasal polyposis; AFRS  allergic fungal rhinosinusitis;
SD  standard deviation; SNOT-22  22-item Sino-Nasal Outcome Test; SE  standard error. Significant p values in bold.
*Preoperative computed tomography score.
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(CRSsNP). However, paradoxically, analysis of the data from this
study also depicts a story of the burden of AFRS on our health care
service, with more than two-thirds of all patients reporting previous
surgical intervention, with an average of two procedures per patient.
Analysis of our data indicates that patients with the highest preop-
erative SNOT-22 scores experienced the greatest reduction of symp-
tom severity over time, which is useful clinically when counseling
patients regarding the benefit that surgery may have in treating their
disease. In this study, only advanced age and a positive smoking
status were associated with adverse outcomes. These data agreed
with previous studies,14,23–25 which indicated very few patient factors
are predictive of QoL outcomes after ESS or other targeted therapies.
Although the requirement for revision surgery did not present a
major burden in this cohort, it must be stressed that our observation
period was comparatively short. Recently published research26 indi-
cates that outcomes stabilize between 6 months and 5 years after
surgery, hence, the long-term outcomes of sinus surgery can only be
seen at 5 years and beyond.27 Higher rates of previous surgery were
seen in the CRSwNP and AFRS subgroups in comparison with the
CRSsNP group (Table 2). The requirement for revision surgery can
often be multifactorial with extent of sinus disease, anatomic abnor-
malities, systemic disease, inadequate surgical intervention, and vari-
able medical management, all being contributing factors. In addition,
the high level of tertiary referrals seen at this unit may confound these
data by including more patients with refractory disease.
Comparison with National Epidemiologic Data
As stated, our study found the highest rate of revision surgery to be
among those patients with CRSwNP and those with AFRS, with rates
of previous surgery almost three-fold that of those patients without
nasal polyps. This is in keeping with recent findings from the CRS
Epidemiology Study, in which the combined (CRSwNP and AFRS)
mean number of previous operations per patient was 3, and 57% had
received previous surgical intervention.25 However, further compar-
ison with the CRS Epidemiology Study data would indicate an overall
lower rate of revision surgery reported by our subgroups (Table 2),
despite a comparatively larger disease burden (54.2 in this study
group versus 43.9 in the CRS Epidemiology Study).
Table 3 SNOT-22 scores in the postoperative period by etiologic category*
Time Point CRSsNP CRSwNP AFRS Total
Pre-ESS 55.46 2.5 (72) 53.7 1.8 (154) 53.2 4.4 (24) 54.2  2.5 (250)
Post-ESS, mo
1 27.5  2.7 (55) 21.3 1.5 (127) 22.2 4.4 (19) 23.1  1.3 (182)
3 27.2  2.7 (56) 20.3 1.5 (139) 16.9 3.4 (22) 21.7  1.2 (214)
6 30.1  3.5 (37) 20.2 2.1 (86) 22.9 4.8 (16) 25.7  1.7 (124)
9 40.4  5.3 (24) 26.1 2.5 (64) 26.0 5.4 (16) 29.3  2.2 (104)
12 35.5  4.8 (21) 25.1 3.3 (41) 24.9 5.6 (16) 28.6  2.4 (78)
SNOT-22  22-item Sino-Nasal Outcome Study; CRSsNP  chronic rhinosinusitis without nasal polyposis; CRSwNP  chronic rhinosinusitis with nasal
polyposis; AFRS  allergic fungal rhinosinusitis; ESS  endoscopic sinus surgery; SE  standard error.
*All values are SNOT-22 score  SE (no. completed questionnaires).
Table 4 Linear mixed effects regression analysis*
Subgroup SNOT-22,
average  SE
95% CI p Value
Post-ESS, 1 mo
CRSsNP N/A N/A N/A
CRSwNP 8.5 5.8 5.8 to 22.8 0.44
AFRS 6.6 6.8 10.2 to 23.4 1.0
Post-ESS, 3 mo
CRSsNP N/A N/A N/A
CRSwNP 1.12  6.6 17.4 to 15.1 1.0
AFRS 3.5 7.7 15.5 to 22.5 1.0
Post-ESS, 6 mo
CRSsNP N/A N/A N/A
CRSwNP 4.9 6.6 11.6 to 21.3 1.0
AFRS 8.7 7.8 10.6 to 27.9 0.81
Post-ESS, 9 mo
CRSsNP N/A N/A N/A
CRSwNP 17.0 7.4 1.3 to 35.3 0.08
AFRS 22.6 8.7 1.2–44.1 0.03
Post-ESS, 12 mo
CRSsNP N/A N/A N/A
CRSwNP 15.6 6.8 1.2 to 32.5 0.07
AFRS 20.2 8.0 0.5–39.9 0.04
SNOT-22  22-item Sino-Nasal Outcome Study; SE  standard error;
CI  confidence interval; ESS  endoscopic sinus surgery; CRSsNP 
chronic rhinosinusitis without nasal polyposis; N/A  not applicable;
CRSwNP  chronic rhinosinusitis with nasal polyposis; AFRS  allergic
fungal rhinosinusitis.
*Smoking (p  0.03) and age (p  0.05) were retained in the final model.
#SNOT-22 is the change in quality-of-life value between the reference
group (CRSsNP) and CRSwNP or AFRS.
Figure 3. Dynamic change in Sino-Nasal Outcome Test (SNOT-22) score
throughout the pre- and postoperative periods. There is a significant change
in SNOT-22 score for chronic rhinosinusitis without nasal polyposis
(CRSsNP) versus allergic fungal rhinosinusitis (AFRS) (9-month postop-
erative score 22.6 [95% confidence interval, 1.2–44.1]; p  0.03; and
12-month postoperative score 20.2 [95% confidence interval, 0.5–39.9]; p 
0.04).
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AFRS
The etiology and pathogenesis of AFRS is not fully understood, and
appropriate treatment for this disease is also controversial. Despite
the need for aggressive surgical and medical treatment, high recur-
rence rates have been reported.25 AFRS has been recognized as a
subcategory of CRS, in which a strong immunoglobulin E mediated
hypersensitivity to the fungal element may drive the inflammatory
process.28 In recent years, results of studies have indicated that a
much wider group of patients with CRS may be mediated by fungal
elements and a subsequent cascade of immune effects through non-
classic pathways.29,30
The term AFRS itself may be inaccurate because a type I hypersen-
sitivity reaction is not always proven, despite the evidence of the
other key clinical features,6 and perhaps the term “reactive” fungal
rhinosinusitis may be more appropriate in describing this condition.
The most implicated fungi in AFRS include Aspergillus, Alternaria, and
Curvularia, but confirmation of this is often suboptimal in the clinical
setting.31 Laboratory studies demonstrate an interaction of the im-
mune system with fungus in a subgroup of patients with CRS,7,8 but
this does not automatically infer that antifungals are the correct
therapeutic approach.32 Although fungi may be ubiquitous in sinuses
and may initiate an inappropriate immune activation, they may not
be the driving pathologic mechanism.29,32,33 To counter this argument,
recent evidence would support antifungals in the appropriate patient
group (identified by the Bent and Kuhn or modified Bent and Kuhn
criteria).34,35 Similarly, some patients have also responded to alterna-
tive treatments, such as Manuka honey, which has proven antifungal
properties.9,36
Differences between AFRS and CRSsNP
SNOT-22 scores in the AFRS group improved significantly when
compared with the reference group of CRSsNP in this study, which
may reflect different disease burdens and/or pathophysiology be-
cause the latter are likely to have ostiomeatal complex occlusion as a
key factor. Those patients with polypoid nasal disease and AFRS in
particular are known to have a higher prevalence of asthma, which
reflected more widespread respiratory tract involvement and a po-
tential different pathophysiology. Association between asthma and
nasal polyposis has also been described, along with aspirin sensitivity
as part of aspirin-exacerbated respiratory disease. This was first de-
scribed in 1922 by Widal et al.37 as a triad of symptoms, including
aspirin sensitivity, asthma, and nasal polyposis, more commonly
known as the Samter triad.38 Aspirin sensitivity is also more prevalent
within the polypoid phenotypes, and particularly AFRS, and again
points to the significant interaction between lower and upper airway
diseases.39 It is likely that patients experience a relief in both upper
and lower airways symptoms through meticulous management of
their nasal disease, and, consequently, a greater increase in QoL,
reflected in the lower SNOT-22 scores.40 A qualitative study of pa-
tients with CRS found the interaction between upper and lower
airways symptoms to be one of the major factors that influence QoL.41
Study Limitations
Limitations of this study included its no-randomized retrospective
design and the relatively small sample size for patients with AFRS.
However, the patients acted as their own controls, and the compari-
son among the subgroups allowed a within-disease analysis. Also,
although most of the relevant clinical factors were represented in this
analysis, it is not possible to accurately quantify patient compliance
with prescribed medications in the postoperative period.
Qualitative research at our center demonstrated that compliance
with treatments is a problem in patients with CRS.41 To counteract
this, patient education at the time of primary management is crucial,
with a need for regular reinforcement. Differing advice from primary
care practitioners may also emphasize the need for greater awareness
of guidelines.42 Analysis of recent data would indicate that clinical
commissioning groups in the United Kingdom are not currently
abiding by evidence-based guidelines for CRS, with 13% having
restrictive referral pathways in place.43 Also, comparison of this co-
hort with larger epidemiologic data sets may be inherently biased,
due to the relatively large number of tertiary referrals received at this
unit.
CONCLUSION
This study demonstrated that patients with AFRS (in comparison
with the CRSsNP cohort) have significantly improved QoL benefit
after ESS and targeted medical therapy, which is likely to reflect a
more-extreme extent of mucosal inflammation, lower rates of depres-
sion, and enhanced interaction between upper and lower airway
disease, which is much more prevalent in the polypoid phenotypes.25
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The Unified Airway Hypothesis
The concept of the Unified Airway (UA) has gained increased 
traction across the fields of respiratory medicine, allergy and 
otorhinolaryngology over the last 20 years [1]. It was first coined by 
Passalacqua et al. as United Airways Disease in 2000 [2], however seems 
to have given over to the term ‘Unified Airway’. Understanding airways 
diseases as an interrelated entity could lead to improved understanding 
of these interdependent conditions and optimise treatment outcomes 
[3].
The central tenet of the unified airway is the concept of a 
contiguous tract, lined with respiratory epithelium encompassing the 
nose and middle ear and extending to the terminal bronchioles [4]. A 
pathological process in one part of this airway is in this way liable to 
affect the function of the rest of the airway, even at a site remote to the 
original insult [2].
Evidence for this hypothesis includes research that respiratory 
diseases such as asthma are linked to higher rates of disease in other 
parts of the airway, including rhinosinusitis [5,6], and that there are also 
common histopathological hallmarks that are shared across clinically 
distinct entities such as asthma and chronic rhinosinusitis (CRS) [7].
Chronic Rhinosinusitis (CRS) as a Component of UAD
Nasal obstruction is a key component of CRS [8]. The nose serves to 
humidify and filter air and mechanical obstruction of the nasal airway 
may serve to thwart this. Mouth-breathing allows cold, unfiltered air 
to directly enter the bronchial tree and irritate the mucosa causing 
bronchospasm-this effect can be seen in exercise induced-asthma. 
A seminal study by Shturman-Ellstein et al. in 1978 demonstrated 
alterations in pulmonary physiology and changes in partial pressures 
of arterial oxygen in mouth-breathers, potentially due to changes in 
bronchial muscle reactivity [9]. Nasal obstruction may therefore also 
contribute to an alteration in the environment of the UA. The role of 
the nose and upper airway in the pathogenesis of respiratory disease is 
explained by four putative mechanisms [10,11]:
Abstract
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1.	 Warming and humidification of inhaled air by the nasal 
mucosa and turbinates
2.	 Inflammatory products from the nose track into the lower 
airways from the upper airway
3.	 Nasal inflammation results in local cytokine release which is 
then absorbed systemically
4.	 Potential existence of a nasal-bronchial reflex via the afferent 
nasal sensory nerve
The observation that rates of asthma are much higher in those with 
CRS [6] is further evidence to strengthen the case for a unifying theory 
of airways disease. In a reciprocal manner, asthma symptoms are also 
shown to improve in patients who have undergone sinus surgery or 
medical treatment of their CRS [12,13]. 
The Role of Macrolides in Respiratory Disease
Macrolides are a commonly-used class of antibiotics used in both 
acute and chronic respiratory infections and in those patients who 
have allergy to penicillin. A recent review article by Wong et al. gives 
a detailed examination of the role of macrolides in the management 
of asthma, stating that they have been shown to have ‘antimicrobial, 
immunomodulatory and potential antiviral properties’ [14]. They are 
mainstays in the management of chronic respiratory conditions such as 
Cystic Fibrosis and bronchiectasis.
The immunomodulatory characteristics that macrolides display 
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beyond their primary bactericidal properties [15] have become of 
increasing interest to those treating diseases of the respiratory tract. 
A key development was a report by a Japanese team in 1984 showed 
that there was a dramatic turn-around in the fortunes of patients they 
treated with diffuse panbronchiolitis (DPB) [16]. Patients with DPB 
traditionally had poor survival rates, however since the introduction of 
a low-dose erythromycin regime this has improved significantly, with 
clinical evidence that macrolides exert an anti-inflammatory response 
which includes the reduction of secretions and inflammatory mediators 
[17,18].
Asthma
Although there is not strong enough evidence to support the 
widespread use of macrolides in asthma, certain specific subset of 
asthmatics may more responsive. Those with poorly controlled severe 
neutrophilic asthma [14] or those with Chlamydophila pneumoniae 
or Mycoplasma pneumonia positive PCR have derived benefit, 
demonstrating decreased airway hyperresponsiveness and increased 
peak flow in a trial of 6 weeks’ Roxithromycin, although this was not 
sustained after cessation of the drug [19].
Cystic fibrosis
In Cystic Fibrosis (CF), trials have consistently shown benefit from 
the use of macrolides [20-22], although the mechanisms are not clear. 
Hypotheses include up-regulation of the multi-drug resistance (MDR) 
gene product P-Glycoprotein. This is thought improve function of the CF 
transporter receptor (CFTR) [23] and cause disruption of biofilms that 
are a characteristic finding in these patients. There is in-vitro evidence 
of a bactericidal effect that is mediated by prevention of adherence of 
bacteria to epithelial cells [24]. Adherence of bacteria to respiratory 
epithelium is known to be enhanced in CF due to thickened respiratory 
secretions and glycosylation of epithelial cells due to abnormalities in 
CFTR [20,24]. The repeat exacerbations and the progressive nature 
of the disease mean that a drug that can improve disease parameters 
is exciting, however this needs to be balanced against promotion of 
macrolide resistant strains [20,25].
Non-CF bronchiectasis
Non-CF related bronchiectasis has historically lacked good evidence 
upon which to base treatment decisions [26]. Empirical treatment has 
been favoured with treatment regimes borrowed from its sister disease 
CF. This is despite there being some evidence that inhaled therapies 
such as Dornase alfa and Tobramycin have unintended negative 
effects on the frequency of exacerbations and lung function [27,28]. 
There is good evidence, at RCT and meta-analysis level that low dose 
azithromycin is of benefit in the reduction of severity and frequency 
of of exacerbations of bronchiectasis. The EMBRACE trial [29], using 
low dose Azithromycin showed a 38% reduction in exacerbations and 
the BLESS trial [30] comparing low dose erythromycin noted 65% 
reduction. Meta-analysis by Wu et al. [31] shows a relative risk of 0.70 
for exacerbations in those receiving long term macrolides vs placebo 
although this is balanced against significant increase in gastrointestinal 
upsets. An trend of increased microbial resistance was also noted, 
however analysis was not possible due to a lack of consistency between 
outcome measures.
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD), is a disease with 
significant clinical burden. It characterised by irreversible airways 
obstruction and acute infective or inflammatory exacerbations and 
has been subjected to investigation regarding response to macrolide 
therapy. A large trial in 2011 (n=1142) by Albert et al. has shown a 
statistically significant benefit to quality of life in a subset of COPD 
patients who were given low dose azithromycin for one year in addition 
to their normal therapies. Acute exacerbations were reduced from 1.83 
to 1.48 episodes per patient year in the treatment vs control group, 
although this resulted in some hearing decrements and colonisation 
with macrolide resistant species in some cases [32]. A 2013 Systematic 
review in the Cochrane database by Herath and Poole looked at 7 RCT’s 
which used either continuous or pulsed prophylactic antibiotic regimes 
(5 vs 2). Only macrolides were used in the continuous regimens-namely 
azithromycin, erythromycin and clarithromycin. The authors found 
statistically significant reduction in the number of exacerbations, odds 
ratio 0.55, number needed to treat avoid one exacerbation was 8 [33]. 
An editorial July 2014 in American Journal of Respiratory and Critical 
Care Medicine makes the point that we are still far from justifying 
routine Azithromycin prophylaxis in COPD as several clinical questions 
remain unanswered-these are [34]:
1.	 Which subsets of patients will benefit most from 
Azithromycin?
2.	 How does Azithromycin fit in to the current COPD 
management guidelines?
3.	 There has not been a prospective RCT that ‘takes into 
consideration all COPD pharmacological interventions and also 
provides guidelines on how to use corticosteroids and/or antibiotics 
during the exacerbations, we cannot conclude that using azithromycin 
prevents “more severe exacerbation.” 
Mycobacterial infections
Macrolides have previously been shown to be effective against 
nontuberculosis mycobacterium, however some varieties including 
M. abscessus and M. massiliense are known to develop rapid resistance 
in vitro [35]. M. tuberculosis is known to exhibit intrinsic macrolide 
resistance via the erm37 gene product which prevents macrolide 
binding to the ribosome [36,37] – one of this class of antibiotics 
main weapons. Despite the lack of antimicrobial effect afforded by 
macrolides it is a possible that the immunomodulatory and synergistic 
effects alongside other antituberculous medicines may be useful in 
treating Mycobacterial infections. Clarithromycin has demonstrated 
a potentiation of the effects of rifampicin, isoniazid, ethambutol 
and pyrazinamide however this has not been validated in a clinical 
setting [38]. Newer forms of tuberculosis resistant to multiple drugs 
– so-called Multidrug Resistant Tuberculosis (MDRTB) have become 
prevalent and this is recognised to be a global health risk. Although 
macrolides need high mean inhibitory concentrations to be effective 
against TB, their propensity to collect in lung tissue, coupled with their 
immunomodulatory effects and synergistics could lead to their use as 
part of a regimen to treat MDRTB [39].
Macrolides in CRS
The current EPOS guidelines [8] remark that there only two placebo 
controlled studies examining the long-term use of macrolide antibiotics 
in CRS.
Wallwork et al. [40] looked specifically at patients with CRS without 
a history of nasal polyposis (CRSsNPs) using a regime of Roxithromycin 
150 mg daily for three months vs placebo and found that:
‘There were statistically significant improvements in SNOT-20 
score, nasal endoscopy, saccharine transit time, and IL-8 levels in 
lavage fluid (P<0.05) in the macrolide group. A correlation was noted 
between improved outcome measures and low IgE levels. No significant 
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improvements were noted for olfactory function, peak nasal inspiratory 
flow, or lavage levels for fucose and a2-macroglobulin’.
Videler et al. [41] compared a regime of three days’ Azithromycin 
500 mg, followed by weekly Azithromyin 500mg for three months. The 
findings were that:
‘the SNOT-22,Patient Response Rating Scale, VAS scores and SF-
36, no significant difference between the AZM and the placebo groups 
was demonstrated. Nasal endoscopic findings, PNIF results, smell tests 
and microbiology showed no relevant significant differences between the 
groups either.al. looked at patients with both CRSsNPs and CRSwNPs.’
These conflicting answers and this may be due to the fact that one 
by Wallwork et al. looked only at CRSsNPs and whereas Videler et al. 
included patients with both CRSwNPs and CRSsNPs. The first study 
showed statistically significant improvements in subjective symptoms 
and biochemical and clinical indicators of disease, in comparison the 
second there were no significant benefits versus placebo. The fact that 
the two trials differed in patient selection may be a reason for this, 
therefore future trials should address this question, with two limbs 
identifying and stratifying these patients. A distinct subgroup existed in 
Wallwork’s trial that had normal IgE levels these patients were identified 
as deriving particular benefit from macrolide use and further resources 
could be directed here. In light of this equivocal evidence, current CRS 
guidelines currently recommend that long-term antibiotics be used 
in CRS only where there is a positive bacterial culture and an acute 
exacerbation of symptoms.
Macrolides-beyond simple antibiotics
We have seen numerous examples of how macrolides have a 
beneficial effect in respiratory conditions that is not adequately 
explained in terms of bactericidal activity. The macrolides and their 
newer derivatives the ketolides are derived from the prototypic 
macrolide erythromycin. This was discovered in the early 1950’s as an 
isolated from the soil bacteria Saccharopolyspora erythraea [42]. 
The chemical structure of erythromycin is a 14-membered 
macrolactone ring, different members of the macrolide family 
being based upon this and the later ‘ketolides’ being characterised 
by the addition of a keto group. The mechanism of Erythromycin 
is primarily bacteriostatic rather than bactericidal and it displays 
instability in acidic conditions, this coupled with increasing 
bacterial resistance has led to the development of the semi-
synthetic macrolides such as clarithromycin and azithromycin 
and the ketolides, which are similar in structure but have superior 
stability and enhanced pharmacological properties [42].
A key property that macrolides (and newer generation 
ketolides) possess is the ability to interfere with protein 
translation at the 50s subunit of the bacterial ribosome [42,43]. It 
is feasible that this action allows macrolides to disrupt the cellular 
processes related to bacterial proliferation and influence the 
inflammatory response. Effects upon white blood cell function, 
such as enhanced degranulation and chemotactic recruitment 
of neutrophils [15] as demonstrated in several in vitro and ex 
vivo studies [44] may further enhance their immunomodulatory 
properties. Extrapolating these observations from laboratory 
bench to the clinic is problematic however. Numerous cytokines 
(IL-6, 8, 10 and TNF) have also shown to be suppressed in a 
dose-dependent fashion by the administration of erythromycin 
in whole blood stimulated with Pseudomonas aeruginosa [45] in 
healthy subjects as well as in cell lines in vitro.
Problems with macrolides
The indiscriminate use of broad-spectrum antibiotics is known to 
promote colonisation with resistant organisms and the occurrence of 
iatrogenic infections such as C. difficile [46]. Any decision to commence 
long-term antibiotics at sub-bactericidal concentration therefore 
requires strong justification on clinical grounds. This is particularly 
true in conditions such as COPD and asthma where there is a large 
population of patients with relative immunocompromised. The risks of 
prescribing macrolides to a large cohort may have unintended harmful 
effects on the wider community due to promotion of resistant strains of 
bacteria, in particular with long-acting macrolides such as Azithromycin 
[47]. The side-effect profile of these drugs also needs to be considered 
as there are reports of significant cardiac events attributed to their use 
– patients should therefore be screened for evidence of QT segment 
prolongation or other cardiac abnormality before commencement [48].
The indiscriminate application of macrolides across the spectrum 
of UAD may be may mask the benefits they give to specific subgroups 
of patients with UAD. Greater benefit is likely to be derived from 
the targeted use of these drugs in specific groups of patients such as 
those with normal IgE levels in CRS or neutrophil mediated asthma 
[14]. This must however be balanced against the danger of promoting 
macrolide resistance in patients who are in some cases already at risk 
of infection, especially if these are used as a monotherapy and for long 
courses at sub-bactericidal doses [20,23,25,42]. In addition, it is yet to 
be determined if the immunomodulatory effects give benefit above and 
beyond traditional management strategies in more than a few select 
scenarios (e.g. DPB). 
Conclusion
There is a growing body of evidence that supports the use of 
macrolides in UAD. Although there are common themes that run 
through the diseases of the airways they remain a heterogeneous group 
of diseases. 
The action of macrolides beyond their antibacterial function is not 
fully understood, however it is thought to be related to a potent anti-
inflammatory action and immunomodulatory properties. Macrolides 
influence protein transcription at the ribosome [42], inhibiting 
the expression of inflammatory cytokines and therefore reduce 
inflammation. In cystic fibrosis models they are able to disrupt bacterial 
adhesion to epithelial cells as well as interfering with the formation of 
biofilms [15]. 
The varied mechanisms of action that macrolides possess make 
them an attractive treatment option as they have the potential to modify 
airways disease and reduce their significant socio-economic burden. 
Greater understanding of their beneficial actions may also lead to novel 
agents to combat UAD. Macrolides are well established drugs with a 
known side-effect profile and low cost and therefore could provide a 
cost-effective alternative to other costly therapies or surgeries.
New studies to examine these effects may benefit from accurately 
identifying subgroups in order to ensure that benefits in these groups 
are not overlooked in the analysis. Robust outcome measures that 
encompass both quality of life indices and hard outcomes such as 
hospital admissions or 5 year survival will also help to determine any 
benefit from these drugs. There may be great benefit to be derived from 
the macrolides for some patient groups but this will only be identified 
with careful study design.
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Objectives: There is currently conflicting level 1 evidence in
the use of long-term antibiotics for chronic rhinosinusitis
without nasal polyps. The primary aim of this feasibility
study was to optimise future randomised trial design by
assessing recruitment and retention of patients alongside
providing preliminary data on symptomatic control.
Design: Prospective, multicentre feasibility (cohort) study
with all patients receiving macrolide therapy for 12 weeks
and a further subsequent 12-week follow-up. Participants
received a 12-week course of clarithromycin 250 mg along-
side twice daily topical mometasone and nasal douching.
Primary outcomes focused on recruitment, retention and
compliance. Clinical and quality-of-life outcomes measures
were also recorded.
Setting: Patients were prospectively recruited from six UK
outpatient clinics.
Participants: Adult patients with chronic rhinosinusitis
without nasal polyps and no prior endoscopic sinus surgery
underwent baseline assessment and then follow-up at 3 and
6 months.
Main outcome measures: Six-month recruitment and
retention data.
Results: Over 13 months, 55 adults were recruited from
five centres. Four patients declined participation. 75% of
patients were retained within the study. Dropouts included
one medication contraindication, three unable to tolerate
medication and 10 not attending full follow-up. Sino Nasal
Outcome Test-22 and endoscopic scores showed statistically
significant improvement. No other clinical or quality-of-life
assessment improvements were seen.
Conclusion: Retention and recruitment to a trial using
long-term clarithromycin to treat chronic rhinosinusitis
without nasal polyps is achievable and this datawill support a
future randomised controlled trial. The study provides vital
insight into trial design, thus informing UK research
networks and rhinology researchers internationally.
Long-term macrolide therapy is recommended in the
treatment of chronic rhinosinusitis (CRS).1 Its potential
benefits were extrapolated from findings in the respiratory
community where marked improvement in both chest and
nasal symptoms was seen in patients with panbronchiolitis
alongside prolonged survival rates.2 The anti-inflammatory
effects of reducing cytokine activity and in turn reducing
airway inflammation and mucus production are well
documented.3 In CRS, there have only been two randomised
controlled trials (RCT) performed to date which show
conflicting evidence; the efficacy ofmacrolides in treating the
condition has been called into question due to this conflict-
ing level 1 evidence.4,5
The first double-blind RCT published showed a signifi-
cant improvement in clinical scores (alongside other
outcomes) with roxithromycin in CRS without nasal polyps
(CRSsNPs), particularly in the normal IgE subgroup.4 A
second RCT with a similar number of patients, using
azithromycin did not show a significant improvement
between the macrolide and placebo groups.5 The Cochrane
review into antibiotics for CRS concluded that Wallwork
et al.’s study supported the therapy, but further large sample
studies were required.6 This was echoed in a recent meta-
analysis which found limited data to support macrolide
therapy in CRS,7 stating further research is required. In
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addition, it is recognised that the data from the most recent
RCT5 may skew outcomes as the study recruited predom-
inantly patients who had failed previous sinus surgery, and
included mixed phenotypes, with both CRSwNP and
CRSsNP. Potentially, more patients with elevated IgE levels
who may not respond to macrolide therapy were recruited,
although subgroup analysis was not performed.1 With the
increasing emergence of antibiotic resistance, it is important
that clinicians use such medications responsibly.8 In addi-
tion, clarithromycin use is associated with an increased risk
of cardiac death particularly in women;9 hence, evaluation of
its use especially in long-term therapy is essential.
A future RCT to clarify the use of macrolides in CRSmust
be sufficiently powered, use appropriate clinical assessment
methods and ensure retention of patients leads to meaning-
ful data collection. To inform this process, we conducted a
UK-based, multicenter feasibility study. The primary out-
come measures were patient recruitment and retention to
the study with secondary outcomes including assessment of
medication tolerance and compliance to the study protocol.
In addition, feedback and clinical outcomes of the study are
reported.
Materials and methods
Ethical considerations
Ethical approval was given to the study from the West
Midlands Research Ethics Committee (reference: 12/WM/
0359), and the study was included on the UK CRN portfolio
(ref: 13417).
Methods
The study was conducted as a multicentre collaboration
between six sites. Study centres included James Paget
University Hospital (Great Yarmouth), Guys & St Thomas
Hospital (London), Royal Surrey County Hospital (Guild-
ford), Queens Medical Centre (Nottingham), Freeman
Hospital (Newcastle) and Queen Elizabeth Hospital (Birm-
ingham). As this was a feasibility study, no sample size was
needed but a target recruitment of 50 patients over a
12-month period was established at the beginning. At the
beginning of the study, the chief investigator hosted a
teleconference with principal investigators and research
nurses at all sites included.
Inclusion criteria. Inclusion criteria comprised of adult
patients between 18 and 70 years, with a diagnosis of
CRSsNPs as per the EPOS guidelines (Fokkens, 2012) who
had not received maximal medical treatment previously.
Previous surgery was not a reason for exclusion although no
patients had undergone previous endoscopic sinus surgery,
and one patient had undergone previous maxillary balloon
sinuplasty.
Exclusion criteria. CRSwNP and secondary CRS (e.g. Weg-
ner’s, immunodeficiency).
Treatment regime. At all sites, patients received a 12-week
course of clarithromycin 250 mg b.d. alongside b.d. nasal
douching and intranasal mometasone (two squirts, each
nostril b.d.), the latter two being continued for a further
12 weeks. Regarding the choice of macrolide used, clar-
ithromycin is a common macrolide used in the UK with
broader microbial coverage than erythromycin.10
Participant flow. Patients diagnosed with CRSsNPs were
recruited from the outpatient clinics at participating sites
and subsequently underwent two face-to-face study visits
and a third interaction via postal correspondence (ques-
tionnaires and feedback only). Patients who completed the
study were asked to comment on their participation in the
trial (Appendix 1). Baseline clinical assessment included
endoscopy (scored using the Lund–Kennedy endoscopic
score,11 mucociliary clearance testing (saccharin test), smell
testing (Sniffin’ sticks), serum IgE levels, skin prick allergy
testing and sinus CT with Lund–Mackay scoring.12 All but
the last three tests were repeated at visit 2 following the
12-week course of clarithromycin. The sinonasal outcome
test (SNOT-22 – a disease-specific measure of HRQOL),
SF-12 and EQ-5D questionnaires (both global measures of
HRQOL.13–15) were completed at all three encounters.
Statistical analysis
Statistical analysis of continuous variables was performed
using paired t-tests and nonparametric tests used for non-
continuous data. In regard to SNOT-22 scores, patients with
a minimum clinical difference of nine points on the SNOT-
22 were considered to have had a clinical improvement in
symptoms.16
Results
Primary outcome measures
Recruitment of patients. Over a 13-month period (January
2013–January 2014), 55 patients were recruited from five
units, 51% were male and the mean age was 55 years
(range from 21 to 81). Sixty-three patients were eligible but
eight declined. Despite ethical approval being confirmed in
November 2012, it took until the following December for
all six sites to finally complete research governance. At
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three sites, Research & Development offices chose to
interpret the research protocol differently from the ethics
committee resulting in a temporary suspension of the
study for 2 weeks while the Medicines and Health
Regulation Authority (MHRA) confirmed the study was
not a Clinical Trial of an Investigational Medicinal Product
(CTIMP). During the first 9 months of the study, only the
lead site was open to recruitment leading to considerably
different numbers of patient participating in each site
(Table 1).
Retention of patients. At the recruitment stage, one patient
was excluded during preliminary work-up as clar-
ithromycin was found to be contraindicated although
underwent all of visit 1 before this was identified. Three
further patients were unable to take the full course of
clarithromycin due to side-effects and 10 patients dropped
out (Table 1). Compliance with the study protocol fell
towards the end of the study with 55 patients attending visit
1, 45 attending visit 2 and 41 completing visit 3. Recruit-
ment and retention rates varied considerably between
hospitals, as shown in Table 1.
Compliance with assessment and treatment. Adherence to
the study protocol varied between sites with poor compli-
ance of the research staff in performing some clinical tests
(Table 2). The use of the Sniffin’ sticks was temporarily
halted during the study due to confusion about their use (by
the sponsor representative) and subsequently their status at
MHRA, but this was later overturned and their use
reinstated. The reasons for poor compliance to the protocol
are varied, and feedback from research nurses taking part is
shown in appendix 2. Logistical issues affected some sites, for
example difficulty getting hold of equipment [in particular
Sniffin’ sticks kit (Burghart Messtechnik GmbHTinsdaler
Weg 175D-22880 Wedel, Germany)]. In addition, poor
conduct of the compulsory elements of the protocol in one
centre was noted.
Medication tolerance and compliance. Three patients suf-
fered adverse effects during taking the medication (acid
reflux, skin reaction, gastrointestinal symptoms) and a
fourth had headaches for the first 2 weeks which resolved
enabling full completion of the 12-week course.
Secondary outcomes
Patient feedback. Twenty-six patients responded to the
postal questionnaire: 18patientpatients reportednonegative
aspects; the same number of patients would be happy to take
part in a placebo study. Three patients reported issues with
the clinical testing (discomfort during mucocilary clearance
and Sniffin’ stick testing). Constructive criticism regarding
communication between the study centre and patients/GP
was also made. Patients also raised the question about the
possibility of breaking the blinding process if there was no
symptomatic improvement in a placebo-controlled trial.
Staff feedback. It came apparent during running the trial
that experience of the research nurses (RN) involved in the
trial was of differing levels from an experienced ENT
trained RN (site 1), to experienced (but not ENT trained)
RN (site 3), to inexperienced RN (site 6). There were issues
with implementation of the protocol, specifically using up-
to-date questionnaires and performing the compulsory
Table 1. The recruitment and retention rates at each of the six centres and summarises the reason for dropout (DNA = did not attend)
Centre No. Visit 1 completion Visit 2 completion Visit 3 completion Reason for dropout
1 38 36 35 2–clarithromycin side-effects; 1 DNA
2 7 1 1 6 DNA
3 6 4 3 1–clarithromycin contraindicated; 2 DNA)
4 1 1 1 –
5 3 2 1 1–clarithromycin side-effects; 1 DNA
6 0 – – Patients deterred by RN
Table 2. The completion rates of each study component at the
three study visits with total completion numbers shown before
elimination for dropouts/intolerance, etc., taken into account. Only
the first threee components were required at visit 3. (Q =
questionnaire). Allergy testing was performedwith either skin prick
tests or RAST
Visit 1
completion
Visit 2
completion
Visit 3
completion
SNOT-22 Q 54/55 45/51 41/51
SF-12 Q 53/55 44/51 41/51
EQ-5D Q 53/55 44/51 41/51
Endoscopic score 38/55 29/51 N/A
Saccharin test 54/55 42/51 N/A
Smell testing 49/55 36/51 N/A
IgE levels 50/55 N/A N/A
Allergy testing 51/55 N/A N/A
LM score 54/55 N/A N/A
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tests. Unofficial feedback from clinicians also highlighted
the fact that some RNs were unfamiliar with certain clinical
tests (Sniffin’ sticks) and the length of time this took to
perform such aspects reflected negatively on patient
recruitment (seen at site six where the RN actively
discouraged patients from taking part due to the perceived
time to perform the test).
Clinical outcomes. Table 3 shows the clinical results from
this feasibility study. Excluding the four patients unable to
take their medication due contraindications/side-effects, 45
and 41 patients completed all surveys at visits 2 and 3,
respectively. Statistically significant reduction in SNOT-22
scores was found at both 3 and 6 months. This was clinically
significant (score reduction of nine points or greater16) in 22
of 45 and 20 of 40 patients at 3 and 6 months, respectively.
Endoscopic scores also showed a statistically significant
improvement. Positive mucopus culture was seen in 12
patients as baseline assessment.
No other statistically significant result was seen in other
clinical outcomes of mucocilary clearance and smell testing.
Serum IgE levels were recorded in 50 patients at visit 1 and 43
patients had both IgE levels and 12-week SNOT-22 data
(Table 4). A greater proportion of responders to therapy
were seen in the patients with elevated IgE levels although
this was not significant (69% versus 47%; P = 0.212) in
contrast to the previous RCT.5
Low levels of inhalant screen positivity were seen in allergy
testing (performed in 51 patients overall, 50 of whom has
RAST and one skin prick testing), nine patients demon-
strated inhalant screen positivity and five of such patients
had elevated IgE also.
Lund–Mackay (LM) scoring of CT paranasal sinuses was
performed in 54 patients. There was no significant
correlation between LM score and symptomatic improve-
ment following treatment using the clinically significant
SNOT-22 score (P = 0.636). At site 1, the number of patients
progressing to surgery was 12 of the 35 patients (34%)
completing the study (11 undergoing sinus surgery and one
undergoing septoplasty).
Patient-reported outcomes. EQ-5D analysis showed no sta-
tistical difference in either mean VAS score or any of the five
health dimensions (Fig. 1a–e) although patients reported
higher rates of pain/discomfort and anxiety/depression.
SF-12 scores (both mental and physical components)
increased at both visits 2 and 3 from baseline. The
improvements were modest and did not improve to that
above the score expected for a ‘typical adult’.
Discussion
Synopsis of key findings
We aimed to investigate the feasibility of a 6-month trial
where clarithromycin was given for 12 weeks, showing a
recruitment rate of 83% and a retention rate of 76%. There
was an average recruitment rate of 4.23 per month across all
sites in the latter part of the study. Compliance to the study
protocol varied from site to site, specific issues regarding this
Table 3. The raw data for each of the clinical components of the study
Clinical test (number of patients
at baseline/3 months/12 months
Test result (standard deviation)
Baseline 3 months P-value 6 months P-value
SNOT-22 total score (54/45/41) 41.09 (21.765) 33.29 (23.96) 0.01 31.48 (24.36) 0.03
SNOT-22 clinically significant* 22/45 patients (48.9%) – 20/40 patients (50%) –
Endoscopic score (38/29) 3.31 (1.26) 1.4 (1.56) 0.000
Smell testing (49/36) 24.05 (9.45) 23.69 (9.99) 0.983
Saccharin test (seconds) (54/42) 800.44 (376.72) 818.97 (531.25) 0.274
IgE levels (ku/l) (50) 100.7 (114.48) –
Allergy testing Positive result 9/50 patients –
LM score (54) 8.65 (4.72)
SF-12
Mental 46.82 (11.96) 47.05 (47.05) 0.705 49.33 (11.13) 0.617
Physical 47.7 (10.64) 48.91 (11.04) 0.279 47.63 (10.04) 0.515
EQ-5D VAS 75.59 (20.95) 76.64 (21.65) 0.967 75.7 (19.40) 0.648
*Clinically significant improvement in SNOT-22 score (>9 points).16 NS, not significant.
Table 4. Theproportions of IgE-positive and IgE-negative patients
with significant clinical improvement in SNOT-22 scores
SNOT-22 clinical
improvement (≥9 points)
SNOT-22 no clinical
improvement
IgE elevated 9 4
IgE normal 14 16
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are discussed below. The lead site recruited significantly
more patients (recruitment rate of 3.17/month) with good
retention rates of 92%, and the results are somewhat skewed
by the poor retention rates in some other centres. This
initiates a discussion about factors that contributed to the
variation seen and how these could be managed to improve
overall study retention and data collection. Recognising
these issues is vital in planning a future RCT.
Comment on recruitment, retention and study protocol
The results show a failure of comprehensive data collection at
all sites. An incorrect version of one study questionnaire was
uploaded onto the central study site at the start of
recruitment which caused some understandable confusion.
At one centre, the RN misinterpreted the requirement to
perform other outcome measures from the protocol, hence
reducing clinical and questionnaire outcomes further. At
another site, eight patients identified by initial screening
failed to consent after assessment with an inexperienced
generic research nurse, and no patients at this site ever joined
the study. Time to perform outcome tests was cited as the
greatest barrier to participation. It is notable that the RN at
this site took over 45 min to perform olfactory testing,
compared to 20 min by an experienced research nurse.
Lastly, the reduced number at some sites was in part due to
significant delays in research governance approval, meaning
some centres were unable to recruit until the last 4 months.
These difficulties were in stark contrast to the lead site which
had an experienced research nurse with an ENT background
who successfully recruited patients to the study throughout
the 13-month duration with the loss of only three patients
(two due to drug side-effects and one dropout).
The experience of the research nurses at the individual
sites had a big impact on their ability to both recruit patients
and perform the relevant investigations, despite a telecon-
ference at the beginning of the study to talk through the
flowchart. This has demonstrated a clear need for a specific
training day for all research nurses involved in any future
trial. Research nurse support provided by UK local clinical
research networks (LCRNs) is often generic in nature butwill
vary from site to site. Any future RCT would include a study
training day to ensure all staff undergo standardised training
and has also inspired a national ENT study day for all generic
research nurses. Due to the limited funding for this study, a
centralised database was not available, but this would be
mandatory if a formal RCT is funded in due course, to allow
for ease of secure data entry at site visits. This feasibility study
has identified significant issues for reflection if a full-scale
RCT is to be conducted effectively. In addition, 93% patients
were able to take the full course of therapy without
significant side-effects with only three subjects unable to
Fig. 1. (a–e) The EQ-5D data is presented as percentage of patients
reporting each level in each of the five dimensions at the three
separate visits. Patients were self-caring, with good mobility (level
1) but had higher rates of problems with anxiety/depression and
pain/discomfort. The two latter dimensions worsened in some
patients at 6 months. baseline—black; 3 months—dark grey;
6 months—light grey.
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tolerate clarithromycin and with appropriate screening, no
serious adverse events, despite concerns from recent publi-
cations.9 There is a growing body of evidence (published
after study design) that macrolide therapy in those with
previous ischaemic heart disease or prolonged QT interval
on ECG is associated with cardiac toxicity.While no patients
in this feasibility study suffered such side-effects, the cohort
was small, and hence, any future RCT should exclude
patients with such risk factors and include an ECG in pre-
treatment investigations.17,18
Clinical results and comparison to other studies
It must be emphasised that this is not a placebo-controlled
trial and that without a control arm, the effect of intranasal
corticosteroids and douching cannot be assessed. While the
clinical results from this case cohort study suggest that a
longer-term course of macrolide therapy may be thera-
peutically advantageous in up to 50% of patients with
CRSsNPs, no firm conclusions regarding clinical effective-
ness can be made without a control arm. However, the
response rate seen in this feasibility study provides valuable
information for trialists considering a formal RCT, as it
can inform power calculations. In addition, it is notable
that no other clinical indicators (e.g. mucocilary clearance,
smell testing) nor generic quality-of-life assessment
showed any statistically significant improvement. The
results support the need for a further RCT as suggested
by a recent meta-analysis7 which found limited data to
support such therapy. In addition, within the wider
medical community it is vital to ensure long-term
macrolides are used responsibly in the face of increasing
antimicrobial resistance.
This study was designed to capture potential issues prior
to recruiting to a full-scale RCT. Limitations in study design
can be acted upon at this early stage, such as the limited data
collected to assess patient compliance with medication. The
study relied purely on patient self-reporting and in the future
questionnaires/diaries could be used to clarify this further.
As patients also raised concerns regarding the time taken to
complete outcome assessments, the number of outcome
measures should be re-evaluated prior to a formal RCT to
minimise participant burden and maximise recruitment.
Encouragingly many patients reported positive experiences
regarding study involvement andwere happy to take part in a
placebo-controlled trial.
Conclusion
This paper presents an honest account of the issues
encountered when conducting a multicentre clinical trial.
The issues identified have been integral in informing study
design for a future RCT into macrolide therapy. In
addition, we are keen to share our experiences with other
researchers in order to reduce research waste through poor
recruitment and retention which can lead to both under-
powered and/or unfinished trials. This is in keeping with
advice in avoiding research waste as identified by Chalmers
and Glasziou.19 Clinical trials require extensive time and
financial commitment. It is the responsibility of researchers
to ensure patients who relinquish their time to participate
in trials are recruited to well-designed, well-conducted
studies; a feasibility study is an essential part of this
process. The research team have recently been awarded a
Programme Grant from the National Institute of Health
research that will include a trial to assess the role of long-
term antibiotics.
Keypoints
• A randomised controlled trial of clarithomycin versus
placebo should be feasible based on the recruitment
and retention seen in this study.
• In order to maximise the potential for trial retention,
research nurses at all sites need to be fully engaged with
the trial processes and provided with suitable training
in ENT outcome measures.
• Long-term macrolide therapy has the potential to
benefit patients with CRS without polyps in up to 50%
of cases but this needs corroborating with a formal
RCT.
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Appendix 1 Feedback from Research Nursing staff
Logistical
‘Running of the study was straight forward’
‘Saccharin tablet took a long time to dissolve in some people
and they left before tasting it (a time limit would’ve been
helpful)’
‘The recording of information needs to be clearer’
‘A negative aspect was the wait for CT scans, some patients
were not recruited because of the wait and were left
disappointed they couldn’t take part’
‘Smell tests take time and it was difficult to re-order new pens
when they passed their best before date’
‘Skin prick tests tested for more allergens but took longer’
Protocol not clear
‘We need to have the correct version of the questionnaires
from the start, (SF12 was upgraded to v2 but v1 was still on
the study link)’
‘Wasn’t sure which tests were compulsory’
Patient related
‘1 patient stopped theirmeds after they felt they had a reaction’
‘Patients liked to do the smell tests to see what improvement
they had.’
‘1 patient improved initially on the antibiotics, but then over
the 12 weeks deteriorated again, he would’ve liked to do the
smell test after 6 weeks before he felt he got worse again.’
‘1 patient withdrawn after an adverse reaction’
Failure to follow protocol
‘Mucopus samples not taken routinely in clinic’
‘Endoscopic score wasn’t done (sorry, this was overlooked)’
‘1 patient had a different consultant for visit 2’
Appendix 2: Patient Macrolide Study Feedback
Twenty-six patients replied to the feedback questionnaire.
Negative
Eighteen patients said there was no negative aspect
1 1 patient said the saccharin tablet burned her nose.
2 1 patient said the sniffin’ sticksmade her feel light-headed.
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3 1 patient felt dizzy and faint with smell test, don’t like
filling in questionnaires.
4 ‘Slight improvement on tablets now back to how I was
before’
5 ‘The tests were fine but I thought the questionnaire could
have included ‘other symptoms’ e.g. headaches,whichwas
one of the worse aspects for me’
1 patient said ‘there needs to be better communication
between the hospital and GP surgery, as the GP thought the
antibiotics were study medication and didn’t need to supply
them’.
Another patient felt the instructions given were not clear/
incorrect, specifically:
1 his nasonex prescription had the incorrect frequency on
(od instead of bd),
2 he wasn’t informed to continue his douching and nasal
spray when the antibiotics finished (could this be put into
the patient instructions.
3 2 CT scans before and after would be better
4 he felt a longer follow up period would be beneficial,
incorporating each season maybe.
When asked if he would have participated if there was a
chance of receiving a placebo, he said yes - but – ‘if there was
no improvement in symptomswould the blinding be broken
and then he gets a prescription for antibiotics if it was shown
he had the placebo?’ If this wasn’t the case then he may not
participate. 2 patients mentioned this point.
Positive
Two patients reported no positive aspects.
Some patients made positive statements regarding
involvement within the study:
1 ‘a positive aspect was feeling as though they have helped
other people by participating in research’
2 ‘knowing it would help me and improve things with
feedback and give more insight for doctors.’
3 ‘The fact that I was able to take part in such a study which
may help others is positive enough’
Some patients commented on their understanding of the
disease/symptoms:
1 ‘I found out I could not smell everything properly’
2 ‘Made me realise this complaint is more common than I
first thought’
3 ‘Although it didn’t solve my problem, I had some relief
from the symptoms and I felt better because something
was being done to help me’
Would you still take part if placebo study?
No: 7
Yes: 18
‘The more you know, more advance the treatment
becomes’
One patient didn’t understand the question about placebo.
© 2016 John Wiley & Sons Ltd  Clinical Otolaryngology
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ABSTRACT
Objectives: The aim of this study was to investigate
the surgical revision rate in patients with chronic
rhinosinusitis (CRS) in the UK CRS Epidemiology
Study (CRES). Previous evidence from National
Sinonasal Audit showed that 1459 patients with CRS
demonstrated a surgical revision rate 19.1% at 5 years,
with highest rates seen in those with polyps (20.6%).
Setting: Thirty secondary care centres around the UK.
Participants: A total of 221 controls and 1249
patients with CRS were recruited to the study including
those with polyps (CRSwNPs), without polyps
(CRSsNPs) and with allergic fungal rhinosinusitis
(AFRS).
Interventions: Self-administered questionnaire.
Primary outcome measure: The need for previous
sinonasal surgery.
Results: A total of 651 patients with CRSwNPs, 553
with CRSsNPs and 45 with AFRS were included.
A total of 396 (57%) patients with CRSwNPs/AFRS
reported having undergone previous endoscopic nasal
polypectomy (ENP), of which 182 of the 396 (46%)
reported having received more than one operation. The
mean number of previous surgeries per patient in the
revision group was 3.3 (range 2–30) and a mean
duration of time of 10 years since the last procedure.
The average length of time since their first operation
up to inclusion in the study was 15.5 years (range
0–74). Only 27.9% of all patients reporting a prior ENP
had received concurrent endoscopic sinus surgery
(ESS; n=102). For comparison, surgical rates in
patients with CRSsNPs were significantly lower; 13%
of cases specifically reported ESS, and of those only
30% reported multiple procedures (χ2 p<0.001).
Conclusions: This study demonstrated that there is a
high burden of both primary and revision surgery in
patients with CRS, worst in those with AFRS and least
in those with CRSsNPs. The burden of revision surgery
appears unchanged in the decade since the Sinonasal
Audit.
INTRODUCTION
Rhinosinusitis is one of the most common
chronic adult health problems in the Western
world with a recent European study estimat-
ing the prevalence of chronic rhinosinusitis
(CRS) at 11%,1 although in studies with
physician-led diagnosis of CRS, a prevalence
of 6–7% has been observed.2 3 Sinonasal
surgery for patients with CRS is commonly
performed by otorhinolaryngologists around
the UK. Hospital Episode Statistics (HES)
data for 2012–2013 suggest that approxi-
mately 40 000 nose or sinus operations are
performed each year in England and Wales;
this is in addition to an estimated 75 000 out-
patient consultations.3 Patients selected for
surgical intervention should have failed to
improve symptomatically on medical treat-
ment, but there is a greater than ﬁvefold vari-
ation in intervention rates across the UK.4
This variation may reﬂect a number of factors
including both underutilisation and overutili-
sation of surgery, a lack of guidelines and a
lack of evidence in well-constructed rando-
mised controlled trials (RCTs) to support
Strengths and limitations of this study
▪ Large cohort of patients from secondary and ter-
tiary care centres around the UK.
▪ Chronic rhinosinusitis is a common disease and
sinonasal surgery is frequently undertaken.
▪ The data are derived from self-reported question-
naire responses by patients.
▪ There is selection bias as only symptomatic
patients returning to secondary care are included
in the study.
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surgery;5 a 2005 Health Technology Assessment commis-
sioned systematic review of sinus surgery identiﬁed the
need for good quality studies comparing surgery with
medical treatment for CRS with nasal polyps
(CRSwNPs).6 Furthermore, the duration of uncontrolled
symptoms before surgery varies considerably between 1
and 10 years.7 This uncertainty regarding the role of
surgery is highlighted by its inclusion in the National
Institute for Health and Care Excellence (NICE)
Database of Uncertainties about the effects of treatment
(DUETs).8 Although level 1 evidence is lacking, recent
studies evaluating the symptomatic and economic bene-
ﬁts of surgical intervention in CRS outside of the UK
National Health Service (NHS) setting favour surgical
intervention over ongoing medical therapy.9–12
In 2000–2001, a total of 3128 consecutive patients
undergoing surgery for CRS at 87 NHS hospitals were
enrolled as part of the UK Sinonasal Audit coordinated
through the Clinical Effectiveness Unit at the Royal
College of Surgeons of England.13 All of the 156 NHS
Trusts in England and Wales performing sinonasal
surgery were invited to take part in the Audit; those who
failed to participate largely cited ﬁnancial constraints as
the reason for refusal. All patients aged 16 years or more
and who had elected to undergo surgical procedures to
treat nasal polyposis and/or CRS were eligible for inclu-
sion. Although this study concluded that sinonasal
surgery is generally safe and effective and that patient
selection for surgery could be improved, the subsequent
long-term follow-up of audit patients also demonstrated
the limitations of sinus surgery in current practice.14
From the 1459 patients who responded to 5-year
follow-up, revision surgery rates increased at each time
point such that 19.1% had undergone further sinonasal
surgery during the 5 years since their original operation.
In CRSwNPs, 20.6% had undergone revision compared
with 15.5% of patients with CRS without nasal polyposis
(CRSsNPs). Looking at cases where a simple polypect-
omy was performed, 21.2% had undergone revision
surgery compared with 20.0% of patients who had also
received additional sinus surgery with an adjusted OR of
0.66 (p=0.04) for the risk of the latter group needing
further surgery.
Given these interventions occurred 13–14 years ago
during which time there have been advances in instru-
mentation and visualisation for sinonasal surgery, the
CRS Epidemiology Study (CRES) provided an opportun-
ity to revisit this scenario using recent data. CRES pro-
spectively collected a national cohort of self-reported
patient data in the UK (excluding Northern Ireland).
The overarching aim of the CRES was to identify any
difference in socioeconomic variables between patients
with CRS and healthy controls using a study-speciﬁc
questionnaire which included demographic and socio-
economic questions as well as disease-speciﬁc and
generic quality of life tools. The study included a qualita-
tive arm exploring patient experiences in detail. The
CRES questionnaire also allowed collection of
information about previous surgical interventions, allow-
ing us to investigate surgical revisions and allow compari-
son of management between subgroups of CRS. Revision
surgery is herein deﬁned as any further surgical interven-
tion for CRS (ie, repeated nasal polypectomy or repeated
endoscopic sinus surgery (ESS).
MATERIALS AND METHODS
The CRES was sponsored by the University of East
Anglia (UEA). Any patients presenting to secondary
care outpatient clinics and diagnosed by an otorhino-
laryngologist with CRS as deﬁned by the criteria laid out
in the European Position Paper on Rhinosinusitis and
Nasal Polyps (EPOS) were invited to participate in the
study regardless of symptom or disease severity or dur-
ation and regardless of any prior interventions. The
study initially started recruitment in the East Anglia
region of the UK but following elevation to the National
Institute of Health Research Clinical Research Network
Portfolio, a total of 30 sites from around the UK (includ-
ing the devolved nations of Wales and Scotland) joined
the study which ran between 2007 and 2013. The study-
speciﬁc questionnaire was anonymous, and therefore no
consent was taken but implied through their participa-
tion. Patients were classiﬁed by subgroup of CRS
(CRSsNPs, CRSwNPs or allergic fungal rhinosinusitis
(AFRS) by a clinician prior to completion of the ques-
tionnaire using the EPOS deﬁnitions for with or without
polyps (using endoscopic and/or radiological conﬁrm-
ation) and the Bent and Kuhn criteria for AFRS.
Questionnaires were either completed before leaving the
clinic or taken home and returned by post in freepost
envelopes. The returned questionnaires were then
scanned into a database electronically but checked by
two members of the research team for accurate correl-
ation with the paper questionnaire and for missing data.
The study questionnaire includes study-speciﬁc questions
relating to socioeconomic, environmental and medical
comorbid variables as well as the validated Short Form
36 (SF-36)15 quality of life measure and the Sino-Nasal
Outcome (SNOT-22)16 questionnaire. A pilot study
demonstrated incomplete responses to the question
“Have you ever had any nasal surgery?” due to some par-
ticipants excluding sinus surgery from their responses.
The questionnaire therefore stated “Have you had any
previous surgery—yes/no?; If yes, please specify what
and when”, followed by a free ﬁeld text box. This cap-
tured all forms of sinonasal surgery; the frequency of
surgery and any other type of surgery undergone by par-
ticipants and the dates provided by participants varied
from exact dates to just the year of surgery. The self-
reported questionnaire was the only means of data
capture in relation to surgery. These surgery-speciﬁc
data were collated and subcategorised where data were
available (see ﬂow chart). If participants did not com-
plete the surgery text box, they were assumed not to
have undergone any previous surgery and as such there
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were no missing data in this respect. The duration of
time since the most recent surgical intervention pro-
vided and completion of the questionnaire is described
as ‘recurrence time’. The study was powered based on
the ability to detect differences in quality of life between
cases and controls since this was the primary purpose of
the study. The percentage of respondents with previous
surgeries were compared across the three subgroups
(CRSsNPs, CRSwNPs and AFRS) using a χ2 test. The
mean SNOT-22, surgical impact and time to recurrence
were compared between the three subgroups using ana-
lysis of variance (ANOVA).
RESULTS
A total of 1470 completed questionnaires were returned
by participants including 1249 patients with CRS, reﬂect-
ing a response rate across all sites of 66%. The age range
of all participants was 18–102 years, mean 52.6 years, with
709 men and 606 women (155 did not identify their
gender; see ﬁgure 1 ﬂow chart). Patients with CRS diag-
nosed by their ENT surgeon included 651 with CRSwNPs,
553 with CRSsNPs and 45 with AFRS. From the total of
1249 CRS participants, 556 (45%) had undergone some
form of sinonasal surgery (deﬁned as one or more of
polypectomy, ESS, septoplasty, turbinate surgery, rhino-
plasty) including 325 (26%) who had received at least
one nasal polypectomy and 169 (14%) who had under-
gone at least one instance of ESS (ﬁgure 2).
Combining data for the subgroups of CRSwNPs and
AFRS (n=696), 396 (57% of those with CRSwNPs or
AFRS) reported previous ‘sinonasal surgery’ of which
99/696 (14%) reported having undergone ESS and
315/696 (45%) nasal polypectomy. Looking speciﬁcally
at patients with CRSwNPs who underwent a polypectomy
(n=281), only 30% (n=85) reported concurrent ESS. In
cases of CRSsNPs (n=553), only 160 (29%) patients
reported sinonasal surgery in whom 70 (13%) speciﬁc-
ally reported ESS (see table 1 for summary data). A χ2
test showed that the difference between the subgroups
was highly signiﬁcant (p<0.001). Other nasal procedures
speciﬁcally reported included septoplasty and turbinate
surgery.
Considering multiple procedures, 157 of 315 patients
with CRS who reported having undergone a nasal poly-
pectomy previously (50%) had received more than one
operation with a mean number of 3.3 polypectomies
(range 2–30; ﬁgure 3). In contrast, in the CRSsNPs sub-
group, 21 of 160 (13%) participants reported repeated
sinonasal surgery. A χ2 test showed that the difference
between the subgroups was again highly signiﬁcant
(p<0.001).
Looking at the timeline for participants who under-
went sinonasal surgery, 318 reported dates for surgery,
with the average duration from ﬁrst reported surgery to
inclusion in the study being 15.5 years (range 0–74;
table 2 and ﬁgure 4). Although patients may have
become asymptomatic for periods between interven-
tions, these data give a perspective on the chronicity of
the disease (from ﬁrst intervention), especially as many
patients will have been symptomatic for months to years
before the ﬁrst referral to secondary care. The duration
of time since the most recent surgical intervention to
completion of questionnaire (most current consultation)
Figure 1 Flow chart for inclusion of surgical data from CRES (CRS, chronic rhinosinusitis; CRES, CRS Epidemiology Study).
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is called ‘recurrence time’ and ranged from 0 to
70 years with a mean of 10 years for all CRS but notably
a mean of 3.68 in patients with AFRS, being signiﬁcantly
shorter than CRSwNPs (p=0.005; table 3 and ﬁgure 5).
The median interval for revision surgery in patients with
AFRS was 2 years.
Asthma and aspirin-exacerbated respiratory disease
were signiﬁcantly more likely to be present in patients
who had had multiple surgeries (60% asthma, 35%
AERD) than those who had not (43% and 11%; χ2
p>0.001). Finally a comparison in SNOT-22 scores
between patients with CRSwNPs/AFRS who have had
multiple endoscopic nasal polypectomies (ENPs) and
those who reported no surgery shows a signiﬁcantly
higher mean score in the multiple surgery group (45.6
vs 37.9; p=0.001); a mean SNOT-22 score of 42.1 in
those patients reporting only one ENP was not signiﬁ-
cantly different. ANOVA for SNOT-22 scores regardless
of surgery showed only a signiﬁcant difference between
CRSwNPs and AFRS subgroups (p=0.043). A more
detailed analysis of factors inﬂuencing disease in CRS
will be reported elsewhere.
Figure 2 Frequency of
sinonasal surgery (AFRS, allergic
fungal rhinosinusitis; CRSsNPs,
chronic rhinosinusitis without
nasal polyps; CRSwNPs, chronic
rhinosinusitis with nasal polyps).
Table 1 Summary data (percentages expressed with total in each subgroup as the denominator)
Variable CRSsNPs CRSwNPs AFRS
CRSwNPs and
AFRS combined
Total number of respondents 553 651 45 696
Male, % 41.4 59.8 55.6 –
Mean age 51.8 56 56.1 –
Previous sinonasal surgery 160 (29%) 359 (55%) 37 (82%) 396 (57%)
Previous ENP 10 (2%) 281 (43%) 34 (76%) 315 (45%)
Previous ESS 70 (13%) 85 (13%) 14 (31%) 99 (14%)
Multiple ESS/ENPs 21 (4%) 131 (20%) 26 (58%) 157 (23%)
Mean ENPs – 2.98 3.12 3.01
Mean SNOT-22 score 44.2 43.1 50.1 –
AFRS, allergic fungal rhinosinusitis; CRSsNPs, chronic rhinosinusitis without nasal polyps; CRSwNPs, chronic rhinosinusitis with nasal
polyps; ENP, endoscopic nasal polypectomy; ESS, endoscopic sinus surgery; SNOT-22, Sino-Nasal Outcome.
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DISCUSSION
The data from the CRES depict a story of the burden of
CRS on the NHS with more than half the cases of
CRSwNPs and AFRS reporting previous surgical inter-
vention and nearly half of those with surgical interven-
tion having had more than one procedure. As these
patients were all at varying points in their journey as suf-
ferers of CRS with some having undergone prior inter-
vention in secondary care and others having previously
received only treatment in primary care (having been
recruited at their ﬁrst appointment in secondary care),
we believe the study population includes a wide range of
CRS sufferers, rather than a speciﬁc surgical cohort, and
the SNOT-22 scores reﬂect a range of severity (0–108)
with overall recruitment across all sites being 66% of
those approached for participation.
Limitations of this study data are that they are self-
reported and patients may not accurately recollect the
details of the procedures. There are no data on non-
responders, given the anonymous nature of the study.
Although there were large numbers of non-surgical
cases reported, there is a potential bias towards those
who had received surgical intervention, given the sec-
ondary care setting of the study and that GPs will often
refer patients when they believe medical treatment has
been exhausted. The study did however aim to recruit
all patients seen with CRS, including those only receiv-
ing medical intervention in the outpatient setting.
There is a selection bias in terms of location as only
patients undergoing treatment in ENT departments
were recruited—there may be many patients who have
had successful previous surgery who will be missed as
they are no longer requiring active care or are only
receiving treatment in primary care; capturing this wider
picture of patient journeys across primary and secondary
care may become more of a reality now, with the advent
of health informatics such as the Clinical Practice
Research Datalink (CPRD).17 The study was designed to
review patients with CRS at one given point of time for
each participant, and since reported duration of disease
for each participant varied considerably, it is difﬁcult to
accurately establish the size of the population at all time
frames. Strengths of the study include the spread of data
from across the UK, representing both smaller district
general hospitals and larger tertiary centres as well as
different urban and rural populations.
Comparison with the UK Audit data
The UK Sinonasal Audit found that 46.1% of patients
had undergone sinonasal surgery before participating in
the study, with 52.5% of those with CRSwNPs reporting
previous surgery, compared with 35.0% of CRSsNPs. In
comparison, CRES has found slightly lower rates of
patients with CRS overall reporting previous surgery,
43% of all patients with CRS, but 57% of CRSwNPs and
29% of CRSsNPs. This may reﬂect the point of recruit-
ment being different; Audit patients were recruited at
the time of surgery, while CRES patients were recruited
at the time of outpatient treatment, recruiting just those
eligible for surgery in the Audit is likely to recruit more
severely affected patients than a cohort being treated in
outpatients; however, the mean SNOT-22 scores were
very similar with a mean preoperative score of 42 in the
Audit and a mean of 43.9 in CRES. The median time to
previous operation in the UK Audit and in CRES was
6 years.
Our study found the highest rate of revision surgery to
be among those with CRSwNPs and AFRS, with rates of
previous surgery almost twice that of those without nasal
polyps which is supported by the UK Sinonasal Audit.
There is a growing acceptance that patients with and
without polyps have distinct differences. This is reﬂected
in the current iteration of EPOS, with different treat-
ment algorithms for the two main phenotypes. The role
of surgery in patients with CRSwNPs is likely to be no
Figure 3 Frequency of multiple ENPs being performed in
patients who have previously undergone surgery. AFRS,
allergic fungal rhinosinusitis; CRSwNPs, chronic rhinosinusitis
with nasal polyps; ENP, endoscopic nasal polypectomy.
Table 2 Surgical impact data
Diagnosis
Number of patients
with available data Mean Median
Standard
deviation Range
AFRS 23 10.7 9 7.9 33
CRSwNPs 212 16.2 13 14.0 74
CRSsNPs 83 15.0 11 13.3 48
AFRS, allergic fungal rhinosinusitis; CRSsNPs, chronic rhinosinusitis without nasal polyps; CRSwNPs, chronic rhinosinusitis with nasal
polyps.
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more than achieving topical access to intranasal therap-
ies, and it may not change the underlying pathophysio-
logical process. The need for recurrent treatment is
therefore not unexpected. A recent study18 found that
ostiomeatal obstruction is not a feature of CRSwNPs,
and surgery, which primarily alleviates obstruction, is
unlikely to be curative. In contrast, ostiomeatal obstruc-
tion is much more common in CRSsNPs, and therefore
ESS which addresses this may well achieve long-term
beneﬁts. This contrasts to one previous study19 which
found no difference in recurrence rates between those
with and without polyps. It is not clear at this time
whether the high revision rates seen in CRSwNPs simply
reﬂect the chronic nature of the condition and the lim-
itations of current medical management, or whether
there are operative variables that may be improved in
order to reduce the ongoing burden of revision surgery.
CRSwNPs patients are likely to reﬂect a diverse group,
with differing individual patient factors (endotypes) that
are yet to be fully understood and characterised. The
presence of asthma appears to represent a higher risk
factor for recurrence.20 Similarly, a previous study has
also shown higher rates for repeat surgery among those
with aspirin-exacerbated respiratory disease21 (risk-OR of
2.7). One additional patient factor which may inﬂuence
rates and times to revision surgery is smoking status, Wu
et al showed that smokers had a shorter time to revision
surgery,22 but with only 11 smokers in those with mul-
tiple ENPs in CRES, this trend was difﬁcult to quantify.
A crucial factor in the success or failure of surgical
intervention will be patient compliance with ongoing
medical management postoperatively. Although informa-
tion on medical treatment was recorded, this cannot be
speciﬁcally aligned with the postoperative period in
these patients and is not considered further in this ana-
lysis. Anecdotal evidence from the qualitative arm of the
CRES suggests that compliance with topical treatments is
a problem and that patient education at the outset of
treatment is crucial with a need for regular reinforce-
ment.23 This may currently be counteracted by differing
advice from primary and secondary care practitioners
and emphasises the need for greater awareness of guide-
lines, but there is also a need for further clinical trials in
terms of medical treatment to underpin this.
We acknowledge that recurrence of disease reﬂecting
its chronic nature is a more common occurrence than
revision due to ‘failed’ surgery in its truest sense. While
we accept the term ‘revision’ suggests failure of the
primary surgery and that recent evidence shows early
postoperative beneﬁts from sinus surgery,24 for the
reasons cited above (extent of surgery and grade of
surgeon) we feel consideration needs to be given to the
longer term perspective on surgical management in
CRS. As such there is a need for trials that address these
factors, so that we can better understand whether these
repeated surgical interventions reﬂect a disease-speciﬁc
burden or are a product of current surgical strategies.
Cost burden
Within the NHS, consideration of the cost of repeated
surgeries is very important. Based on annual HES data
for 2012/2013 on admissions for sinus surgery for
CRSwNPs,25 and considering NHS reference costs of
approximately £1500 per case for each surgical admis-
sion,4 the total cost to the NHS is likely to be over £30
Figure 4 Duration of time since first sinonasal surgery for
patients with chronic rhinosinusitis with nasal polyps (surgical
time impact).
Table 3 Time to recurrence data
Diagnosis
Number of patients
with available data Mean Median
Standard
deviation Range
AFRS 22 3.7 2 3.6 12
CRSwNPs 208 10.8 7 11.9 70
CRSsNPs 82 12.9 8 13.2 46
AFRS, allergic fungal rhinosinusitis; CRSsNPs, chronic rhinosinusitis without nasal polyps; CRSwNPs, chronic rhinosinusitis with nasal
polyps.
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million per year. Although the exact proportion of revi-
sion surgeries across the NHS is not precisely known, if
50% of surgical cases are revision cases, then £15 million
is spent each year on revision sinus surgery or polypec-
tomies. As well as the ﬁnancial burden to the NHS,
there is a risk we may be subjecting patients to surgery
and its attendant complications without good evidence
of effectiveness from level 1 evidence. However, the
beneﬁt in terms of reduced healthcare costs as seen in
an American model suggests that surgery may prove
more cost-effective than continued medical therapy
alone. This recent study showed that patients with CRS
have healthcare utilisation levels at the time of surgery
that are eight times greater than baseline, but also
reach baseline levels within 13 weeks postoperatively.26
However, given the costs of surgery, good evidence on
the cost-effectiveness of repeated interventions is needed
and must be weighed up against both the direct and
indirect costs of the condition.
CONCLUSIONS
Data from the CRES show that 13 years after the
Sinonasal Audit, there is still a high burden of revision
surgery in CRS to both patients and healthcare provi-
ders. It is therefore essential, now more than ever, that
carefully designed clinical trials are undertaken that
build on the existing evidence to support surgery in
CRS and assess the effectiveness of surgery before
making such decisions. A possible trial design might
consider comparing early surgical intervention alongside
continued medical therapy versus delayed surgical
intervention on continued medical therapy to show
beneﬁt from surgery per se and also to investigate
whether or not surgery is cost-effective. Further trials are
then needed to examine the beneﬁts of extended sinus
surgery over minimal surgical intervention (eg, ENP).
This study emphasises the need for ongoing research to
improve the care of patients with CRS in order to min-
imise the need for repeated specialist care and operative
intervention.
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ABSTRACT 
Background: Previous research has suggested that sodium citrate improves hyposmia by decreasing 
mucus calcium levels in the nose. This study aimed to confirm or refute this effect in a single 
application and assess potential side effects.  
Methodology: Study design was a randomised double-blind controlled trial of sodium citrate nasal 
spray (intervention) versus sterile water (control) in a tertiary care clinic. Fifty-five patients with non-
conductive olfactory loss were randomised to receive the intervention or placebo. The primary 
outcome measure was improvement in measured olfactory thresholds for phenyl ethyl alcohol (PEA) 
over 2 hours. Other outcome measures assessed were Improvement in olfactory thresholds in 1-
butanol, eucalyptol and acetic acid; number of responders with a clinically relevant response in each 
arm; adverse effects.   
Results: A significant effect was seen in the intervention arm for PEA and for 1-butanol and 
eucalyptol when compared to the control arm (P<0.05); 32% of the intervention arm responded in 
terms of improved sensitivity towards some of the odours. Minor adverse effects noted included 
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sore throat, nasal paraesthesia, slight rhinorrhoea and itching. The duration of effect of the citrate is 
transient, peaking at 30-60 minutes after application. 
Conclusions: Sodium citrate yields some potential as a treatment for non-conductive olfactory loss, 
however these findings require corroboration in further clinical trials looking at longer-term regular 
use of the spray as a viable therapeutic option for patients where it would be applied at frequent 
intervals such as before meal times. 
 
Keywords: olfaction disorders, clinical trial, smell, sodium citrate, viral respiratory tract infections 
 
INTRODUCTION 
Background 
   Olfactory disturbances represent a frustration for both patients and otorhinolaryngologists; the 
effects may be profound for some patients especially if their profession or safety depends upon it 
and clinicians often feel unable to do much more than identify the problem. Disorders of olfaction 
have a widespread heterogeneous aetiology from nasal to central causes. They lead to a significant 
impact on nutritional intake, are frequently associated with weight loss, decreased social pleasure, 
diminished interpersonal relationships and poor psychological well-being 1. Olfactory disorders 
increase in incidence with age and may be as common as 1 in 5 in the over 65 population2, 3. 
Underlying the challenge of management has been a lack of understanding of the olfactory system 
and a lack of therapeutic options available to clinicians. 
 
  The current understanding of olfactory transduction suggests that olfactory receptor cells in the 
olfactory cleft bind odour molecules to a large family of receptors in the ciliary membrane. These 
subsequently activate a G protein-coupled intracellular cascade ending with synthesis of cAMP by 
adenylyl cyclase. The rise in intracellular cAMP leads to the opening of cyclic nucleotide-gated 
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channels and an influx of Na+ and Ca2+, which eventually may lead to axonal firing. Calcium plays a 
key, conflicting, role in the responses of the olfactory receptor cells. It acts both as an excitatory 
second messenger to increase the magnitude of receptor current but also as an inhibitory 
messenger important in response termination and adaptation. It is well established that cytoplasmic 
Ca2+ regulates sensitivity to cAMP4, 5. By entering the cilium during the odorant response Ca2+ 
reduces the sensitivity of cyclic nucleotide gated (CNG) channels to cAMP6.   
   A rise in mucosal Ca2+ through the above-described mechanism increases negative feedback on the 
olfactory pathway ultimately reducing sensitivity to odorant stimulus. In the normosmic patient this 
provides a mechanism for long-term odour adaptation. It is therefore possible that in the patients 
with olfactory loss, reducing mucosal Ca2+ levels may reduce the negative feedback, which in these 
circumstances may contribute to their anosmia/hyposmia. This effect is supported by an animal 
study that found prolonged olfactory stimulation in frog olfactory receptor cells when creating a 
similar environment5, 7.  Modulation of calcium concentrations in the olfactory environment would 
therefore certainly be an attractive target for pharmacologic intervention in humans, with an 
established underlying physiological basis. 
   Sodium citrate, a solution licenced and used safely in other body cavities (e.g. stomach and 
bladder) is known to buffer calcium ions, leading to a reduction in mucosal Ca2+ and subsequent 
reduction in negative feedback. A previous study by Panagiotopoulos et al has suggested that the 
application of sodium citrate improves hyposmia by decreasing mucus calcium levels in the nose 8.  
On the basis of the above physiological rationale, reduction in free Ca2+ ions is likely to increase the 
excitability of olfactory neurons, thus improving the sense of smell.  The sodium citrate solution 
douched in the nose should have the effect of binding free calcium ions in the nasal mucus, thus 
reducing mucosal calcium. The Panagiotopoulos study did, however, have certain limitations 
including the small number of participants and the method of application as well as the use of an 
identification test as the main assessment of olfactory performance. 
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Objectives 
Primary objective: To measure the effect of sodium citrate nasal spray on short-term olfactory 
performance compared to placebo.    
Secondary objectives: To determine the acceptability of sodium citrate nasal spray as a treatment 
for olfactory disorders.  
 
MATERIALS AND METHODS 
Ethical approval and funding 
Ethical approval was sought and obtained from the Eastern Multicentre Research Ethics committee 
(REC reference number 06/MRE05/16) in accordance with the provisions of the Declaration of 
Helsinki and Good Clinical Practice guidelines. Sodium citrate solution and corresponding sterile 
water placebo were supplied by the James Paget University Hospital pharmacy. The study was 
funded by the James Paget University Hospital Research & Development Department and sponsored 
by the University Hospitals of Leicester NHS Trust. 
 
Trial Design 
The study was conducted as a randomised double-blind controlled trial recruiting 55 patients who 
met criteria below. 
Participants 
Patients referred to a tertiary Smell & Taste Disorders clinic were assessed for eligibility and 
approached by the lead author. Basic demographic data including age and sex were collected.   
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Inclusion criteria: 
• All patients with non-conductive olfactory disorders (NCODs) as confirmed by history and 
examination 
•  
Exclusion criteria:  
• Patients with any endoscopic findings of conductive loss including chronic rhinosinusitis 
with/without nasal polyposis and severe nasal septal deviation (preventing passage of 4mm 
endoscope) 
• Patients with congenital anosmia 
• Patients with any inhalant allergies 
• Patients with asthma 
• Children under the age of 16  
All patients provided written informed consent after the aims and methods of the study had been 
described to them and after they had received an information sheet.  
 
Interventions 
Participants were randomly allocated to one of two groups. In the treatment arm, participants were 
sprayed with 1ml of 9% sodium citrate solution; 0.5ml to each side of the nose. Participants in the 
control arm received the corresponding volume of sterile water. The solution was applied using a 
nozzle adapted to target the olfactory cleft (figure 1) as can be found on other nasal spray kits such 
as co-phenylcaine; the nozzle was manipulated to point upwards prior to insertion into the nose. 
Sodium citrate concentrations used did not exceed those used in other body cavities. Sterile water 
was chosen as the control agent as the ionic composition of saline may have a local effect on the Na+ 
ion concentrations that we hypothesised might modulate olfaction. 
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Outcomes 
Primary outcome measure:  
Best improvement in olfactory thresholds compared to baseline as defined by threshold shift in 
logarithmic dilutions in the direction of the weaker odour concentration for PEA odour. 
 
Secondary outcome measures:  
• Best improvement in olfactory threshold compared to baseline for all odours as defined by a 
threshold shift of at least more than one in the direction of the weaker odour concentration. 
• Number of individuals who responded; (for those individuals who responded we also recorded 
the time until best improvement)  
• Adverse events 
Subjects underwent a series of threshold smell tests using the phenyl ethyl alcohol (roses), 1-butanol 
(pear), acetic acid (vinegar) and eucalyptol (menthol) on the basis of previous work by the senior 
authors9 and in conjunction with accepted threshold testing formats previously validated10, 11.  A 
50ml volume of each of 4 odours in 250ml bottles were arranged in seven 10-fold dilutions from 10-1 
to 10-7 for 1-Butanol, Acetic acid and Eucalyptol and 10-2 to 10-8 for phenyl alcohol. At the beginning 
of the trial the odour mercaptan was used but was subsequently replaced with 1-Butanol due to the 
need to replenish the odour solutions more frequently than the others and was deemed an 
unreliable test odour.  
The format of the test had been fully explained to the subject beforehand by the research nurse who 
tested the patient. This format of olfactory testing was chosen as it would allow for quicker 
reassessment at repeat intervals compared to a full Sniffin’ Sticks test battery, but would provide a 
more accurate assessment of olfactory performance than an identification only test 12. The subject 
was then started with the smallest concentration of each odour and with sterile water for 
comparison, ascended through the odour concentrations in a forced response format until they 
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correctly detected the odour as distinct from the sterile water 10. Once the subject had correctly 
identified two concentrations of a single odour in a row, the weaker concentration of the odour 
detected was taken as their threshold and recorded. This was then repeated for the remaining 3 
odours and the four thresholds obtained were considered the baseline olfactory performance. The 
format of the test had been fully explained to the subject beforehand by the research nurse who 
tested the patient 10, 12. 
 
After application of the intervention, the olfactory threshold tests to the four odours were then 
repeated every fifteen minutes up to a maximum of 120 minutes. At each 15-minute interval, 
patients were started two places below their previous threshold to avoid unnecessary extra steps. 
The maximum change in threshold was recorded for each odour, as was the duration of any effect if 
seen. If no improvement was noted for all four odours by 60 minutes then further testing was 
abandoned. 
At the end of the trial participants were asked to report any adverse effects from the spray they had 
received. 
 
Sample size 
To detect a moderate to large Cohen's effect size of 0.75 (mean difference /standard deviation of 
the difference), at 80% power at the 5% level of significance, would need 30 patients in each arm.  
 
Randomisation 
Sequence generation, allocation concealment and implementation: 
The code randomisation sequence was computer generated and coded bottles of solution were 
provided to researchers who had no knowledge of the contents of each bottle.  The random 
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sequence was generated by Microsoft Excel number randomiser generator in the hospital pharmacy 
who assigned enrolled participants to the intervention. Once the participant agreed to be in the 
study the study nurse phoned the pharmacy who then provided a coded bottle to use in the clinic. 
Blinding: 
Both the research team and the participants were blinded to the intervention. At the end of the trial 
the bottle code was obtained from the pharmacy and revealed showing allocation of participants to 
the two groups.  
 
Statistical methods: 
The analysis included all randomised individuals who had valid outcome measurements. The primary 
analysis compared the best improvement with the PEA odour between control and intervention 
groups using a Mann-Whitney test as the outcome was not normally distributed. The same analysis 
was also performed separately for each odour tested for the best improvement and the duration. 
Response to treatment, defined by a difference of at least two thresholds, was tested using a chi-
squared test. We considered p<=0.05 as significant and all statistical analyses were conducted using 
Stata 14.0/SE.     
 
RESULTS 
Participant flow: 
A total of 98 patients were assessed for eligibility and after exclusion or declining, 61 participants 
were randomised, with 31 allocated to the treatment arm and 30 to the control arm, but 4 
participants did not attend their appointment on the day and 2 didn’t complete the sequence of 
testing after application (see figure 2). The trial ran from October 2007 to December 2014 and 
stopped when the target sample size had been recruited. 
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Baseline data: 
Female participants accounted for 76% of those in the trial with an age range of 20 to 79 (mean of 
53) in all subjects. The underlying diagnoses were post-viral olfactory loss (26, 42%), post-traumatic 
olfactory loss (9, 16%) and idiopathic (20, 36%). On psychophysical olfactory testing (using the 
Sniffin’ Sticks), 29 (52%) were functionally anosmic and 17 (30%) were hyposmic; the TDI score was 
irretrievable for 2 subjects and not performed in 7 subjects. The balance of the two treatment arms 
is shown in table 1, it can be seen that there is some difference between the groups in terms of 
gender and diagnosis.  
 
Numbers analysed: 
As participation in the trial only required one visit and one intervention, all participants completed 
the trial once randomised except for four in the control arm who failed to attend the study visit and 
a further two that failed to complete the sequence of tests on the study visit.  Due to the small 
number of participants that had been tested with mercaptan (7), no specific analysis of this data was 
undertaken. 
Outcomes and estimation: 
Based on a best improvement in thresholds (logarithmic concentration being lower than baseline), 
there were significant differences between the intervention and control groups (p<0.05) for all 
odours except for ACA (Table 2a). Based on a clinically significant shift in thresholds of 2 or more, 10 
participants responded to PEA, 10 to 1-BUT, 9 to ACA and 9 to EUC; again these were clinically 
significant for 1-BUT and EUC and approaching significance for PEA (table 2b). In seven patients who 
were evaluated with mercaptan instead of 1-butanol, 4 hyposmic patients (out of the 7) showed a 
positive threshold shift of ≥2 places in response to citrate. Table 3 shows the proportions of anosmic 
and hyposmic patients demonstrating that baseline olfactory performance does not necessarily 
appear to be a reliable indicator of potential to respond to the intervention.  
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Ancillary analyses 
Of the 10 intervention subjects (32%) who found an improvement for at least one odour, 5 of the 10 
had improved at 15 minutes with 3 reaching peak improvement at 15 minutes. For the other 7, peak 
improvement was reached at 30 minutes for five subjects, 45 minutes for one and 60 minutes for a 
another one (two examples are provided in figure 3). The average time for subjects to register 2 
logarithmic dilution improvements in threshold was 38.7 minutes with the average time to 
maximum effect 47.4 minutes and the average duration 54 minutes. In most patients the threshold 
levels for all odours had returned to baseline (+/- 1 threshold step) by the end of the 2-hour test 
period. Fourteen patients did not continue repeat threshold testing beyond 60 minutes due to a lack 
of response following the intervention. 
 
Harms: 
None of the participants in the trial reported any persistent symptoms but transient localised 
symptoms were reported in both arms with rhinorrhoea and sore throat affecting only the citrate 
recipients (Table 4). None were reported as excessively unpleasant. 
 
DISCUSSION 
Generalisability 
   These results mark a promising development in the treatment of NCODs disorders. We have shown 
that sodium citrate nasal spray may temporarily improve the ability to detect certain odours in those 
quantitative olfactory disorders. Sodium citrate therefore has the potential to be a treatment or 
adjunct to treatment to improve the olfactory performance of those with NCODs. We have shown 
that sodium citrate spray appears to be relatively quick acting in those who find improvement, is 
acceptable to patients, and could feasibly be used in a clinical setting. The current treatment 
armoury for this condition is limited with oral and topical corticosteroid and methylxanthine class 
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drugs (e.g. Theophylline 13) showing the most promise to date. Of these the only level I evidence is 
for prednisolone 14, 15 in NCODs. The topical intranasal spray allows an easy and well-tolerated mode 
of application that is vital when considering its development as a therapeutic solution. It may 
facilitate short-term olfactory enhancement allowing patients greater enjoyment of meals, 
improving quality of life and nutritional intake, or it may be used as a regular application to allow 
better baseline olfactory function; the specific nature of the improvement cannot be elucidated 
from these results, although the quick time to improvement is encouraging since it would make 
timing of use of the spray practicable. It is notable that amongst those who responded, the effect 
was not universal across all 4 odours. 
Limitations 
Whilst a positive effect was seen in 10 participants in the intervention arm, there remained 21 
participants who perceived no discernible effect on their olfactory performance and therefore this 
cannot be seen as a panacea for all patients with NCODs. The sample size here is too small to allow 
for a subgroup analysis by diagnosis, however, there does not appear to have been a specific 
clustering of responders within one subgroup (PVOL), suggesting that more than one group may 
stand to benefit from this intervention (table 5). Therefore although the diagnostic group with the 
greatest number of responders is the PVOL group, it is notable that patients in the idiopathic group 
also responded. It is however possible that the idiopathic cases are indeed post-viral in nature even 
if lacking in the temporal relation to an upper respiratory tract infection. It should also be noted that 
the different subgroups may well reflect different sites of pathology within the olfactory apparatus 
(i.e. olfactory epithelium/receptors in PVOL, olfactory nerves/secondary cortex in PTOL, etc), so 
future studies will need to power for individual subgroups. Seven participants were tested with 
mercaptan rather than 1-butanol but and so this data was not used in the analysis, but we do not 
believe this detracts from the findings presented here. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
The trial as reported here is designed to assess the use of sodium citrate in a single application for 
NCODs. However, to be effective as a treatment for patients, this positive effect would need to be 
repeatable on subsequent applications and to be tolerated by patients. In practice, due to the short 
duration of effect, this would involve patients having to apply the spray to their noses at frequent 
intervals such as meal times, however, feedback from patient panels at our institution favour this 
possibility. Other concentrations of sodium citrate could have been considered, however we decided 
to select the highest concentration currently available to reduce the sample size needed for this trial. 
As our primary outcome we used was olfactory threshold tests that only assessed 4 odours, it is 
possible that testing a wider array of odours might have enabled more positive responses, albeit that 
practically speaking this would have been difficult to achieve with 15-minute intervals for threshold 
tests, but achievable with an identification test. 
Interpretation 
   The data presented here do not thrust sodium citrate spray forwards as a therapeutic option 
immediately, but do suggest merit in undertaking further multicentre trials to evaluate this 
intervention further. Seen in conjunction with the previous trial 8 of sodium citrate in olfactory 
disorders, the results do not appear to be spurious. In fact a recent trial at the Dresden Smell & Taste 
Clinic performed using one nostril as the test site and the contralateral one as a control has shown 
benefit in the PVOL diagnostic group too16. A subsequent trial would need to address the issue of 
subgroup analysis by diagnosis as well as age, gender and degree of olfactory impairment with an 
appropriate sample size.  As this trial evaluated a single application of sodium citrate spray, further 
work needs to consider the benefits or otherwise of repeated use of the treatment over the short to 
medium term. Comparing efficacy between pH and sodium matched controls using validated 
olfactory outcome measures would also test our hypothesis that it is the citrate and our postulated 
mechanism of action that is conferring the improvement, rather than adjustment of any other 
intracellular signalling pathway or enhancement of the enzymatic mediators of olfaction through 
optimisation of their acid-base environment.  
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CONCLUSION 
This work offers proof of concept that sodium citrate nasal spray may enhance olfaction in some 
patients with NCODs. Further investigation through well-designed clinical trials may deliver better 
evidence to suggest that it has a place in the rhinologist’s armamentarium. If further proven to 
enhance olfaction, sodium citrate could safely and easily be formulated into a commercial applicator 
to allow temporary relief of smell loss. This may serve to enhance the quality of life of such patients 
with few side effects or contraindications, by providing relief for meal times for example. 
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TABLES 
Table 1: Demographic and baseline information 
 Control (n= 24) Intervention (n= 31) 
 Mean (SD) Mean (SD) 
Female n (%) 16 (66.7) 26 (83.9) 
Age (years) 52.5 (10.4) 54.1 (14.3) 
Threshold score  2.0 (1.7) 2.4 (2.5) 
Discrimination score 6.5 (3.4) 6.8 (2.7) 
Identification score 7.7 (3.5) 5.6 (2.5) 
TDI score * 16.2 (7.3) 14.8 (5.9) 
Diagnosis n (%)  
  IDIOPATHIC 7 (29.2) 13 (41.9) 
  PTOL 5 (20.8) 4 (12.9) 
  PVOL 12 (50.0) 14 (45.2) 
Classification (Based on TDI)  
   Functional anosmia 13 (61.9) 16 (64.0) 
  Hyposmia 8 (38.1) 9 (36.0) 
* Not available in 9 subjects 
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Table 2a: Best improvement measured in number of threshold levels improved 
Odour tested Control (n= 24) Intervention (n= 31)
Median (IQR) Median (IQR) p-value
PEA  0 (0-0.5) 1 (0-2) 0.0139
BUT 0 (0-1) 1 (0-2) 0.0111
ACA 0 (0-1.5) 1 (0-2) 0.2827
EUC 0 (0-0) 1 (0-2) 0.0001
 
Table 2b: Number of respondents  
Odour tested Control (n= 24) Intervention (n= 31)
Median (IQR) Median (IQR) p-value
PEA  3 (12.5) 10 (32.3) 0.087
BUT 3 (12.5) 14 (45.2) 0.009
ACA 6 (25.0) 9 (29.0) 0.739
EUC 1 (4.2) 9 (29.0) 0.018
 
Table 3: Number of responders to citrate by baseline olfactory performance in the intervention 
arm 
Responders by odour Functionally anosmic Hyposmic Total 
PEA 3 7 10 
BUT 4 6 10* 
ACA 6 3 9 
EUC 6 3 9 
* 4 unclassified as did not have a TDI score 
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Table 4: Side-effects of the intranasal spray 
Side effect Citrate Control
Nasal irritation 7 4
Rhinorrhoea 11 0
Nasal congestion 3 1
Sneezing 2 0
Sore throat 12 0
Dysgeusia 1 1 
 
 
Table 5: Numbers of responders to citrate by diagnostic group in the intervention arm 
Responders by odour PVOL PTOL Idiopathic 
PEA 6 1 3 
BUT 6 1 3 
ACA 5 1 3 
EUC 4 1 4 
 
FIGURE LEGENDS 
Figure 1: Spray bottle and nozzle 
Figure 2: Citrate RCT participant flow chart 
Figure 3 and 4: Time and duration of effect in two example responders by odour 
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